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Stroke is characterized by sudden 
disruption of blood flow into the 
brain resulting in disability and 
death. This thesis focuses on model-
ling the heterogenic conditions of 
human stroke in preclinical settings. 
This study demonstrates that preced-
ing infection, diet and genetic com-
position of the animal models alter 
the ischemia induced inflammatory 
status especially in aged mice. Our 
data pinpoint the need to consider 
heterogeneity of human stroke in 
preclinical settings when testing new 
potentially neuroprotective drugs. 
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ABSTRACT 
Ischemic stroke, characterized by sudden reduction in blood flow into one or more of the 
cerebral arteries, often affects the elderly population accompanied by co-morbid conditions 
such as atherosclerosis, infections and diabetes. Novel therapeutic compounds with 
neuroprotective properties in preclinical models have failed in human clinical trials. The 
reason for the failure may be partly explained by the use of the homogenous cohorts of 
young healthy animals in preclinical studies bearing little relevance to heterogenic 
conditions of human stroke. Especially, the interaction between aging and inflammation in 
patients predisposed to co-morbid conditions is poorly understood. In this study, we aimed 
to elucidate the impact of co-morbid conditions on ischemic inflammation in experimental 
settings and develop clinically more relevant rodent models that bear resemblance to 
human stroke.  
We investigated the role of ApoE4 on aged mice fed with a high-fat diet and assessed the 
inflammatory and behavioral outcome following permanent middle cerebral artery 
occlusion (pMCAo). We show that aged transgenic mice expressing human ApoE4 isoforms 
fed with a high fat diet were more susceptible to sensorimotor deficits. These deficits were 
accompanied by increased astrogliosis, impaired neurogenesis, increased cyclooxygenase-2 
immunoreactivity and increased peripheral IL-6 levels in plasma. 
Next, we carried out a study where we assessed the effect of aging and predisposing 
peripheral infection on the outcome of cerebral ischemia in mice. Induction of chronic Th-1 
polarized systemic infection by administration of gut parasite T. muris induced significant 
brain damage specifically in aged mice, and this damage correlated with pre-stroke plasma 
level of RANTES. In addition, significant infiltration of neutrophils in the infarct core and 
increased plasma levels of interleukin-17α and tumor necrosis factor-α were evident in 
aged infected mice when compared to their young counterparts. 
Finally, we applied therapeutic intervention to inhibit proinflammatory receptor, cluster 
of differentiation 36 (CD36), in order to halt the brain damage following ischemia. We 
tested the therapeutic potential of a well-known inhibitor of CD36, sulfosuccinimidyl oleate 
sodium (SSO) against ischemic brain damage. Orally administered SSO reduced the infarct 
size of the animals that underwent surgery with the concomitant decrease in COX-2 
immunoreactivity and microgliosis in the peri-ischemic area. SSO reduced the phagocytotic 
activity of BV2 microglial cells following LPS stimulation.   
The results of this thesis show that 1) chronic peripheral infection and a high fat diet in 
combination with ApoE4 isoform in aged mice renders the brain more vulnerable to 
ischemic insults by altering the brain inflammatory status and 2) therapeutic intervention 
targeting the proinflammatory receptors like CD36 may be a suitable approach for 
designing treatment strategies. Our results show that co-morbid conditions alter the 
ischemia induced inflammatory status especially in aged mice pointing out the need to 
consider heterogeneity in preclinical modeling of stroke. 
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TIIVISTELMÄ 
 
Aivohalvaus on maailman toiseksi yleisin kuolinsyy. Intensiivisestä tutkimuksesta 
huolimatta aivohalvaukseen ei ole olemassa tehokasta hoitomuotoa. Monet uusista 
eläinkokeissa tehokkaiksi havaituista lääkehoidoista eivät ole osoittautuneet toimiviksi 
potilaskokeissa. Tätä uusien lääkeaineiden huonoa toimivuutta potilaskokeissa kutsutaan 
translationaalisuus ongelmaksi. Sen ajatellaan johtuvan siitä, että käytetyt prekliiniset 
eläinmallit eivät vastaa ihmisessä aivohalvauksen aikana tapahtuvia muutoksia. Vaikka 
aivohalvauspotilaat ovat iäkkäitä, usein naisia ja kärsivät erilaisista liitännäissairauksista, 
kuten sydän- ja verisuonisairauksista ja erilaisista infektioista, käytetään uusien 
lääkeaineiden testaamiseen vielä poikkeuksetta nuoria, terveitä uroshiiriä. Tämä on 
johtanut siihen, etteivät aivohalvaukseen suunnatut uudet lääkehoitojen kohteet eivät ole 
relevantteja aivohalvauspotilailla. 
Tämän väitöskirjatyön tarkoituksena oli testata miten ikä ja erilaiset liitännäissairaudet 
vaikuttavat aivohalvauksen aiheuttamaan solutuhoon. Tutkimuksessa käytettiin kahta eri 
mallia, joilla pyrittiin mallintamaan ihmisillä esiintyviä, aivohalvauksen riskiin vaikuttavia 
tiloja. Tutkimuksen ensimmäisessä vaiheessa määritettiin, miten apolipoproteiini E4 
(ApoE4) alleeli vaikuttaa aivohalvauksen aiheuttamiin motorisiin vaikeuksiin hiirillä, jotka 
saivat länsimaiselle väestölle tyypilliseen tapaan runsaasti kolesterolia sisältävää ruokaa. 
Tutkimuksessa näytettiin, että korkeakolesterolista rehua syöneiden, ihmisen ApoE4 
alleelia ilmentävien hiirten aivohalvauksen jälkeiset motoriset vaikeudet olivat 
merkittävästi kasvaneet verrattuna ApoE3-alleelia ilmentäviin hiiriin. Nämä vaikeudet 
liittyivät ApoE4-alleelia ilmentävien hiirten aivojen kohonneeseen tulehdusvasteeseen, 
vähentyneeseen uusien hermosolujen muodostumiseen sekä lisääntyneeseen plasman IL-6 
tasojen nousuun. Väitöskirjatyön toisessa vaiheessa näytettiin, että perifeerinen infektio, 
jota mallinnettiin Trichuris Muris parasiitilla, lisäsi aivohalvauksen aiheuttamaa solutuhoa 
erityisesti ikääntyneillä hiirillä. Tämä liittyi aivojen kohonneeseen tulehdussolujen 
infiltraatioon sekä kohonneisiin plasman tulehdusvälittäjäaineiden tasoihin. 
Väitöskirjatyön kolmannessa osatyössä näytettiin, että tulehdusvasteen inhiboiminen on 
potentiaalinen hoitomuoto aivohalvauksessa. Tähän käytettiin CD36 inhibiittoria, joka suun 
kautta annosteltuna pienensi aivohalvauksen aiheuttamaa solutuhoa ja vähensi 
tulehdusvastetta sekä aivohalvaus aivoissa että soluviljelyolosuhteissa. 
Nämä tulokset osoittavat, että erilaiset aivohalvauksen liitännäissairaudet lisäävät 
aivohalvauksen aiheuttamaa solukuolemaa ja motorisia vaurioita. Lisäksi tulehdusvasteen 
säätelyn osoitettiin laskevan aivohalvauksen aiheuttamaa solutuhoa. Väitöskirjatyön 
tulokset osoittavat, että ikä ja erilaiset liitännäissairaudet vaikuttavat merkittävästi 
aivohalvauksen lopputulemaan. Tämä on erittäin tärkeää ottaa huomioon tutkimuksissa, 
joissa mallinnetaan tätä nimenomaan ikääntyvien ihmisten sairautta.  
 
Yleinen Suomalainen asiasanasto: Aivohalvaus; Apolipoproteiinit, Eläinkokeet, Ikääntyminen, Infektiot, 
Inflammasomit, Kemokiinit; Liitännäistaudit, Mallintaminen, Riskitekijät, Sytokiinit 
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1 Introduction  
The human brain needs a continuous supply of metabolic energy in order to maintain its 
cellular and molecular integrity. Since the brain cannot store enough glucose as a substrate for 
the production of adenosine triphosphate (ATP), there needs to be a continuous supply of 
oxygen and glucose in the brain. Thus, even a slight disturbance in the supply of nutrients by 
the blood may result in tissue damage that is characterized as stroke.  
Cerebrovascular accident or stroke is the second leading cause of death and disability 
worldwide (Donnan et al., 2008). In the United States alone, an average of 795,000 people 
experiences new or recurrent stroke every year. Someone experiences stroke every 40 seconds 
and someone dies of stroke every 4 minutes (Roger et al., 2012). In Europe, stroke accounts for 
1.1 million deaths each year (ESC, 2012). In Finland alone, the incidence of stroke is 
approximately 14,000 per year. Stroke is becoming an economic burden as it results in long term 
disability and extended hospitalization of the patients and post-stroke rehabilitation. Despite 
extensive research, thrombolysis is the only cure for stroke. However, the therapeutic time 
window is about 3 to 4.5 hours (Hacke et al., 2008, The NINDS t-PA Stroke Study Group, 1995) 
and only 3% to 5% of stroke patients benefit from the tissue plasminogen activator (tPA) due to 
timely hospitalization (Roth, 2011). There is also a risk of developing hemorrhage after 
thrombolysis, which contributes to mortality associated with this traditional treatment 
paradigm (The NINDS t-PA Stroke Study Group, 1997). Therefore, further understanding of the 
pathophysiology of ischemic stroke and development of suitable treatment paradigms is of 
utmost importance. 
Stroke can be either ischemic or hemorrhagic. Ischemic stroke caused by blockage of arteries 
by either thrombus or embolus accounts for 85% of all stroke cases. Hemorrhagic stroke results 
from the rupture of the artery supplying blood and it accounts for the remaining 15 percent 
(Roger et al., 2012). Blockage of blood flow to the brain results in irreversible brain damage at 
the core area. The infarct can further evolve to the surrounding area known as the penumbra 
that can be salvaged by therapeutic means. Ischemic damage to the neuronal tissue initiates a 
variety of inflammatory responses as defense mechanisms to maintain tissue homeostasis 
through clearance of cellular debris as well as promoting neurogenesis and tissue repair 
(Iadecola and Anrather, 2011). However, in the acute phase of stroke, inflammatory reactions 
appear to be detrimental and also contribute to the development of delayed brain damage over 
time. Inflammation in the ischemic area is mediated by astrocytes, microglia and infiltrating 
peripheral leukocytes, primarily neutrophils and monocytes into the brain parenchyma. These 
inflammatory cells then produce a variety of cytotoxic molecules, including pro-inflammatory 
cytokines and chemokines, and reactive oxygen (ROS) and –nitrogen species. Thus, anti-
inflammatory strategies have been suggested to be beneficial for stroke patients. A number of 
therapeutic compounds that have been reported to be beneficial in pre-clinical trials have 
undergone clinical trials, but none of them has been effective in humans. One of the reasons for 
the translational failure is suggested to be the heterogeneity of human stroke when compared to 
homogenous cohorts of young animals used in pre-clinical trials (Endres et al., 2008). In clinical 
condition, stroke typically affects elderly individuals with significant co-morbidity risk factors, 
such as hypertension, diabetes, atherosclerosis, Alzheimer’s disease (AD), and infections, etc. 
So, inclusion of these factors in the preclinical setting should provide the next level of 
understanding and provide insights into effective therapeutic strategies in treating the disease. 
Several lines of evidence suggest the role of aging, atherosclerosis, infections and genetic risk 
factors to the outcome of cerebral ischemia and hence to the pathophysiology of ischemic brain 
damage that is often accompanied by neurological deficits. However, the impact of 
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confounding risk factors such as infections, different apolipoprotein E (ApoE) isoforms and 
atherogenic diet in aging are not well studied. In this thesis, we studied the impact of high fat 
(HF) diet on sensorimotor functions and inflammation in aged mice expressing E3 and E4 
isoforms of human APOE in C57Bl/6j background. Second, we investigated the impact of age 
and peripheral infection on the outcome of ischemic stroke. Finally, we studied the therapeutic 
efficacy SSO, a known inhibitor of CD36, against ischemic damage.  
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2 Review of the Literature 
2.1 STROKE 
2.1.1 Epidemiology 
2.1.1.1 Mortality and prevalence 
Stroke is characterized by diminished blood flow and hence compromised delivery of oxygen 
and nutrients into the discrete area of the brain. In addition to life-threatening properties, stroke 
often leaves the patients with long term disability and long term institutionalization and 
therefore adds to the economic burden of the society. Stroke is a disease affecting mostly older 
people. Annually, about 16 million people suffer from new stroke which claim the lives of 
nearly 5.7 million worldwide (Strong et al., 2007). About 85%-87% of the deaths are accounted 
on low and middle income countries. In the United States alone, approximately 610 000 of new 
stroke cases are reported every year. In addition, 185 000 people are susceptible to recurrent 
stroke. Between the ages of 55-75, the lifetime risk of stroke in women is about 20% and in men 
is 14%-17% (Roger et al., 2012).  The situation is worse in Europe where stroke accounts for 
almost 1.1 million deaths each year. In the European Union alone, stroke is the second most 
common cause of death after cardiovascular disease and accounts for over 460 000 death each 
year. In particular, women have higher mortality and poorer outcome compared to men (ESC, 
2012). Mortality from stroke is higher in Eastern and Central Europe (Truelsen et al., 2006). In 
Finland, approximately 14 000 people suffer from stroke every year according to the data from 
2007 (Ruuskanen et al., 2010). Stroke prevalence in Finland in 2009 was estimated around 82,000 
which is approximately 1.5% of the total population (Meretoja et al., 2010).  
2.1.1.2 Economic burden 
Given the second largest cause of disease worldwide, it is no wonder that the economic global 
burden caused by cerebral infarction is huge. Stroke accounts for approximately 3% of the total 
health care expenditure in the industrialized nations. The direct and indirect cost of stroke in US 
in 2008 was around $34.3 billion (Roger et al., 2012). In EU, Stroke cost around €19 billion of the 
health care system due to direct health care costs. An additional cost of productivity losses and 
informal care is estimated to cost €19 billion more. In Finland, annual nationwide cost for stroke 
is around €1.1 billion which is around 7% of the national health care expenses (Meretoja et al., 
2011). 
2.1.2 Types of stroke 
2.1.2.1 Ischemic stroke  
Ischemic stroke can be classified into thrombotic, embolic, lacunar stroke and stroke of other 
known and unknown etiologies. Cerebral thrombosis or thrombotic stroke accounts for 50% of 
all ischemic strokes and results from thrombus formation at the clogged part of the vessels. 
Embolic stroke constitutes about 20% of all cases and results from the clot formed at a distinct 
site that often dislodges and enters into the bloodstream and travels to block one of the brain 
arteries. Lacunar stroke or small vessel disease is caused by blockage of deep penetrating 
branches of large vessels and accounts for 20% of stroke cases (Warlow et al., 2003). Occlusion 
of the blood vessels by either thrombus or embolus limits the supply of nutrients and oxygen to 
the brain tissue. This event activates ischemic cascade that ultimately damages the core area of 
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the brain and often leads to sensorimotor deficits and cognitive impairments on the affected 
individuals. 
2.1.2.2 Hemorrhagic stroke 
Hemorrhagic stroke is caused by the rupture of the weaker vessels inside the skull, either into 
the brain or into the fluid that surrounds the brain. Intracerebral hemorrhage (ICH) occurs 
when the blood vessels inside the brain rupture and leak into the surrounding area of the brain 
tissue. It accounts for 10% of all stroke cases (Roger et al., 2012). ICH is usually  caused by 
hypertension, brain tumors, aneurysms, amyloid angiopathy, arteriovenous malfunctions, etc. 
(Caplan, 2006). Primary ICH caused by rupture of arteries due to hypertension and amyloid 
angiopathy accounts for 78-88 % of all cases. Secondary ICH is caused by  vascular 
abnormalities and accounts for the remaining cases (Qureshi et al., 2001).  ICH mainly occurs in 
basal ganglia, cerebral lobes, thalamus, cerebellum and brain stem and is usually associated 
with hematoma formation that may expand over time into the surrounding area due to 
continuous bleeding from the primary source (Brott et al., 1997).   
 Subarachnoid hemorrhage (SAH) occurs due to rupture of the arteries between the pia mater 
and arachnoid space and hence the extravasation of blood into the subarachnoid space (Suarez 
et al., 2006). It is most commonly due to aneurysm, ballooning of the weakened region of the 
blood vessels and accounts for 3% of all stroke cases (Roger et al., 2012).  The mortality from this 
type of hemorrhage  is high, and 40% of the patients die within 30 days following the accident 
(Kissela et al., 2002). Smoking, hypertension and alcohol abuse are the most common cause of 
SAH. Other types of hemorrhage, epidural and subdural hemorrhage, are most commonly 
caused by traumatic brain injury (TBI). 
2.1.3 Cerebral metabolism and ischemic stroke 
The brain’s metabolic requirement accounts for 20% of the total oxygen consumed by our body. 
The brain cannot store enough glucose substrate necessary to produce ATP for the maintenance 
of membrane potentials, ionic transport and transport of neurotransmitter. Thus, the brain 
needs a constant supply of oxygen and glucose in order to maintain functional and structural 
integrity. 
In a normal adult brain, Cerebral Blood Flow (CBF) through the whole brain is 
approximately 46ml/100g/min (Lund Peter et al., 1993). CBF threshold for gray and white 
matter are about 75ml/100g/min and 45ml/100g/min respectively. CBF remains relatively 
constant despite moderate hypoperfusion through a mechanism of cerebral autoregulation. In 
the case of ischemia or hypoperfusion, the reduction in blood flow is compensated by the 
vasodilation of blood vessels, cumulative extraction of oxygen and glucose from the circulation. 
With the further fall in CBF below 15-20ml/100g/min, neuronal electrical activity cease, ATP 
declines, lactate level rises and pH declines. With further decline in CFB, potassium floods out 
of the cell, the intracellular level of calcium and sodium increases and the cell viability is lost 
(Hossmann, 1994, Markus, 2004). The amount of permanent damage depends on the degree and 
the duration of ischemia. The reduction in CBF is most severe in the central territory known as 
the core. However, the peripheral area is less severely affected due to additional flow provided 
by collateral circulation (Symon et al., 1976). Cells that are in the central area or the core are 
destined for death while those in the periphery or penumbra area are potentially salvageable by 
intervention (Astrup et al., 1981). In rodent models, when the blood flow is reduced to about 5-
10%, cells in the core area die within a matter of minutes due to homeostatic failure, neuronal 
and glial depolarization and loss of synaptic transmission. Energy failure further leads to the 
accumulation of glutamate in the extracellular space. Elevated glutamate in synaptic terminals 
binds to NMDA and AMPA receptors in post synaptic neurons and results in excessive calcium 
influx into the postsynaptic neurons ultimately initiating ischemic cascades contributing to cell 
death (Dirnagl et al., 1999). 
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Cells in the penumbra area are functionally impaired but might recover if the biochemical 
processes leading to cell death are interrupted by therapeutic means. In the penumbra, CBF is 
reduced to about 10-20ml/100g/min (Ginsberg, 2003). In this state, electrical neuronal function 
does not exist but the levels of ATP are maintained to preserve cellular energy stores. Cells in 
the penumbra region can thus be rescued if the CBF is restored. 
 
Figure 1: Ischemia thresholds for various metabolic and functional disturbance and formation of 
ischemic lesion. The values of CBF might vary between the animals. (Figure modified from Markus, 
2004) 
2.2 PATHOPHYSIOLOGY OF ISCHEMIC STROKE 
This blockage of blood flow during ischemic stroke results in destruction and damage of the 
brain cells and is often accompanied by sensorimotor deficits and cognitive impairment in both 
clinical and preclinical subjects. Ischemia can be either of short duration with subsequent 
restoration of blood flow and hence minimal damage to the brain tissues or of long duration 
without restoration of blood flow and significant damage to brain tissues. Ischemic stroke is a 
cascade of complex and coordinated events and leads to cell death through either necrosis or 
apoptosis. Ischemic insult for a few minutes results in a dramatic reduction of blood flow and 
subsequent energy failures that are accompanied by ionic imbalance, acidosis, excitotoxicity, 
oxidative stress, cytotoxicity, blood brain barrier (BBB) disruption, glial cell activation and 
leukocyte infiltration. These series of events lead to acute, irreversible necrotic cell death at the 
core area which is characterized by cellular swelling, disruption and disintegration of cellular 
components and extrusion of cellular content into the extracellular space (Woodruff et al., 2011). 
In addition, an excitotoxic mechanism during the early phase of ischemia triggers a number of 
cellular and molecular events that contribute to delayed cell death through inflammation and 
apoptosis (Dirnagl et al., 1999). 
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Figure 2: Acute and delayed damage following focal cerebral ischemia. Excitotoxic mechanisms can 
damage neurons and glial cells very early following the ischemic insults. Excitotoxicity can give rise 
to peri-infarct depolarization, inflammation and apoptosis that can lead to subsequent brain damage 
over the course of days. The X and Y axis represent the evolution of the cascade over time and the 
impact of individual elements of the cascade respectively. (Figure modified from Dirnagl et al. 
1999). 
2.2.1 Lactic acidosis 
The brain needs a constant supply of ATP to maintain the ionic gradient across the cell and 
synaptic integrity. However, following ischemia, brain cells cannot produce ATP and the 
metabolism shifts towards anaerobic respiration that contributes to the rise in the level of lactic 
acid and hence  a fall in pH (Combs et al., 1990). The increased amount of H+ ions attracts water 
molecules inside the cells and causes swelling and edema.  Even though lactic acidosis is not a 
sole contributor to injury following cerebral ischemia, it does contribute to the pathophysiology 
of ischemia and impairs post-ischemic outcome especially in hyperglycemic cases (Rehncrona et 
al., 1981, Siesjö et al., 1990). The levels of lactate are more in the penumbra region than the core 
due to residual blood flow. In addition, pre-ischemic hyperglycemia has been shown to further 
increase the lactate production resulting in deleterious effects in experimental animals 
(Folbergrova et al., 1992, Young et al., 1992).  
2.2.2 Necrosis 
Necrosis results in premature death of cells and is morphologically characterized by swelling of 
the cell and organelles, disruption of plasma membrane and loss of intracellular contents. 
(Kroemer et al., 2009). Necrosis, also known as mortification of tissues, results from extrinsic 
insults like hypoxia, ischemia, hypoglycemia, TBI, etc. Disruption of membrane structure and 
functional integrity, influx of water and Ca2+ , impairment of oxidative phosphorylation, 
depletion of high energy phosphate and subsequent dissolution of the cells are hallmarks of 
necrotic cell death (Martin et al., 1998). Necrotic cell death can be classified into edematous and 
homogenizing cell death. Edematous cell death is characterized by irregular clumping of 
chromatin and fragmentation of the endoplasmic reticulum (ER), Golgi apparatus and 
polysome. Ribosomes often accumulate around the nucleus. In this type of cell death, 
microtubules and other filamentous structure are  absent, and cytoplasm is often clear (Lipton, 
1999).  Homogenizing cell change is accompanied by pronounced darkening and shrinkage of 
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the nucleus and cytoplasm with irregular chromatin clumping (pyknosis). The cells often 
assume triangular shape with strong acidophilic cytoplasm (Lipton, 1999).  
Necrotic cell death has been widely described in both focal ischemia and global ischemia. 
Cornu Ammonis area 1 (CA1) neurons of the hippocampus in an animal model of global 
ischemia has been shown to exhibit morphological features of necrotic cell death (Colbourne et 
al., 1999, De Souza Pagnussat et al., 2007). In focal ischemia, necrosis accounts for acute cell 
death within the core area in contrast to apoptosis that primarily occurs in the penumbra area 
(Kametsu et al., 2003, Li et al., 1995). Metabolic changes leading to cell death by necrosis in focal 
ischemia involves excitotoxicity triggered by overactivation of glutamate receptors, intracellular 
calcium overload, and downstream activation of catabolic enzymes and increased production of 
free radicals (Snider et al., 1999). Oxidative stress is the key mediator of cell death in ischemia 
reperfusion injury. During this process, mitochondrial permeability transition pore (MPTP) 
opens in response to Ca2+ overload. Opening of the MPTP pore allows water, ions and large 
molecules to enter freely into the mitochondrial matrix and hence impairs the mitochondrial 
respiratory chain. The impairment in mitochondrial respiratory chain is followed by release of a 
large amount of ROS  and subsequent necrotic cell death (Gouriou et al., 2011). Inflammation 
often accompanies necrosis due to cytoplasmic contents spilling into the extracellular space 
triggering the activation of inflammatory mediator cells (Festjens et al., 2006). In the case of 
cerebral ischemia, necrosis and apoptosis overlap and elements of both processes can occur 
within the same cell. Programmed necrosis or necroptosis has been shown to be initiated by 
death domain receptors including TNF receptor (TNFR)-1, Fas receptor (FasR) and TRAIL-
Receptor (Kroemer et al., 2009). In addition, Toll like receptors (TLR)-3 and TLR4 also 
participate in necrosis (Kroemer et al., 2009). 
2.2.3 Apoptosis 
Apoptosis or programmed cell death is essential for embryonic development, normal cell 
turnover, and development and functioning of the immune system (Elmore, 2007). However, 
apoptosis also contributes to neuronal death in various neurodegenerative diseases including 
ischemic stroke, AD and Parkinson’s disease (PD) (Elmore, 2007). During apoptosis,  there is 
rounding-up of cells, chromatin condensation, nuclear fragmentation, reduction in cellular 
volume, plasma membrane blebbing and finally engulfment by phagocytic cells (Kroemer et al., 
2009). Cell death by apoptosis occurs via several receptors or factors and involves two different 
mechanisms; caspase dependent pathways and caspase independent mechanism 
Caspases are the family of structurally related cysteine protease enzymes consisting of a 
pentapeptide motif Gln-Ala-Cys-X-Gly where X is Arg, Gln or Gly (Earnshaw et al., 1999). 
These proteases cleave target proteins after an aspartate residue and irreversibly commit the 
cells to die (Earnshaw et al., 1999). Caspases are synthesized as inactive zymogens. These 
inactive zymogens contain a prodomain which when cleaved in presence of several apoptotic 
upstream signals results in two separate subunits of 10kD and 20kD that dimerize to form the 
active enzyme (Rotonda et al., 1996). Caspases can be classified into two different subfamilies, 
pro-apoptotic and non- apoptotic. In human, caspases 2, 3, 6, 7, 8, 9 and 10 are pro-apoptotic 
candidates and are involved in mediating cell death signaling.  Non-apoptotic caspases include 
caspase 1, 4, 5 and 14 and are involved in cytokine maturation during inflammation (Pop and 
Salvesen, 2009). Alternatively, caspases can be classified as “initiator caspases” that are 
activated by oligomerization induced autoprocessing and “effector caspases” that are activated 
by initiator caspases and cleave a diverse array of cellular target. Initiator caspases include 
caspases 1, 2, 4, 5, 8, 9 and 10; and effector caspases includes caspases 3, 6 and 7 (Li and Yuan, 
2008, Pop and Salvesen, 2009).  
Depending on the origin of death stimuli, the caspase cascade can be activated by either 
intrinsic pathway involving mitochondria or extrinsic pathway involving death receptors 
(Danial and Korsmeyer, 2004). The intrinsic pathway mediated by mitochondria involves 
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release of several proteins into the cytoplasm from the intermembrane space of the 
mitochondria in response to apoptotic stimuli. Of the various proteins released into the 
cytoplasm, proapoptotic protein cytochrome c binds to ATP and activates apoptotic protease 
activating factor 1 (Apaf-1). Apaf-1 oligomerizes and recruits procaspase 9 to form apoptosome. 
Activated caspase 9 further cleaves procaspase 3 to generate active caspase 3 to induce 
apoptosis by cleavage of downstream mediators (Zou et al., 1997). The extrinsic or death 
receptor pathway involves binding of the death ligand like FasL to its receptor FasR and 
forming a death-inducing signaling complex (DISC) (Muzio et al., 1996). The DISC complex 
catalyzes the proteolytic cleavage of procaspase 8 to form caspase 8. The activated caspase 8 is 
then released from the DISC complex to initiate  downstream cleavage of caspase 3 (Kischkel et 
al., 1995). 
Another form of caspase independent apoptotic cell death has been documented in a number 
of studies in which proapoptotic protein like apoptosis inducing factor (AIF) and endonuclease 
G (Endo G) induces neuronal death due to increase intracellular Ca2+ concentration. Endo G and 
AIF are released from mitochondria in response to cellular stress and translocate to the nucleus 
where they promote DNA fragmentation and chromatin condensation (Joza et al., 2001, Li et al., 
2001a). 
 
Figure 3: Activation of the caspase cascade by a) extrinsic pathway and b) intrinsic or mitochondrial 
pathways. The extrinsic or death receptor pathway is initiated at the plasma membrane whereas the 
intrinsic or mitochondrial pathway is triggered by intracellular stimuli. In both pathways, initiator 
caspases catalyze the activation of executioner caspase like caspase 3 ultimately leading to cell 
death by apoptosis. Figure modified from (Galluzzi et al. 2009). 
In an animal model of focal ischemia, rapid depletion of energy leads to cytotoxic 
accumulation of intracellular Ca2+ that in turn initiates a series of events in both cytoplasm and 
nucleus ultimately leading to cell death. Focal ischemia promotes delayed neuronal death in the 
penumbra through FasR activation, mitochondrial release of cytochrome c, AIF and calpain in 
response to elevated intracellular Ca2+ and ROS thus leading to activation of caspase 3. Caspase 
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3 activation results in DNA fragmentation and cell death (Cho and Toledo-Pereyra, 2008, D'Orsi 
et al., 2012, Fujimura et al., 1998, Martin-Villalba et al., 1999, Namura et al., 1998).  
2.2.4 Glutamate and excitotoxicity 
Neurotransmitters such as glutamate and aspartate are vital for neuronal plasticity and are 
essential for normal neuronal function. Following ischemia, glutamate is released in excessive 
amounts into the extracellular space as a result of ionic pump failure as well as failure of 
reuptake mechanism which is an active energy dependent process (Choi and Rothman, 1990). 
This subsequent accumulation of glutamate leads to the prolonged activation of glutamate 
receptors in surrounding neurons enhancing the influx of Ca2+, Na+  and water into the 
postsynaptic neurons. Excessive accumulation of Ca2+ in the postsynaptic neurons or calcium 
overload triggers various downstream processes that have a detrimental effects on cellular 
integrity through activation of proteases, lipases and nucleases (Ankarcrona et al., 1995, Lo et 
al., 2003). In addition, production of nitric oxide (NO), arachidonic acid and superoxides by 
enzymatic reaction of neuronal nitric oxide synthase (nNOS), phospholipase A2 and other 
calcium dependent enzyme further enhances the cell death (Moskowitz et al., 2010). 
 Glutamate receptors can be subdivided into two main groups, ionotropic and metabotropic 
glutamate receptors (mGluRs). Ionotropic glutamate receptors are directly coupled to ion 
channels. Unlike ionotropic glutamate receptors, mGluRs are coupled G protein and 
phospholipase C to produces inositol-1, 4, 5-triphosphate (IP3) and diacylglycerol both of which 
act as intracellular second messenger (Traynelis et al., 2010, Niswender and Conn, 2010). The 
directly coupled ionotropic receptors are of three different types: N-methyl-D-aspartate 
(NMDA) receptors, α-amino-3-hydroxy-5-methyl-isoxazolepropionate (AMPA) receptors and 
kainate receptors (Traynelis et al., 2010). The mGluRs are divided into 3 families (group I, II and 
III) consisting of eight different receptors (Niswender and Conn, 2010). 
The NMDA receptors are glutamate gated ion channels that have an essential role in many 
neurological processes ranging from regulation of synaptic function, memory, cognition and 
learning (Carroll and Zukin, 2002, Mori and Mishina, 1995). In the brain, functional NMDA 
receptors are expressed in microglia, astrocytes and oligodendrocytes in addition to neurons. 
The NMDA receptors are composed of an NR1 subunit that combines with one or more NR2 
subunits (NR2A-NR2D) and in some cases an NR3 subunit (Chen et al., 2008). Thus, the identity 
of the NR2 subunit determines biophysical and pharmacological properties of NMDA receptors 
that ultimately influence the downstream signaling.  
AMPA receptors are also widespread in the CNS like NMDA receptors with fast synaptic 
transmission at excitatory synapses. AMPA receptors are composed of four subunits GluR1-
GluR4 and are encoded by separate genes. These receptors are crucial for normal neuronal 
development, synaptic plasticity, and structural remodeling (Liu and Zukin, 2007). AMPA 
receptors devoid of GluR2 subunit typically present in spiny neurons are permeable to Ca2+ and 
can contribute to neuronal injury following ischemia (Szydlowska and Tymianski, 2010). In 
addition, ischemic events promote internalization AMPA receptors containing GluR2 subunit 
from the synaptic terminals and mobilize AMPA receptors lacking GluR2 to the synaptic site 
thus contributing to bigger damage (Liu et al., 2006).  
Kainate receptors, also known as non-NMDA receptors, are difficult to distinguish from 
NMDA receptors. Kainate receptors are involved in synaptic plasticity (Lerma, 2003). They are 
localized in presynaptic and postsynaptic terminals of excitatory neurons.  Subunits of kainate 
receptors bear resemblance to NMDA receptors in transmembrane topology and stoichiometry. 
Kainate receptors can be divided into two groups based on the affinity to kainic acids. High 
affinity KA1 and KA2 and low-affinity GluR5-7 are found to be involved in excitotoxic cell 
death (Collingridge et al., 2004). 
Metabotropic glutamate receptors, mGluRs, are also important for synaptic plasticity in 
addition to contributing to excitotoxicity (Doyle et al., 2008). There are 8 subtypes of receptors 
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that are divided into three groups. Group I receptors (mGlu1 and mGlu5) are abundantly 
expressed in the postsynaptic membrane and modulate NMDA and AMPA receptors activity 
thus increasing neuronal excitability. Group II (mGlu2 and mGlu3) and group III (mGlu4, 
mGlu6, mGlu7, mGlu8) are found in presynaptic terminals of neurons as well as in astrocytes 
and are involved in inhibition of glutamate release at synaptic cleft (Bruno et al., 2001).  
Both ionotropic and mGluR have been implicated in the pathophysiology of stroke. NMDA 
receptors are calcium permeable channels and further opening of these channels by glutamate 
leads to greater Ca2+ load contributing the excitotoxic cell death (Doyle et al., 2008). Likewise, 
Ca2+ impermeable AMPA receptors containing GluR2 is reduced with a concomitant increase of 
Ca2+ permeable AMPA receptor contributing to delayed cell death in hippocampal cell in 
response to global ischemia (Liu et al., 2006, Pellegrini-Giampietro et al., 1992). MGluR like 
mGluR1/5 acts via phospholipase C and IP3 and triggers the release of Ca2+ from intracellular 
stores like ER thereby triggering ER stress and apoptosis. The potential culprit, Ca2+, in addition 
to activating various phospholipase, protease and nucleases can also trigger mitochondrial 
outer membrane depolarization and contribute to excitotoxic cell death (Green and Kroemer, 
2004).  
Given the plethora of effect of calcium toxicity in the preclinical settings, it has attracted 
numerous attentions to developing a therapeutic antagonist or drugs against glutamate 
receptors to treat stroke patients. Indeed, a number of drug targeting AMPA and NMDA 
receptors have undergone clinical trials but with no positive outcome (Ginsberg, 2008). This 
might be attributed to the fact that the NMDA-AMPA pathway is just part of a bigger picture 
given that glutamate independent calcium influx also ensues following ischemia. In addition, 
subunit composition of NMDA receptors also differentially regulates neuronal survival and 
death. Moreover, the drugs might have targeted almost all the receptors so an alternative 
approach should be chosen to target only the excessive channel opening. Thus, more in-depth 
knowledge about the diverse response following the receptor interaction and response of 
secondary messenger during ischemic stroke would provide a clue for successfully targeting 
excitotoxicity for the treatment of ischemic stroke (Moskowitz et al., 2010). 
2.2.5 Oxidative and nitrosative stress 
Cells can detoxify oxidants and free radicals that are produced during normal aerobic 
metabolism. However, during ischemia and other neurodegenerative events, ROS such as 
hydrogen peroxide (H2O2), superoxide anion (O2-) and hydroxyl radicals (·OH) are produced in 
overwhelming amounts through various mechanisms leading to oxidative stress. Mitochondria, 
for example, are the main producers of oxygen free radicals following ischemic injury due to 
high levels of calcium, sodium and adenosine diphosphate (ADP). The formation of MPTP 
following ischemia in response to Ca2+ overload leads to an oxygen-free radical burst. In 
addition, inflammatory processes involving synthesis of prostanoid and hypoxanthine 
degradation also produces oxygen radicals (Lo et al., 2003). Likewise, Nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase also produces superoxide anions during NMDA 
receptor activation following ischemia devoid of mitochondrial origin (Girouard et al., 2009). 
Brain have limited amount of antioxidant enzymes (superoxide dismutase (SOD), catalase 
and glutathione peroxidase) and antioxidant molecules (α-tocopherol, ascorbic acids and 
glutathione). Following neuronal injury, endogenous scavenging mechanism cannot detoxify 
excessive generation of free radicals. These excessive free radical thus damages lipids, proteins 
and nucleic acids (Chan, 2001). Free radicals inactivate and damage cellular proteins like ionic 
Ca2+ and Na+ pumps, creatine kinase and mitochondrial dehydrogenases through oxidation of 
side chains and disulphide bonds. Nucleic acid damage by free radicals occurs through the 
breakage of single- and double-stranded DNA and chemical modification that link the protein 
to DNA (Mohr et al., 2011). In mitochondria, oxygen radicals and oxidative stress participate in 
the release of apoptosis-related protein like cytochrome c through the formation of MPTP and 
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thus triggers apoptosis (Kroemer and Reed, 2000). Beside cellular damage, free radicals also 
promote BBB damage through the activation of matrix metalloproteinase (MMP) and 
endothelial dysfunction (Brouns and De Deyn, 2009).   
NO and related oxidation products are also key players in metabolic stress. NO, synthesized 
by nNOS in neurons, is an important mediator for NMDA mediated downstream signaling and 
synaptic plasticity. In addition, NO is involved in NMDA mediated excitotoxicity, inhibition of 
key mitochondrial enzymes, DNA damage and Poly ADP ribose polymerase (PARP) activation, 
etc. (Moskowitz et al., 2010). NO can combine to superoxide anions thereby forming 
perioxynitrite. Following ischemia, peroxynitrite can oxidize key mitochondrial enzymes like 
cytochrome c oxidase promoting the formation of a mitochondrial transition pore thus releasing 
AIF and causing the apoptosis of the cells. Peroxynitrite can produce hydroxyl radicals, the 
most reactive oxygen free radicals, and superoxide anions that are efficient in damaging the 
tissues in a very short time (Brouns and De Deyn, 2009, Kunz et al., 2007b).  
The importance of oxidative and nitrosative stress in cerebral ischemia have been highlighted 
in a number of studies.  In experimental stroke models, transgenic mice overexpressing SOD 
have been demonstrated to have smaller brain infarcts while those with reduced expression 
(SOD deficient mouse) have been found to have bigger ischemic damage (Fujimura et al., 1999, 
Kinouchi et al., 1991, Sheng et al., 1999). Likewise, nNOS and inducible nitric oxide synthase 
(iNOS) deficient mice are also found to exhibit reduced ischemic damage compared to their 
wild-type counterparts (Huang et al., 1994, Iadecola et al., 1997). Neuroprotection in cerebral 
ischemia have also been shown in a number of rodent studies that used agents with antioxidant 
properties like vitamin E, ebselen, tirilizad, etc. (McColl, 2004). Owing to the neuroprotective 
effect of antioxidants, a novel way of suppressing deleterious radicals without interfering their 
endogenous functions is critical for designing and testing the efficacy of antioxidant therapies 
(Moskowitz et al., 2010). 
2.2.6 Inflammation 
Inflammation is a biological response or defense mechanism of the immune system to harmful 
stimuli, such as pathogens, irritants or damaged cells in order to eliminate them and repair the 
surrounding tissues. Classically, inflammation is characterized by redness, swelling, heat and 
pain as well as loss of function in some cases.  Inflammation can be divided into two types. 
Acute inflammation is the transient and early response of tissue to injury and is characterized 
by movement of leukocytes and plasma to the injured tissues (Medzhitov, 2008). Chronic 
inflammation is an inflammatory response of prolonged duration lasting for months to years 
due to the persistence of the causative stimulus like persistent infections, immune-mediated 
inflammatory disease and prolonged exposure to harmful toxins (Kumar et al., 2012, 
Medzhitov, 2008). Inflammation is mediated by complex sets of mechanisms that involve both 
the cellular and molecular components.  
In cerebrovascular disease, acute inflammatory reaction occurs in the affected area for days 
to weeks post injury and contributes to the progression of the delayed brain damage with 
worsened neurological outcome. Following ischemic stroke, depletion of energy and increase in 
ROS induce the synthesis of several transcription factors, including nuclear factor-kappaβ (NF-
kB), hypoxia inducible factors and Stat3, ultimately leading to the production of inflammatory 
cytokines and chemokines (Dirnagl et al., 1999). Likewise, expression and activation of adhesion 
molecules on the endothelial surface leads the early accumulation of inflammatory cells from 
the periphery into the ischemic brain. These blood borne inflammatory cells along with cells in 
the brain like microglia and astrocytes constitute the cellular components of inflammation. They 
together produce a variety of cytotoxic cytokines and chemokines which function as molecular 
mediators of inflammation contributing to the tissue damage (Emsley and Tyrrell, 2002, Wang 
et al., 2007) 
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2.2.6.1 Cellular components of inflammation 
Following ischemia, inflammatory response is characterized by a rapid activation of the 
resident phagocytic microglial cells. This activation is followed by the subsequent infiltration of 
circulating inflammatory leukocytic cells including neutrophils, monocytes/macrophage and T 
cells (Jin et al., 2010). Recently, the role of astrocytes in mediating post-ischemic inflammation 
has also been addressed in many studies. 
Leukocytes 
Leukocytes have been demonstrated to be involved in a number of preclinical and clinical 
stroke studies (Kochanek and Hallenbeck, 1992). Leukocytes are produced and derived from 
multipotent hematopoietic stem cells and can be divided into granulocytes (polymorphonuclear 
leukocytes) and agranulocytes (mononuclear leukocytes). Granulocytes include neutrophils, 
basophils and eosinophils while agranulocytes include lymphocytes, monocytes and 
macrophages. Acute phase of ischemia is characterized by the production of cytokines like IL-
1β, IL-6 and TNF-α, and chemokines including monocyte chemoattractant protein-1 (MCP-1) 
and macrophage inflammatory proteins (MIP)-1α. These mediators induce the expression of the 
adhesion molecules such as intracellular cell adhesion molecule-1 (ICAM-1), E-selectin, P-
selectin and integrins on the endothelial cells and leukocytes and promote the transmigration of 
circulating leukocytes (Amantea et al., 2009, Yilmaz and Granger, 2008). Infiltrating leukocytes 
have the capacity to release a wide array of cytokines and chemokines further activating 
resident cells as well as promoting even more infiltration of leukocytes thus leading to BBB 
damage, neuronal death and edema (Amantea et al., 2009, Jin et al., 2010). 
Neutrophils are the first leukocytes to infiltrate into the brain in response to ischemia and 
may cause injury by secreting inflammatory mediators (Hallenbeck, 1996). They appear as early 
as 30 minutes to a few hours after the onset of ischemia with the peak at 24-72 hours and then 
diminish rapidly within 7 days in ischemic brain parenchyma of rodent models (Garcia et al., 
1994, Jin et al., 2010, Kriz, 2006). However, in disagreement with current views, one study 
proposed the infiltration of other inflammatory cells, including macrophages, lymphocytes and 
dendritic cells prior to neutrophils (Gelderblom et al., 2009). The importance of neutrophil 
infiltration into the brain parenchyma have been demonstrated in a number of studies and 
inhibition of neutrophil infiltration has been linked with the significant reduction in brain 
damage (Wang et al., 2007).  
Monocytes/macrophages are also the abundant immune cells that enter the brain after 
ischemia. Circulating monocytes are detected in capillaries of the ischemic area 4-6 hours after 
the onset (Garcia et al., 1994). Concomitantly, macrophages infiltrate to the core within 24 hours 
and persist for up to 14 days (Schroeter et al., 1994). Blood derived macrophages are found to be 
abundantly recruited into the ischemic area at day 3-7 post-stroke in contrast to resident 
microglial cells which are already activated at day 1 after ischemic onset (Jin et al., 2010). 
Lymphocytes, especially T lymphocytes, recruit into the brain at the later stage of brain 
injury. T cells were found to infiltrate the border zone 3 days after an ischemic event and their 
infiltration further increased between days 3 and 7 (Jander et al., 1995, Stevens et al., 2002). 
However, other studies have shown that T cells accumulate in ischemic brain within 24 hours 
following ischemia/reperfusion injury (Jander et al., 1995, Schroeter et al., 1994). Like 
neutrophils, lymphocytes are also associated with an increase ischemic brain damage and 
attenuation of lymphocytes was found to reduce stroke induced cell death (Becker et al., 2001). 
Clinical studies have shown lymphocytes to be implicated in stroke recurrence and death 
(Nadareishvili et al., 2004). 
Microglia 
Microglial cells are the resident immunocompetent and phagocytic cells in the CNS that renew 
throughout adult lifetime. Microglia have a plethora of physiologically important functions in 
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the brain. They control the synapse number, remodel the developing brain and remove cellular 
debris (Patel et al., 2013). Microglia exist in several different morphological phenotypes and 
exhibit various stages of activation. However, three major morphological phenotypes are 
described in the literature: amoeboid (activated phagocytic state), ramified (resting) and 
intermediate forms (activated state) (Kettenmann et al., 2011). Resting ramified microglia 
comprise about 5-20% of the neuroglia cell population in the CNS and act together with 
astrocytes and neurons to maintain normal brain homeostasis (Hansson and Rönnbäck, 2003, 
Kim and de Vellis, 2005). Resting microglia are capable of extensive movement through their 
thin ramified processes and provide surveillance system in mature and uninjured adult brain 
(Hanisch and Kettenmann, 2007, Nimmerjahn et al., 2005). This population of cells is less 
common in white matter compared to gray matter and can alter their morphology according to 
the brain microenvironment (Lawson et al., 1993). In response to various insults, resting or 
surveying microglia undergo morphologic transformation to the activated amoeboid 
phagocytes and increase their expression of cell surface markers that make them virtually 
indistinguishable from peripheral macrophage (Yenari et al., 2010). 
In response to the changing environment, activated microglia can undergo either classical 
activation (M1) or alternate activation (M2) and can release a wide variety of both cytotoxic and 
cytoprotective molecules. M1 is a proinflammatory state and is associated with upregulation of 
proinflammatory mediators, production of ROS and NO and secretion of proteolytic enzymes 
ultimately leading to destructive neuronal cell death (Kreutzberg, 1996, Patel et al., 2013, Yenari 
et al., 2010). Proinflammatory mediators released through M1 activation include interferon 
(IFN)-γ, IL-1β, TNFα and IL-6 (Hanisch, 2002, Patel et al., 2013). Likewise, proteases such as 
MMP9 and MMP3 can lead to BBB damage by damaging extracellular matrix.   
In contrast, M2 state is characterized by resolution of inflammation and maintenance of 
homeostasis through release of anti-inflammatory mediators like IL-10, transforming growth 
factors-β (TGF-β), IL-4, IL-13, Insulin-like growth factor 1, etc. TGF-β with a special role in 
tissue development and immune response acts to reduce the proinflammatory mediators thus 
alleviating the injury (Hanisch, 2002). The shift in the activation of microglia from resting stage 
to the activated stage involves various stages including the replacement of the ramified 
branches with a new type of mortile protusions (Stence et al., 2001).   
Upon ischemia, microglia are rapidly activated within hours and the activation persists for 
weeks.  Highly ramified resting microglia predominate the penumbra area whereas amoeboid 
microglia are abundant in the ischemic core (Perego et al., 2011). Amoeboid microglia and their 
shortened retracted processes are clearly seen in the ischemic core area 24 hours after 
reperfusion following 60 minutes of transient middle cerebral artery (MCA) occlusion (MCAo) 
(Mabuchi et al., 2000, Morrison and Filosa, 2013). Microglial activation after ischemic stroke 
involves activation of a variety of receptors in microglia. Upon ischemia, purinergic receptors 
mainly P2X7 and P2X12 on microglia are upregulated in the ischemic area. Upregulation of P2X7 
have been shown to promote microglial proliferation in addition to production of superoxide 
and release of proinflammatory IL-1β and TNFα (Yenari et al., 2010). In contrast, P2X12 receptor 
interact with integrin-β1 and is involved in microglial process extension and microglial 
migration towards the injury sites (Ohsawa et al., 2010). Microglia are also activated by 
stimulation of TLR, namely TLR-2 and TLR-4 leading to upregulation of several 
proinflammatory genes via NF-kB signaling. Endogenous ligands like purines, peroxyredoxin, 
heat shock proteins (HSP), high-mobility group box-1, etc. can act on TLRs and produce 
proinflammatory cytokines like IL-17, IL-33, IL-1β, TNFα and IL-6 (Patel et al., 2013, Yenari et 
al., 2010). Many experimental studies have demonstrated an adverse role of TLR-4 upon 
ischemia and a TLR-4 deficient mouse has been shown to have a robust neurological outcome 
following stroke (Becker et al., 2001, Nadareishvili et al., 2004, Perego et al., 2011). In addition, 
microglia expresses a wide variety of other receptors including cytokine receptors, 
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prostaglandin receptors and glutamates receptors. The activation of these receptors may 
ultimately influence the extent of brain damage following cerebral ischemia (Yenari et al., 2010). 
Astrocytes 
Astrocytes are the most abundant glial cells in the CNS and account for up to 50% of the human 
brain volume (Abbott et al., 2006). These cells contain 8-10 nm wide microfilaments composed 
of polymerized strands called glial fibrillary acidic protein (GFAP), a biomarker for astrocytes 
that can be visualized by immunohistochemistry. Astrocytes, mainly protoplasmic astrocytes, 
are endowed by extremely elaborated fine processes and are localized in gray matter. The 
processes of the protoplasmic astrocytes are in contact with the blood vessels to form 
perivascular endfeet in addition to forming multiple contacts with neurons. In contrast, fibrous 
astrocytes have less elaborate but long processes and are found in the white matter (Sofroniew 
and Vinters, 2010).  
Astrocytes serve a variety of functions that are vital for brain development and physiology. 
They guide the migration of developing axons and are involved in the regulation of 
synaptogenesis (Barres, 2008, Powell and Geller, 1999). In addition, astrocytes provide 
structural support and form functional architecture for neurons in the CNS through scaffold 
formation. Astrocytes in particular form a glial-vascular interface and are involved in the 
regulation of cerebral microcirculation across the BBB. These astrocytes provide metabolic 
support to neurons by providing energy substrates without which the neurons will essentially 
die (Sofroniew and Vinters, 2010). Astrocytes also control the CNS microenvironment through 
regulation of extracellular ion concentrations, extracellular pH, removal of neurotransmitters 
from extracellular space and maintenance of brain water homeostasis (Verkhratsky and Butt, 
2007). A growing number of evidence also support the notion that astrocytes are also involved 
in the synaptic signaling via intracellular calcium wave (Volterra and Meldolesi, 2005).  
Astrocytes are affected by ischemic injury very rapidly. Failure of energy driven pumps on 
astrocytes impair their ability to uptake glutamate that can subsequently lead to excitotoxic cell 
death and infarct expansion. In addition, reduced potassium spatial buffering also initiates a 
wave of peri-infarct depolarization further increasing the ischemic injury (Anderson and 
Swanson, 2000, Nedergaard and Hansen, 1993). Following neuroinjury, astrocytes can produce 
and respond to a broad array of cytokines including IL-1, -4, -6, - 10 and -12, IFN-α,-β and –γ, 
colony stimulating factors like granulocyte macrophage-colony stimulating factor, macrophage-
colony stimulating factor and granulocyte-colony stimulating factor (G-CSF), TNF-α, TGF-β.  In 
addition, they also produce chemokines such as regulated on activation, normal T cells 
expressed and secreted (RANTES), IL-8, MCP-1, and IFN-ϒ induced protein 10 (IP-10) 
(Benveniste, 1998). Following ischemia, astrocytes undergo proliferation, change in morphology 
and increase their GFAP expression, collectively known as astrogliosis (Hatten et al., 1991). 
Astrogliosis can affect the injured tissue in both positive and negative ways. It can promote 
neuronal survival through the secretion of growth factors and neurotrophins. Astrocytes can 
also protect the compromised tissue from further damage by taking up excess glutamate, 
rebuilding the blood brain barrier and providing essential metabolic support (Barreto et al., 
2011, del Zoppo, 2009, Sofroniew and Vinters, 2010). In contrast, astrocytes can inhibit neuronal 
survival and function through formation of a physical barrier known as an astroglial scar in the 
affected area. Following ischemia, the astrocytic gap junctions can open leading to the influx of 
proapoptotic factors through syncytium ultimately expanding the infarct size (Lin et al., 1998). 
Production of high levels of proinflammatory cytokines can be detrimental to ischemic recovery 
through apoptosis of neurons and inhibition of neurogenesis (Barreto et al., 2011).  
Astrocytes are almost dead in the ischemic core area whereas in the penumbra or peri-infarct 
area viable astrocytes undergo reactive astrogliosis. Astroglial activation can be seen within 
hours after ischemic insults rapidly peaking within 24 hours (Chen et al., 1993, Raivich et al., 
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1999). Taken together, these data suggest an important role of astrocytes in the pathophysiology 
of ischemic stroke and other neurodegenerative diseases. 
2.2.6.2 Molecular components of inflammation 
During the course of ischemic stroke and other neurodegenerative diseases, a wide array of 
inflammatory molecules is secreted by various signaling that can ultimately affect the outcome 
after the injury. Several cytokines, chemokines and inflammatory proteins are produced during 
the time course of an ischemic cascade and these are described hereunder. 
2.2.6.2.1 Cytokines 
Cytokines are a group of low molecular weight glycoproteins that are produced in response to 
an antigen and thus regulate both innate and adaptive immune responses. Cytokines are 
essential for the regulation of normal cellular functions during development in addition to 
maintaining homeostasis during infection, inflammation and traumatic and ischemic injury 
(Holloway et al., 2002). In the periphery, cytokines are secreted by activated macrophages, 
monocytes, endothelial cells, platelets and other cell types. However, in the CNS, cytokines are 
also expressed by resident neurons and glial cells in addition to being expressed by the cells of 
the immune system (Barone and Feuerstein, 1999). Peripheral immune cells like T lymphocytes, 
natural killer (NK) cells and polymorphonuclear leukocytes produce a variety of cytokines that 
can also contribute to the inflammation of the  CNS thus affecting the clinical outcome 
(Ferrarese et al., 1999). Following cerebral ischemia, proinflammatory cytokines like IL-1β, TNF-
α and IL-6 aggravate the inflammatory response. In contrast, anti-inflammatory cytokines like 
TGF-β, IL-10 and IL-1 receptor antagonist (IL-1ra) inhibit the expression of proinflammatory 
cytokines and reduce inflammation (Allan et al., 2005, Lakhan et al., 2009, Wang et al., 2007). 
Other cytokines are also involved in tissue damage and repair; however, the effects of these 
cytokines are less pronounced. 
Interleukin 1 (IL-1) 
The IL-1 family comprises of a group of 11 cytokines and is closely linked to innate immune 
responses. All IL-1 proteins except IL-1ra are synthesized as a precursor protein that is 
enzymatically cleaved to the mature forms by specific cellular proteases. Of these cytokines, IL-
1α, IL-1β and IL-1ra are extensively studied in experimental stroke (Dinarello, 2009).  
IL-1α is a dual-function cytokine as it takes part in extracellular receptor mediated effect 
characteristics of classical cytokines as well as its role in the nucleus (Cohen et al., 2010). IL-1α 
precursor protein is proteolytically cleaved by to its mature form by calcium activated cysteine 
protease, calpain. Biologically active precursor IL-1α are constitutively expressed in cell 
membrane of different cell types and can contributes to inflammatory properties of necrotic 
cells in response to insults (Werman et al., 2004).  
IL-1β is metabolically inactive and is converted to mature active IL-1β by an enzyme called 
IL-1β converting enzyme (Cerretti et al., 1992).  IL-1β is expressed at very low levels in the 
brain. However, in response to insult or injury, IL-1β is dramatically upregulated for several 
days (Allan and Rothwell, 2001). Following ischemia, elevation of IL-1β mRNA is observed 
within 15-30 minutes followed by increased levels of IL-1β protein in the next few hours 
(Buttini et al., 1994, Davies et al., 1999). Biphasic expression of IL-1β is also observed at 1 hours 
and 6-24 hours after reperfusion in transient global cerebral ischemia in the rat (Haqqani et al., 
2005). Activated microglia, astrocytes, neurons and endothelial cells account for the early 
production of IL-1β while the late production is accompanied by the influx of inflammatory 
cells into the CNS (Ceulemans et al., 2010, Legos et al., 2000, Rothwell and Luheshi, 2000). The 
toxic effect of IL-1β on brain damage was shown after the intraventricular administration of 
recombinant IL-1β after MCAo in rat (Yamasaki et al., 1995b). Even though IL-1β has been 
found to have a deleterious effect on cerebral ischemia; studies using knockout and transgenic 
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animals show how the situation is far more complex. For example, mice deficient in both IL-1α 
and IL-1β exhibited significantly attenuated ischemic damage after 30 minutes of transient 
occlusion whereas deficiency in either IL-1α or IL-1β had no effect on infarct size. This might be 
attributed to the compensatory mechanism of the IL-1 system (Boutin et al., 2001). IL-1β 
contributes to the neuronal loss through production and expression of other proinflammatory 
mediators in addition to stimulating its own production. In addition, it also contributes to the 
activation and proliferation of glial cells, stimulation of calcium influx into neurons and 
priming of endothelial cells for leukocyte adherence. Moreover, induction of IL-1β will also lead 
to increase level of IL-1ra that serves as an antagonist to IL-1β suggesting there is a balance 
between the level of IL-1β and IL-1ra following ischemia (Ceulemans et al., 2010). Likewise, IL-
1β also elevates the levels of IL-6 that is involved in worse neurological outcome and 
aggravated brain damage (Acalovschi et al., 2003, Vila et al., 2000). 
IL-1ra is an endogenous inhibitor for both IL-1α and IL-1β without any known agonist 
activity in the periphery and brain (Rothwell, 1999).  IL-1ra increases right after brain damage in 
rodents. Generally, expression of IL-1ra peaks after 30-60 minutes following IL-1β expression 
mainly in neurons (Loddick et al., 1997, Toulmond and Rothwell, 1995). In animal models of 
permanent and transient MCAo, administration of IL-1ra has been shown to reduce the infarct 
size, edema, glial activation and neuronal loss and improve neurological outcome (Banwell et 
al., 2009, Rothwell, 1999). In contrast, a neutralizing antibody to IL-1ra  has been shown to 
increase brain damage (Deb et al., 2010). Delayed administration of IL-1ra after 3 hours 
following 60 min occlusion of MCA was still significantly reducing the damage volume in rat 
(Mulcahy et al., 2003). Even though IL-1α and IL-1β are upregulated after the ischemic insults, 
the primary targets for IL-1ra might be IL-1β since of these two IL-1β is predominantly 
upregulated early after brain ischemia (Rothwell, 1999). IL-1ra has garnered a lot of attention 
since methionylated form of human IL-1ra was proven to be safe and effective in improving the 
neurological outcomes in patients with cortical infarct (Emsley et al., 2005).  
Tumor Necrosis factor-α (TNF-α) 
Tumor necrosis factor is a pleiotropic inflammatory cytokine with both neurotoxic and 
neuroprotective effects and is rapidly upregulated in response to CNS injury and inflammation 
(Pan and Kastin, 2007). TNF-α exerts its effects by binding to two different high affinity 
receptors, TNFR1 and TNFR2. TNF-α activates a number of other secondary proteins including 
transcription factors like NF-kB, activator protein 1 (AP-1), protein kinases, phospholipases, 
mitochondrial proteins and caspases  to elicit the inflammatory process (Idriss and Naismith, 
2000). For example, TNF-α upon binding to TNFR can recruit TNF-α receptor associated death 
domain (TRADD) that serves as a platform for additional protein binding. Binding of Fas 
associated death domain to TRADD can activate caspases leading to cell death. In addition, 
TRADD can recruit TNF-α receptor associated factors (TRAFs) like TRAF-1 and TRAF-2 that 
can lead to activation of NF-kB. Especially, TRAF-2 is involved in transcriptional regulation of 
NF-kB. NF-kB can in turn regulate the expression of several pro and anti-inflammatory 
cytokines. Likewise, Mitogen-associated protein kinases (MAPKs) like JNKs and p38 kinases are 
also activated. These kinases lead to the activation of transcription factor AP-1 that is involved 
in several inflammatory processes (Chen and Goeddel, 2002, Gaur and Aggarwal, 2003, Wajant 
et al., 2003).  
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Figure 4: TNF signaling pathways. TNFR1 recruits and forms a complex with TRADD. More adapter 
molecules are then assembled on this platform where they initiate downstream events ultimately 
leading to inflammation and apoptosis. Figure modified from (Aggarwal, 2003).  
In addition to IL-1β, TNF-α also has a biphasic release pattern following ischemia, first peak 
at 1-3 hours and a second peak at 24 hours (Wang et al., 2007). TNF-α is expressed by both 
neurons and glia (Liu et al., 1994, Uno et al., 1997). The expression of TNF-α in neurons occurs 
earlier than in glial cells. A detrimental role of TNF-α has been documented in many studies 
where it contributes to neuroinflammation and neurodegeneration following brain injury. 
Inhibition of TNF-α has been shown to reduce brain injury while administration of recombinant 
TNF-α has been shown to exacerbate brain injury (Barone et al., 1997, Yang et al., 1998a). TNF-α 
promotes activation and proliferation of glial cells thus upregulating its own production and 
production of other neurotoxic mediators (Ceulemans et al., 2010). However, other studies have 
reported the protective effects of TNF-α and deletion of TNFR appears to have larger infarcts 
(Bruce et al., 1996). This inconsistency can be attributed due to different signaling pathways 
induced by binding of TNF-α to its receptors. Binding of the soluble form of TNF-α  to TNFR1 
can activate both pro and anti-inflammatory signaling via death receptors and can be a turning 
point for cell death or cell survival (Wang et al., 2007). Alternatively, membrane bound TNF-α 
that binds to TNFR-2 might be responsible for neuroprotection following injury (Ceulemans et 
al., 2010). Thus, neuroprotective and neurotoxic effects depend on the extent of glial cell 
activation, soluble and membrane forms of TNF-α signaling as well as the receptors that are 
activated in question. 
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Interleukin 6 (IL-6) 
IL-6 is another proinflammatory cytokine that is upregulated upon ischemia. IL-6 is detected as 
early as 4 hours following stroke and remains elevated in neurons and microglia in ischemic 
penumbra up to 14 days post-stroke (Block et al., 2000, Ceulemans et al., 2010, Suzuki et al., 
1999). Even though IL-6 contributes to inflammation, IL-6 deficient mice don’t show 
exacerbated lesions and neurological deficits compared to their wild type (WT) counterparts 
(Clark et al., 2000). This suggests that IL-6 has no influence in acute ischemic injury. However, 
there are other studies reporting either the beneficial or deleterious role of IL-6 (Clark et al., 
2000, Herrmann et al., 2003, Loddick et al., 1998, Matsuda et al., 1996). Following acute ischemic 
injury, levels of IL-6 are also upregulated in peripheral circulation and several studies have 
reported the association between peripheral levels of IL-6 and infarct volume (Acalovschi et al., 
2003, Fassbender et al., 1994, Smith et al., 2004, Vila et al., 2000). So, IL6 is often suggested as a 
good peripheral marker in patients with acute ischemic stroke (Smith et al., 2004). 
Transforming growth factor-β (TGF-β) 
TGF-β is an anti-inflammatory cytokine that is involved in a variety of cellular processes 
ranging from apoptosis, cell proliferation and differentiation to initiation and resolution of 
inflammation (Buckwalter and Wyss-Coray, 2004). In the CNS, three isoforms of TGF-β (TGF-
β1, TGF-β2 and TGF-β3) are widely expressed in neurons and glial cells.  Specifically, TGF-β1 is 
primarily produced by activated microglia with some production occurring in neurons as well. 
In contrast, TGF-β2 is primarily secreted by astrocytes and neurons (Ceulemans et al., 2010). 
Following ischemia, TGF-β can have both neuroprotective and neurotoxic effects. It can protect 
neurons by reducing glial activation and hence expression of cytokines, suppressing oxidative 
and nitrosative stress, promoting angiogenesis and reducing neutrophil adherence to 
endothelial cells (Pantoni et al., 1998). On the other hand, TGF-β can also promote glial scarring 
and fibrosis (Buckwalter and Wyss-Coray, 2004).  
Following stroke, increased expression of TGF-β1 mRNA and its protein have been observed 
in both human and rodent subjects (Krupinski et al., 1996, Yamashita et al., 1999). Several 
studies have suggested a link between increased levels of TGF-β1  and neuroprotection after 
cerebral ischemia (Ma et al., 2008, Pang et al., 2001, Wang et al., 1995b) while inhibition of TGF-
β1 leads to exacerbated brain damage (Ruocco et al., 1999). Since TGF-β expression mostly 
occurs in the recovery phase of some CNS diseases, it is suggested to have a protective function, 
and targeted overexpression of TGF-β1 might be a candidate for neuroprotection in stroke. 
Interleukin 10 (IL-10) 
IL-10 is another constitutively expressed anti-inflammatory cytokine that is produced mainly by 
microglia and astrocytes.  IL-10 can inhibit cytokines like IL-1 and TNF-α and their receptors 
thus providing neuroprotection after stroke. IL-10 can also promote cell survival by inhibiting 
both ligand and mitochondrial induced apoptotic pathways (Strle et al., 2001). Administrations, 
as well as gene transfer of IL-10, have been shown to reduce brain damage following brain 
ischemia (Ooboshi et al., 2005, Spera et al., 1998).  
2.2.6.2.2 Chemokines  
Chemokines also known as chemotactic cytokines are small inducible molecules that are 
structurally and functionally related to cytokines. Chemokines are 8-10 KDa molecules and are 
classified into four main subfamilies: CXC, CC, CX3C and XC (Mélik-Parsadaniantz and 
Rostène, 2008) and include more than 40 different members (Mennicken et al., 1999). Even 
though the majority of cytokines promote inflammation and adhesion between leukocytes and 
endothelial cells, they are poor attractants for guiding leukocytes and monocytes to the brain 
parenchyma (Pantoni et al., 1998). Thus, chemokines come into play to attract these 
inflammatory cells and guide their migration into the brain parenchyma. In addition to their 
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chemotactic properties, chemokines also participate in cytotoxicity, tumor cell growth, 
degranulation, T-cell activation, cell migration, apoptosis and cellular adhesion (Mélik-
Parsadaniantz and Rostène, 2008, Mennicken et al., 1999). Chemokines and their receptors are 
constitutively expressed in astrocytes, microglia and neurons and are upregulated in response 
to various neurodegenerative diseases and disorders (Luster, 1998). Chemokines bind to seven 
specific transmembrane domains and exert their effects through activation of G-protein and 
subsequently intracellular kinases (Baggiolini et al., 1997).  
Cytokines like IL-1α, IL-1β and TNF-α stimulate the production and secretion of chemokines 
following injury mediated inflammation. Chemokines, including cytokines induced neutrophil 
chemoattractant (CINC), monocyte chemoattractant protein (MCP), MIP, IL-8 and RANTES are 
expressed following cerebral ischemia and are thought to have deleterious effects by increasing 
leukocyte infiltration (Lakhan et al., 2009, Mennicken et al., 1999). 
Monocyte chemoattractant protein-1 (MCP-1)  
MCP-1, also known as chemokine ligand (CCL)2, is a member of the CC chemokine subfamily 
and is involved in the recruitment of monocytes to the site of injury and inflammation (Fuentes 
et al., 1995). MCP-1 is rapidly induced in neurons and glial cells following ischemia and is 
thought to exacerbate brain injury (Mélik-Parsadaniantz and Rostène, 2008). MCP-1 mRNA 
expression was shown to increase in the ischemic cortex at 6 hours followed by a peak at day 2 
after transient MCAo in models (Wang et al., 1995a, Yamagami et al., 1999). Blocking the 
activity of MCP-1 with antibodies or using MCP-1 deficient mice in transient and permanent 
MCAo are associated with smaller infarct size demonstrating that MCP-1 is involved in cerebral 
injury (Hughes et al., 2002, Kumai et al., 2004, Ono et al., 1999). In contrast, upregulation of 
MCP-1 was shown to have larger infarcts and increased infiltration of monocytes and 
macrophages to the ischemic core (Chen et al., 2003). MCP-1 also contributes to the migration of 
bone marrow stromal cells into the ischemic brain (Wang et al., 2002). In addition, MCP-1 
promotes the migration of neuroblast from ventricular region to the injury area suggesting its 
role in neurogenesis (Yan et al., 2007). Thus, MCP-1 might be deleterious in the early stage after 
stroke while beneficial at later stages. 
Macrophage inflammatory protein (MIP-1α and MIP-1β) 
MIP-1α, also known as CCL3, is involved in microglial and monocyte infiltration into the 
injured brain parenchyma. Increased expression of MIP-1α mRNA was observed at 6 hours and 
persisted for up to 48 hours following MCAo in rats (Kim et al., 1995). Microglia/macrophages 
were found to be the main sources of MIP-1α (Takami et al., 1997). MIP-1α can also mediate 
neutrophil infiltration into the injured brain through the release of other inflammatory 
mediators like leukotrienes (Reichel et al., 2009). MIP-1β or CCL4 binds to C-C chemokine 
receptor (CCR)5 receptors and induces the recruitment of monocytes to inflammatory sites 
(Mirabelli-Badenier et al., 2011). 
Regulated on activation, normal T-cell expressed and secreted (RANTES) 
RANTES, also known as CCL5, binds to three different transmembrane chemokine receptors 
(CCR1, CCR3 and CCR5) and plays an active role in recruiting leukocytes into the inflammatory 
sites (Mirabelli-Badenier et al., 2011).  RANTES is produced by a variety of cells including T 
lymphocytes, endothelial cells and glial cells that can ultimately contribute to the pathogenesis 
of stroke (Terao et al., 2008). Mice deficient in RANTES have  significantly smaller infarcts and 
decreased BBB permeability in focal cerebral ischemia highlighting the deleterious role of blood 
cell derived RANTES in cerebral ischemia and reperfusion (Terao et al., 2008). In contrast, 
another recent study showed that mice deficient in CCR5, the major receptor of RANTES, have 
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larger ischemic brain damage when compared to wild-type counterparts suggesting the 
neuroprotective role of CCR5 and other CCR5 ligands.  
Interleukin 8 (IL-8)  
IL-8, also known as Chemokine (C-X-C motif) Ligand (CXCL)-8, is reported to be present in 
humans but not in rodents. Rodents have a similar CINC, which is equivalent to human IL-8. In 
the rabbit, IL-8 was shown to be produced in the brain, and the anti-IL-8 antibody was 
associated with reduced infarct size and brain edema (Matsumoto et al., 1997). The levels of 
CNIC in brain and blood was found to precede and correlate with brain edema and cerebral 
neutrophil infiltration during early reperfusion in the murine model (Yamasaki et al., 1995a). 
Concurrently, inhibition of CINC with neutralizing antibodies reduces ischemic brain damage 
in transient MCAo models when administered 24 hours before and immediately after 
reperfusion (Yamasaki et al., 1997) 
2.2.6.2.3 Adhesion molecules 
The recruitment of leukocytes and platelets in the cerebral microvasculature following cerebral 
ischemia and other inflammatory processes involves different adhesion molecules that are 
expressed on vascular endothelial cells and circulating cells.  Selectins, integrins and cellular 
adhesion molecules (CAMs) are the adhesion molecules that participate in the transmigration of 
inflammatory cells into the brain parenchyma from the blood vessels (Ceulemans et al., 2010). 
During this process, the leukocytes roll on the endothelial surface in a process mediated by E- 
and P selectins. This rolling is followed by adhesion which is mediated by interaction of β-
integrins on leukocytes with ICAM-1 on endothelial cells (Yilmaz and Granger, 2008). 
Following ischemic stroke, upregulation in the levels of P-selectin occur as early as 15 min while 
E-selection upregulation is induced within 2 hours after the onset of  ischemia (Zhang et al., 
1998). Vascular upregulation of P- and E-selectins has been demonstrated to promote an 
inflammatory response and exacerbate brain injury following ischemic stroke (Wang et al., 
2007). Consequently, overexpression of P-selectin exacerbates brain infarcts while inhibition of 
P- and E-selectins leads to improved neurological outcome (Huang et al., 2000, Mocco et al., 
2002).  
Among the cellular adhesion molecules, vascular cell adhesion molecule (VCAM-1) and 
ICAM-1 are widely reported in ischemic stroke. ICAM-1 expression is increased within hours 
after stroke in both primates and human subjects upon stimulation by cytokines such as IL-1β 
and TNF-α (Lindsberg et al., 1996, Okada et al., 1994). ICAM-1 also contributes to a 
proinflammatory status following cerebral ischemia and blockage or inhibition of ICAM-1 was 
associated with improved outcome following stroke (Wang et al., 2007). Likewise, ICAM-1 
deficient mice were shown to have a smaller infarct compared to WT mice (Connolly et al., 
1996, Kitagawa et al., 1998). Integrins are transmembrane cell surface proteins found in 
leukocytes and are activated by various chemokines and cytokines. Binding of leukocytes to the 
endothelium is mediated by CD18 or β2 integrins after stroke and inhibition of β2 integrins that 
include three subclasses is neuroprotective in stroke (Wang et al., 2007). 
 2.2.6.3 Inflammatory and other enzymes 
Cerebral ischemia is involved in the upregulation of various pro- and anti-inflammatory 
mediators and proteins that ultimately influence the outcome after stroke. In addition, 
upregulation of various enzymes including cyclooxygenase (COX)-2, nitric oxide synthase 
(NOS) and MMPs are also observed during the course of ischemia and contribute to ischemic 
brain damage.  
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2.2.6.3.1 Cyclooxygenase  
Cyclooxygenase is an integral glycoprotein involved in normal pathological processes such as 
vascular function, wound healing and renal maintenance (Nurmi, 2004). It is the rate-limiting 
enzyme for the synthesis of prostanoids like prostaglandins and thromboxanes from 
arachidonic acid substrates. Two major isozymes known to catalyze the conversion of 
arachidonic acid to its end products are COX-1 and COX-2. COX-1 is constitutively expressed in 
virtually all types of cells and produces physiological levels of prostanoids (Vane et al., 1998). 
COX-2 is the product of immediate early response gene and is rapidly induced upon various 
stimuli, such as growth factors, hypoxia and inflammatory mediators (Andreasson, 2010, 
Seibert et al., 1995). 
In the brain, controversial data exist for the role of COX-1 in cerebral ischemia. One study 
showed that mice deficient in COX-1 were more vulnerable to ischemic brain damage 
supporting a protective role for COX-1 in MCAo (Iadecola et al., 2001). On the other hand, in 
transient global ischemia, COX-1 was found to be involved in the delayed neuronal damage of 
hippocampal CA1 neurons (Candelario-Jalil et al., 2003). 
The role of COX-2 and its participation in the progression of cerebral ischemic damage have 
been demonstrated in a number of studies (Iadecola et al., 2001, Koistinaho et al., 1999, 
Nagayama et al., 1999, Nogawa et al., 1997). In rodent models of cerebral ischemia, COX-2 
mRNA and proteins are upregulated in neurons, microglia and vascular cells 12-24 hours after 
injury (Miettinen et al., 1997, Nogawa et al., 1997).  In addition, COX-2 activation has been 
demonstrated in the human brain after ischemic stroke (Iadecola et al., 1999, Sairanen et al., 
1998). Inhibition of COX-2 has been shown to improve neurological outcome in several studies 
whereas its overexpression is associated with exacerbated brain damage (Doré et al., 2003, 
Nogawa et al., 1997, Sugimoto and Iadecola, 2003). It is suggested that the deleterious effects of 
COX-2 are associated with the production of superoxides and prostanoids (Candelario-Jalil and 
Fiebich, 2008). However, other reports have concluded that prostanoids and not ROS contribute 
to the COX-2 dependent neurotoxicity (Kawano et al., 2006, Kunz et al., 2007a, Manabe et al., 
2004). Specifically, the interaction of prostaglandin E2 with its receptor prostaglandin E1 was 
found to contribute to neurotoxicity through Ca2+ dysregulation and suppression of protein 
kinase B (Akt) (Kawano et al., 2006, Zhou et al., 2008). 
2.2.6.3.2 Matrix Metalloproteinases  
MMPs are the proteases that are responsible for degradation as well as remodeling of the 
extracellular matrix. MMPs are tightly regulated and secreted as inactive enzymes and are 
cleaved by other proteases and free radicals to yield their activated state (Rosenberg, 2002). 
MMPs are nearly undetectable in the brain under normal physiologic conditions. However, 
following brain injury, MMPs are expressed in astrocytes, microglia, neurons and endothelial 
cells (Lakhan et al., 2009, Montaner et al., 2001). Inhibition of MMPs has been shown to reduce 
BBB damage and thus ischemia induced infarct size, brain edema and hemorrhage 
transformation (Pfefferkorn and Rosenberg, 2003, Ramos-Fernandez et al., 2011). Even though 
both MMP-2 (gelatinase A) and MMP-9 (gelatinase B) are implicated in cerebral ischemia, mice 
deficient in MMP-9 but not MMP-2 have been shown to develop smaller infarcts compared to 
wild-type mice. Thus, MMP-9 plays a more detrimental and prominent role in cerebral ischemia 
(Asahi et al., 2000, Asahi et al., 2001). Rather than brain cell-derived MMP-9, peripheral 
inflammatory leukocyte-derived MMP-9 was shown to contribute to ischemic brain damage 
following transient focal cerebral ischemia (Gidday et al., 2005). MMP-9 can disrupt the BBB by 
degrading tight junction proteins and basal membrane proteins like fibronectin, laminin and 
collagen (Yamashita and Abe, 2011). However, in later phases of ischemia, MMPs are involved 
in plasticity, recovery and repair through their association with vascular endothelial growth 
factor, a known growth factor for regulating angiogenesis (Zhao et al., 2006). In addition, 
delayed appearance of MMPs  facilitates the migration of macrophages into the ischemic area in 
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order to clear the cellular debris (Romanic et al., 1998). MMP-9 in plasma have been suggested 
to predict the volume of infarcted tissue, stroke severity and functional outcome following 
acute cerebral ischemia (Ramos-Fernandez et al., 2011) 
2.2.6.3.3 Nitric oxide synthase  
NO is a potent dilator of cerebral vessel and is produced during the enzymatic conversion of L-
arginine to L-citrulline by NOS. There are three subtypes of NOS: nNOS, iNOS and endothelial 
NOS (eNOS) (Moncada et al., 1991). Neuronal NOS and eNOS are constitutively expressed in 
blood vessels under normal conditions. However, iNOS is upregulated upon pathological 
conditions such as ischemic stroke and contributes to increased amounts of NO (Faraci and 
Heistad, 1998). 
 As described earlier, nNOS synthesized by neurons has potential harmful effects on 
ischemic stroke through NMDA mediated toxicity, DNA damage, PARP activation and 
formation of peroxynitrites (Brouns and De Deyn, 2009, Kunz et al., 2007b, Moskowitz et al., 
2010). Following ischemia, nNOS also strongly interacts with postsynaptic density protein-95 
thus negatively affecting neurogenesis and dendritic remodeling. Disruption in the nNOS-
PSD95 interaction has been shown to rescue ischemic damage in rodent models of transient 
middle MCAo (Luo et al., 2014, Zhou et al., 2010). Similarly, iNOS is also involved in 
cytotoxicity by inducing inflammation and is thought to be present in cells involved in the 
inflammatory response mediated by leukocytes, microglia and astrocytes (Murphy and Gibson, 
2007, Wang et al., 2007). In the brain following transient or permanent ischemia, iNOS mRNA 
and protein levels are upregulated and associated with increased iNOS enzymatic activity and 
NO production as evident by accumulation of peroxynitrites (Grandati et al., 1997, Hirabayashi 
et al., 2000, Iadecola et al., 1995). There are a number of studies showing the neurotoxic effect of 
iNOS in ischemic brain damage. Administration of an iNOS inhibitor or using iNOS deficient 
mice has been associated with smaller brain infarct and better neurological outcome compared 
to wild-type controls (Iadecola et al., 1996, Iadecola et al., 1995, Zhao et al., 2000).  Likewise, 
suppression of iNOS expression by hypothermia, estrogen and progesterone appeared to have 
neuroprotective effects (Wang et al., 2007). 
2.2.7 Endogenous protective mechanism 
Depending on the time course of ischemic brain damage, cell death and cell survival pathways 
are activated at several points. Research has mainly focused on the cytotoxic mechanisms since 
the impact of endogenous protective mechanisms induced upon injury are overwhelmed by 
destructive pathways. However, boosting the endogenous protection following stroke has been 
suggested to be a potential therapeutic strategy to combat ischemia induced brain damage.  
Following ischemic brain injury, various protective mechanisms are activated as a defense 
mechanism to combat necrotic and apoptotic cell death. One such protein that is  rapidly 
activated is heat shock protein (HSP) 70 and its induction in animal models was shown to 
attenuate infarct volume (Yasuda et al., 2005). HSP is known to protect the cells from both 
necrosis and apoptosis. Specifically, HSP 70 is suggested to interfere proapoptotic molecules 
while also increasing the levels of anti-apoptotic Bcl-2 proteins (Giffard and Yenari, 2004). Bcl-2 
inhibits not only apoptosis but also promotes cell survival in response to necrotic cell death (Li 
and Yuan, 1999, Tamatani et al., 1999). HSP-70 also can interacts with Apaf-1 and hinders 
caspase 9 activation (Saleh et al., 2000).  In addition, HSP-70 interacts with AIF and JNK to 
prevent apoptosis. 
Neurotrophins are the tropic growth factors required for neuronal survival and maintenance. 
Following ischemia, neurotrophins promote cell survival by binding to tyrosine kinase 
receptors and activating phosphoinositide 3-kinase (PI3K) and MAPK pathway. Activated PI3K 
phosphorylates Akt which in turn phosphorylates Bad and procaspase 9 thus inhibiting 
apoptosis. MAPK pathway also phosphorylates Bad in addition to cAMP response element 
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binding  and interferes with cell death (Mohr et al., 2011). Neurotrophin-3 has been shown to be 
altered during ischemia and treatment with a low-dose of Neuroptophin-3 was associated with 
protection against neuronal loss in neonatal hypoxic/ischemic brain injury (Galvin and 
Oorschot, 2003, Yang et al., 1998b).  
G-CSF is a hematopoietic growth factor produced by many types of cells like neurons, 
monocytes and endothelial cells (Schneider et al., 2005b). The neuroprotective effect of G-CSF in 
stroke has been discussed in a number of studies (Lee et al., 2005, Ohmori et al., 2011, Schäbitz 
et al., 2003b). In addition, G-CSF has been shown to protect human cerebral neurons following 
oxygen glucose deprivation in vitro using cerebral-neuroblastoma hybrid cell lines (Jung et al., 
2006). G-CSF is involved in neuroprotection through the activation of various cell survival 
pathways including the Akt/PKB pathway, reduction of infarct volume and promotion of 
plasticity and angiogenesis (Lee et al., 2005, Schneider et al., 2005b). Even though G-CSF has 
been shown to be beneficial in preclinical stroke, it failed to improve neurological outcome in 
acute ischemic stroke patients in clinical trials (Ringelstein et al., 2013). 
Post-stroke neurogenesis where acute brain injury signals the stem cell population to divide 
and migrate towards the injured area is also one mechanism of endogenous neuroprotection 
after stroke. Neurogenesis occurs in the subventricular zone and subgranular layer of the 
dentate gyrus of the hippocampus in rodent models of both transient and permanent ischemia 
(Jin et al., 2001, Komitova et al., 2002, Zhang et al., 2001). In a mouse model of transient 
ischemia, neurogenesis has been shown to be induced bilaterally in both brain sides of the 
subventricular zone and dentate gyrus at around 2 days following ischemia and peaking at 7-14 
days post-stroke (Jin et al., 2001, Takasawa et al., 2002, Zhang et al., 2001). Neurogenesis then 
returns to basal levels by 3-4 weeks after stroke. Most of the neural progenitor cells that survive 
migrate from the subgranular layer to the granular cell layer and from the subventricular zone 
to the striatum and neocortex where they mature into functional neurons (Tobin et al., 2014). 
Also, the amount of newly born neurons is affected by the type and the severity of cerebral 
ischemia. For example, MCA occlusion for 2 hours was shown to induce more proliferation 
than an occlusion of a 30 min (Arvidsson et al., 2001). In permanent focal ischemia, cellular 
proliferation in the SVZ was also dependent on the size of the infarct (Moraga et al., 2014). 
Neurogenesis and angiogenesis are a coupled process and endothelial cells when activated by 
ischemia promote the release of stromal derived factor 1α that attracts neuroblasts expressing 
its receptor CXCR4 and thus promotes proliferation and migration (Imitola et al., 2004, Robin et 
al., 2006). In addition, angiogenesis after stroke promotes the formation of new vessels, and 
these vessels allow the migration of the newly formed neuroblast to migrate out of 
subventricular zone (Thored et al., 2007). 
In addition to growth factors and chaperones, anti-inflammatory cytokines like IL-10, IL-1ra, 
and TGF-β are also involved in the neuroprotective mechanism following brain injury as 
already discussed above. 
2.3 CO-MORBIDITIES AND RISK FACTOR FOR STROKE 
Stroke is a heterogeneous disease that develops due to the predisposition of multiple 
underlying pathological risk factors in individual during their lifetime. The risk factors can be 
classified as either modifiable or non-modifiable. Major modifiable risk factors include 
hypertension, hyperlipidemia, smoking, diet and physical inactivity accounting for more than 
80% of the risk of all stroke (Goldstein et al., 2006, O'Donnell et al., 2010). Non-modifiable risk 
factors include age, race, sex, and genetics.  
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2.3.1 Hypertension 
Hypertension is one of the most important modifiable risk factor for both ischemic and 
hemorrhagic stroke. Framingham Heart Study has shown that hypertension was associated 
with about 3 times the risk for stroke in both men and women (Burt et al., 1995, Kannel et al., 
1970) when compared to non-hypertensive subjects. Hypertension increases the risk of stroke 
with both increasing systolic and diastolic blood pressure. People with systolic blood pressure 
of 160 mmHg or higher and diastolic blood pressure of 95 mmHg have a higher risk of stroke 
when compared to normotensive people (Sacco et al., 1997).  Systolic increase in blood pressure 
alone has been shown to increase the risk of stroke (Kannel et al., 1981).  
In ischemic stroke, hypertension causes sheer stress in endothelium thus affecting atheroma 
formation and subsequent atherosclerosis (Dubow and Fink, 2011). In addition, elevation of 
blood pressure is associated with endothelial damage and enhances leukocyte adhesion and 
local thrombus formation subsequently leading to thrombotic stroke (Johansson, 1999).  
Moreover, hypertension can cause lipohyalinosis of small penetrating arteries and cause 
lacunar stroke as well as deep hemispheric hemorrhage (Fisher, 1971).  Chronic hypertension 
can cause pathological changes in smooth muscle cells and endothelium and contribute to ICH 
(Johansson, 1999). 
2.3.2 Atherosclerosis 
Atherosclerosis is one of the major risk factors for stroke and about half of the entire stroke is 
caused by atherosclerosis either by thrombus or by embolus. Atherosclerosis is a disease 
characterized by thickening of the artery due to the inflammatory response of macrophage and 
lymphocytes to pathogenic lipoproteins into the arterial walls (Libby et al., 2002). 
Atherosclerosis is a slow and progressive disease that advances with age. Various risk factors 
for atherosclerosis like smoking, hypertension, diabetes, hyperlipidemia, etc. cause the damage 
to the endothelial cells on the inner lining of the arteries. The damage to the endothelial lining 
upregulate adhesion molecules on the endothelial cell surface and leukocytes and platelets 
adhere to the endothelium (Weber et al., 2008). Monocytes migrate into the arterial wall where 
they differentiate into macrophages. The differentiated macrophages then take up the lipids and 
oxidized low density lipoprotein (oxLDL), leading to foam cell formation and development of 
fatty streak lesions. As the lesion progresses, foam cells macrophages die and contribute to the 
formation of necrotic core through release of cytoplasmic content that further induce 
inflammation (Weber et al., 2008). During this process, vascular smooth muscle cells migrate 
from the tunica media to tunica intima, proliferate and form fibrous caps which ultimately lead 
to narrowing of the artery and plaque formation and eventually rupture (Figure 5). The rupture 
of the plaque and narrowing of the arteries lead to clinical events such as stroke and 
cardiovascular disease (Weber et al., 2008). 
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Figure 5: Progression of an atherosclerotic lesion. a) Endothelial dysfunction and leukocyte and 
platelet adhesion on the endothelial cell. b) Recruitment and differentiation of monocytes into 
macrophages that take up lipids to form foam cells and build up fatty streaks and subsequent 
plaques. c) Formation of necrotic core and fibrous caps due to the apoptosis of macrophage and 
other plaque cells.  d) Thinning and erosion of fibrous caps into unstable plaques due to matrix 
degradation by protease and ultimate rupture of the plaque. This further leads to arterial occlusion 
which is the main cause of myocardial infarction and stroke. (Figure adopted from Weber et al, 
2008) 
Large artery atherosclerosis causes stroke in three different ways; (1) hypoperfusion due to 
severe narrowing of the arterial lumen that transport blood to the brain, (2) hypoperfusion 
contributed by thrombi that block the main branch of the occluded arteries and, (3) emboli 
causing the disturbances and blockage of the distal artery (Higashida et al., 2005) 
2.3.3 Hyperlipidemia 
Hyperlipidemia refers to elevated amounts of lipids and lipoproteins in the blood. Increased 
serum cholesterol has been shown to increase the incidence of coronary heart disease. However, 
such types of associations are less well documented in ischemic stroke and are rather 
conflicting. Hypercholesterolemia has been shown to increase the plasma levels of 
inflammatory sensitive proteins and contributes to increased incidence of stroke (Engström et 
al., 2002). Secondary to that, hypercholesterolemia in combination with inflammation might 
26 
 
 
 
accelerate the progression of atherosclerosis. Several studies have shown that the total serum 
cholesterol, high levels of low density lipoproteins (LDL) and triglycerides increase the risk of 
stroke where as high density lipoproteins (HDL) are associated with decreased risk of stroke. In 
contrast, low levels of serum cholesterol have been found to increase the incidence of ICH 
(Yano et al., 1989).  Indeed, ischemic stroke and ICH are differently related to cholesterol levels. 
Hyperlipidemia conditions modeled by feeding the high cholesterol diet in ApoE deficient mice 
was found to attenuate angiogenesis and pericyte coverage of endothelial cells thus impairing 
cerebral blood flow (Zechariah et al., 2013). Upregulation of Rho-associated kinase activity has 
been proposed as one of the mechanisms of vascular dysfunction in hyperlipidemic condition in 
ischemic stroke and that its inhibition is associated with improved stroke outcome (Shin et al., 
2008, Shin et al., 2014). In addition, CD36 has been shown to exacerbate brain injury in 
hyperlipidemic conditions through MCP1/CCR2 axis (Kim et al., 2008).    
2.3.4 Diabetes 
Diabetes mellitus is another highly ranked independent risk factor for stroke, and people with 
diabetes have 2-3 fold risk of having stroke compared to people without diabetes (Air and 
Kissela, 2007, The Emerging Risk Factors, 2010).  The effect of diabetes mellitus has been 
demonstrated by Honolulu Heart Program, where subjects with diabetes and asymptomatic 
hyperglycemia were prone to increased ischemic stroke independent of age and other risk 
factors (Burchfiel et al., 1994). People with both type I and type II diabetes have increased 
susceptibility for atherosclerosis and small artery occlusive disease and, therefore, develop 
thromboembolic, larger arteries and lacunar stroke (Jackson and Sudlow, 2005, Mankovsky et 
al., 1996, Ohira et al., 2006). Diabetes and hyperglycemia contribute to progression of 
atherosclerosis through endothelial dysfunction which in turn promotes proinflammatory, 
vasoconstrictive and prothrombotic processes leading to plaque formation and rupture 
(Castilla-Guerra and Fernandez-Moreno, 2007). Diabetes also promotes hypertension and 
dyslipidemia which are the major risk factors of stroke.  Moreover, diabetes increases the level 
of fibrinogen that subsequently leads to thrombosis and stroke (Lukovits et al., 1999).  
Increased blood glucose or hyperglycemia through intraperitoneal injection of dextrose was 
found to increase the infarction volume in both permanent and transient MCAo (Liu et al., 
2007). Hyperglycemia has been reported to increase the oxidative stress and MMP-9 activation 
and these events are linked to promote BBB dysfunction (Kawai et al., 1998, Kamada et al., 
2007). In addition, the mechanism of ischemic damage by hyperglycemia was attributed to 
exacerbated leukocyte-endothelial cell adhesion, increased IL-1 and ICAM expression (Howells 
et al., 2010). However, gender specific response to ischemic insult where females were more 
resistant to damage than males was observed in genetically engineered diabetic db/db mice 
(Vannucci et al., 2001). Even though the mechanism of brain damage in diabetic condition are 
less than clear, recent study points towards decreased levels of MCP-1, IL-6 and CCR-2 gene 
expression in brains of mice fed with a diabetic diet (Kim et al., 2014). 
2.3.5 Infections 
Pre- and post-ischemic infections have been known to be associated with stroke with pre-
ischemic infections increasing the risk of stroke and post-ischemic infections aggravating the 
damage and neurological functions (Emsley and Tyrrell, 2002, Grau et al., 2010). Both acute and 
chronic infections are involved in the aggravation of brain damage. Inflammation is a 
mechanism to combat the infection, however, aggravated inflammation caused by infections 
can subsequently increase the deleterious effect of stroke (Emsley and Hopkins, 2008). The 
incidence of stroke is more pronounced during cold season (Hindfelt and Nilsson, 1977). A 
number of infectious diseases of bacterial, viral and fungal origin have been found to increase 
the risk of ischemic stroke. Infections, especially of bacterial origin, affecting the respiratory and 
urinary tracts have been shown to increase the risk of stroke 3 days after the preceding infection 
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(Clayton et al., 2008, Smeeth et al., 2004). Bacterial infections have been shown to increase the 
prevalence of brain infarction in young and middle aged patients (Syrjänen et al., 1988). Viral 
infections like influenza, also predict the outcome after stroke (Grau et al., 2005, Lavallée et al., 
2002). Chronic infections by several pathogens like Chlamydia pneumonie, Helicobacter pylori and 
porphyromonas gingivalis have also been suggested to contribute to stroke outcome. However, 
the results are either inconclusive or conflicting. 
Both acute and chronic infections induce brain infarctions by several mechanisms. Infections 
induce procoagulant pathways via cytokines, interleukin (IL)-1 and tumor necrosis factor 
(TNF). These cytokines  released by monocytes and other inflammatory cells can transform the 
endothelium from anticoagulant to the procoagulant cell layer by lowering endogenous tPA 
and thrombomodulin and increasing tissue factor and plasminogen-activator inhibitor 1 
expression (Grau et al., 2010). In addition, these cytokines along with C-reactive protein also 
induce the expression of tissue factors by circulating monocytes and macrophages (Cermak et 
al., 1993). Acute infection has also been shown to decrease the level of circulating 
antithrombotic activated protein C and increase plasma concentration of C4b-binding protein 
which is an inhibitor of anticoagulant protein (Macko et al., 1996). Likewise, increased fibrin D-
dimer, cardiolipin immunoreactivity and fibrinogen concentration was also observed in stroke 
patients with preceding infections (Ameriso et al., 1991). Gingivalis infections have been shown 
to induce platelet aggregation (Lourbakos et al., 2001). Recently, Streptococcus pneumonia  was 
also shown to exacerbate inflammation in the brain via the activation of IL-1 and platelet 
glycoprotein 1bα (Dénes et al., 2014). Specifically, the production of microglial IL-1α was 
augmented. Thus, infections can further enhance the coagulation cascade to form thrombus and 
stroke.  
Infections have also been shown to promote the development of vascular disease. Even 
though atherosclerosis originates starting from the childhood, infection can also give rise to 
atherosclerosis and subsequent plaque rupture and ultimately stroke. Infection of the cells 
lining the arterial wall can lead to endothelial dysfunction and increased levels of 
proinflammatory cytokines thus leading to atherosclerotic plaque formation (Epstein et al., 
2009). In some unstable atherosclerotic plaques, antigen from the microbial agents can activate 
specific T cells and might contribute to the plaque inflammation, rupture and stroke (Niessner 
et al., 2006). In addition to promoting atherosclerosis, infections can also damage the normal 
arterial walls and might cause coronary intimal thickening thus contributing to coronary artery 
disease or cryptogenic stroke (Grau et al., 2010). 
Aging is one of the risk factors for infection. Pneumonia, most frequently occurring in 
elderly, is associated with higher morbidity and mortality rates when compared to younger 
population (Yoshikawa and Marrie, 2000). Likewise, urinary tract infections are also most 
common in the elderly population (Gavazzi and Krause, 2002). With aging, a big proportion of 
the elder populations have asymptomatic bacteriuria where they carry a significant number of 
bacteria in the urine without any usual symptoms (Gavazzi and Krause, 2002). Thus, aged 
infected patients have a bigger chance of suffering from stroke when compared to the young 
patients. 
2.3.6 Aging and sex 
Aging is a non-modifiable independent risk factor with aged people having higher incidence of 
stroke and risk of mortality when compared to young people (Weir and Dennis, 1997). 
Approximately, 88% of people who die from stroke are over 65 years old. Even though stroke 
can affect people of all ages, the risk of stroke increases rapidly after the age of 55 in both men 
and women. Women have a lower incidence of stroke between ages 55-74 when compared to an 
age-matched male. However, this trend reverses with advancing age with women above 80 
having a higher risk for stroke when compared to men (Manwani and McCullough, 2011). 
Atherosclerosis, atrial fibrillation and hypertension are the main factors contributing to the 
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ischemic stroke in this group. Atrial fibrillation especially in women is the main risk factor for 
stroke after reachin the age of  75.  
Irrespective of the sex, aging is associated with shrinkage of brain tissue. White matter 
atrophy is prominent in the brain compared to the gray matter as demonstrated by MRI 
(Guttmann et al., 1998). Regional changes in the brain have also been shown to be affected by 
aging. In Framingham heart study, elderly above the age of 50 showed greater decline in the 
volume of the frontal lobe (~12%) and temporal lobe (~9%) when compared to modest decline in 
parietal and occipital lobes (DeCarli et al., 2005). The physical changes in the brain have been 
suggested to occur due to a change in neuronal volume rather than the loss of the neurons 
themselves. In addition, changes in dendritic spines and synapses might contribute to the 
decline in neuronal volume which ultimately lead to cognitive decline (Peters, 2006). Likewise, 
glial cells thicken and increase with age such that the distance between the glia and shrinking 
neuronal process is preserved for glial-neuronal exchange (Glorioso and Sibille, 2011). In 
addition to the morphological changes at the cellular level, neurons also display increased DNA 
damage and ROS, mitochondrial dysfunction, calcium dysregulation, and inflammatory 
processes as evident in clinical and experimental studies (Yankner et al., 2008). When these 
neurons are injured, they release ATP, neurotransmittors, growth factors and cytokines, which 
ultimately activate microglial cells (Hanisch and Kettenmann, 2007). Upon activation, microglia 
releases a number of both pro- and anti-inflammatory molecules (Lucin and Wyss-Coray, 2009).  
Following ischemic stroke, the inflamed aged brain has been shown to react strongly with 
accelerated astrocytic and microglial activation (Badan et al., 2003). Several inflammatory 
chemokines (CCL2, CXCL-1) and cytokines (TNF-α, IL-1 and IL-6) are upregulated in aged rats 
upon ischemia. In addition inflammation related transcriptional genes like IL-6, transforming 
growth factor beta receptor I, ribosomal protein S2, Prostaglandin E synthase 3 were found to 
be upregulated in aged rats following transient ischemia (Buga et al., 2008). However, other 
studies point towards the attenuated inflammatory response of pro-inflammatory cytokines like 
TNF-α, IL-1β and IL-6 and chemokines like Mip-1α and IL-10 as a result of elevated cytokines 
in the aged brain preceding ischemia that may result in preconditioning (Sieber et al., 2011).  
2.3.7 Apolipoprotein E 
2.3.7.1 Overview 
Apolipoprotein E (ApoE) is a class of lipoproteins that are primarily synthesized in the liver 
and are essential in maintaining lipid homeostasis through the catabolism of triglyceride-rich 
lipid components. ApoE was identified as an arginine rich protein constituent of very low 
density lipoprotein (VLDL) in 1973 (Shore and Shore, 1973). Subsequently, it was demonstrated 
to be present in chylomicrons, LDL and HDL (Zannis and Breslow, 1982). ApoE is incorporated 
into the surface of these four lipoprotein constituents where they act as ligands for lipoprotein 
receptors (Li et al., 1988). ApoE has been found to be present also in other tissues than liver, 
such as the brain, spleen, muscle and lungs (Mahley, 1988). In the central nervous system 
(CNS), ApoE is mainly synthesized by glia, particularly astrocytes but also microglia (Holtzman 
et al., 2012, Pitas et al., 1987). ApoE is primarily secreted in HDL-like particles although it is 
present in all forms of lipoproteins (Holtzman et al., 2012).  
2.3.7.2 Genotypes and polymorphism 
ApoE is polymorphic and exists in three human isoforms (ApoE2, ApoE3 and ApoE4) that are 
encoded by corresponding allele APOE ε2, ε3 and ε4. The polymorphism results from the 
difference in three alleles in single gene locus on chromosome 19. ApoE2 (cys112, cys158), 
ApoE3 (Cys112, Arg158) and ApoE4 (arg112, Arg158) differ from each other by only one or two 
amino acids at residue 112 and 158 (Holtzman et al., 2012). A single amino acid substitution 
among the isoforms alters the structure of the protein and hence influences its lipid association 
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and receptor binding (Hatters et al., 2006). ApoE2 have reduced affinity for its receptor, low-
density lipoprotein receptor (LDLR), as a result of substitution of arginine with cysteine at 
position 158 and hence the disturbance in the conformation of α-helical structure. Thus, ApoE2 
transport lipids less efficiently and results in hyperlipoproteinemia. Likewise, ApoE4 binds to 
large lipoproteins and is associated with increased risk of cardiovascular disease (Bu, 2009). 
APOE ε3 allele is the most common form of allele and is considered a neutral risk phenotype in 
the majority of the population. APOE ε3 is found in approximately 78% of the population 
whereas  APOE ε4 and APOE ε2 are found in 14 and 7 percent of the population respectively 
(Davignon et al., 1988). These APOE genetic polymorphisms result in 6 different genotypes, 
three homozygous (ε2/ε2, ε3/ε3 and ε4/ε4) and three heterozygous (ε2/ε3, ε3/ε4 and ε2/ε4) with 
higher occurrence of ε3/ ε3 (55%), ε3/ε4 (25%) and ε2/ε3 (15%) (McColl, 2004).  
2.3.7.3 Structure and function 
The human ApoE protein is a 34kDa glycoprotein containing 299 amino acids and was 
originally identified as a main constituent of lipoproteins in plasma. ApoE contains an 
amphipathic α-helical lipid binding domain that can switch reversibly between the lipoprotein 
bound state and lipid free state (Hatters et al., 2006). In the lipid free state, ApoE contains two 
structural domains that are separated by a hinge region: the N-terminal domain containing four 
helical structures and C-terminal domain containing α-helical structure (Segrest et al., 1992, 
Wilson et al., 1991). The N-terminal domain (amino acids 1-191) contains a receptor binding 
region and binds to LDLR whereas a lipid binding domain (amino acid 224-272) has been 
shown to reside in C-terminal domain (Mahley, 1988, Mahley et al., 2009, Westerlund and 
Weisgraber, 1993). 
ApoE is involved in a wide range of physiological functions, the most important being the 
lipid transport. ApoE is involved in transport of triglyceride and cholesterol from the intestine 
to the liver as a constituent of chylomicron. It also directs triglyceride and cholesterol from the 
liver to extrahepatic tissues as a constituent of VLDL. HDL-bound ApoE also take part in 
reverse cholesterol transport for efflux of cholesterol to the liver for excretion. ApoE2 is 
metabolically different from ApoE3 and ApoE4. ApoE4 binds selectively to VLDL that is rich in 
triglycerides where as ApoE2 and ApoE3 bind to HDL.  APOE ε4/ε4  and APOE ε3/ε4 
genotypes have been found to be associated with elevated systolic blood pressure that might 
result in myocardial infarction and atherosclerosis (Lenzen et al., 1986). In the brain, ApoE has 
also been proposed to be involved in lipid transport similar to that in plasma (McColl, 2004). In 
addition, ApoE is involved in neuronal sprouting and synaptogenesis (Masliah et al., 1995, 
Mauch et al., 2001). 
2.3.7.4 ApoE receptors 
ApoE is the critical component of various lipoproteins and serves as ligands for a group of 
receptors known as the LDL receptor family. Ten different types of receptors have been 
identified up to date and these include LDLR, VLDL Receptor (VLDLR), ApoE receptor 2 
(APOER2), Multiple EGF-like domain 7 , LDLR related protein (LRP)1, LRP1B, LRP2, LRP5, 
LRP6) and  Sortilin-related receptors with A-type repeats that are essentially unchanged during 
the course of evolution (Herz and Beffert, 2000). All the receptors have single membrane 
spanning structures followed by a cytoplasmic tail containing NPXY motif.   
LDLR was first identified as a cell surface receptor that can uptake LDL from the circulating 
blood and mediate internalization and endocytosis via clathrin-coated pits  (Brown and 
Goldstein, 1986). Inactivation of LDLR through loss-of-function mutation in LDLR gene is 
associated with elevated plasma levels and familial hypercholesterolemia and atherosclerosis. 
LDLR receptors are widely expressed in both periphery and brain. VLDLR and ApoER2 share 
structural similarities with LDLR but are involved in reelin signaling that are crucial for 
neuronal migration, dendritic spine development and synaptic plasticity (Beffert et al., 2005, 
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Niu et al., 2008, Trommsdorff et al., 1999). LRP1, another receptor, is also highly expressed in 
the liver and brain and serves as a receptor for more than 30 different types of ligands including 
APOE, tissue type plasminogen activator (tTPA) and Amyloid precursor protein (APP) (Bu, 
2009). LRP1 is involved in cellular trafficking and processing of beta Amyloid (Aβ) that can 
have pathophysiological consequences in AD (Kounnas et al., 1995). LRP1 also functions similar 
to LDL receptors in internalization and endocytosis but at a faster rate (Li et al., 2001b). In 
addition to being the receptor for endocytosis in brain, LRP1 is also involved in synaptic 
transmission and motor functions.  
2.3.7.5 Role of ApoE in Alzheimer’s disease (AD) 
AD, originally described by Alois Alzheimer in 1907, is a devastating progressive 
neurodegenerative disease that is often characterized by an irreversible loss of neurons leading 
to dementia. Approximately 26 million people are affected by this disease worldwide. Early-
onset familial AD typically accounts for a small proportion of the population and is caused by a 
mutation in APP gene, Presenilin 1 or Presenilin 2 gene.  Late-onset AD accounts for the 
majority of the population and is mainly attributed to the impairment in clearance of Aβ (Liu et 
al., 2013). Among the various susceptibility genes that have been discovered so far, APOE ε4 
gene located on chromosome 19 was shown to be a risk factor for both sporadic and late-onset 
AD (Corder et al., 1993, Saunders et al., 1993, Strittmatter et al., 1993).  However, APOE ε2 
alleles have been suggested to have a protective role against AD (Corder et al., 1994). Increased 
risk of AD  is approximately 12 fold in people with two ε4 alleles and 3 fold in people with a 
single ε4 allele when compared to people lacking ε4 allele at all (Holtzman et al., 2012). The 
onset of disease also shifts to earlier time points  in people carrying one or two APOE ε4 alleles 
either in sporadic cases of APP or  Presenilin 1 mutation  or  late-onset AD (Nacmias et al., 1995, 
Pastor et al., 2003, Saunders et al., 1993). In all the AD cases, Apo ε4 allele carriers account for 
50% of cases. In addition to being one of the significant risk factors in development of AD, 
ApoE ε4 is also involved in production and aggregation of both Aβ and tau which are the 
hallmark of AD pathology (Verghese et al., 2011).   
2.3.7.6 Role of ApoE in Stroke 
ApoE has been shown to be associated with cholesterol metabolism, atherosclerosis, ischemic 
heart disease and cerebral amyloid angiopathy (CAA) which might ultimately influence the 
stroke outcome. Especially, the APOE ε4 allele is associated with an increased level of 
cholesterol that can accelerate atherosclerosis and hence ischemic heart disease (Sudlow et al., 
2006). Thus, it is possible that APOE is also linked to ischemic stroke especially thrombotic 
stroke. Indeed, a meta-analysis linked the significant association between APOE ε4 allele and 
ischemic stroke (McCarron et al., 1999). Moreover, APOE ε4 allele has been demonstrated to be 
a risk factor for the recurrence of ischemic stroke (Kim et al., 2003). However, opposite 
association has been found in other studies, in case of ischemic stroke (Martínez-González and 
Sudlow, 2006). 
Even though contradicting results exist between the ApoE polymorphism and ischemic 
stroke, there are a number of other studies that link ApoE polymorphism with increased risk of 
ICH and SAH. CAA is a form of angiopathy that is caused by deposition of Aβ peptide in the 
walls of blood vessels of CNS. Several studies have reported that CAA is an important cause of 
lobar cerebral hemorrhage in elderly and APOE ε4 allele enhances the amyloid deposition in 
blood vessels. In addition, the APOE ε2 allele also enhances the vasculopathic change that leads 
to the rupture of amyloid laden vessels (Greenberg et al., 1998, McCarron and Nicoll, 2000). 
Thus, carriers of APOE ε4 and APOE ε2 have an increased chance of having lobular ICH. 
Likewise, APOE ε4 alleles have been demonstrated as a risk factor for SAH and poorer outcome 
in number of studies (Guo et al., 2011, Kokubo et al., 2000, Lanterna et al., 2007, Lanterna and 
Biroli, 2009).  
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2.3.7.7 ApoE transgenic animal 
Rodent models have been widely used to study the molecular and cellular basis of diseases. 
Several transgenic mice lines that either overexpress or underexpress several genes have been 
developed to study the molecular basis of various diseases including cancer, heart disease, 
obesity, stroke, aging and PD and hence develop therapeutic treatment regimen. In the context 
of this thesis, human APOE-targeted replacement mice are discussed. It is well known fact that 
rodent models express only one isoform of ApoE in contrast to the three isoforms found in 
humans. Thus, the generation of transgenic animals expressing human isoforms of ApoE is 
important in order to determine the effect of APOE polymorphism in context to human disease 
like stroke and AD.  
APOE transgenic mice were initially developed using microinjection of allele-specific human 
genomic fragments to establish the founder mice that were then bred with APOE-knockout 
mice (Xu et al., 1996). In this model, ApoE levels were comparable to ApoE levels in WT mice. 
Later, transgenic mice  expressing APOE ε3 and APOE ε4 under the control of GFAP promoters 
were developed to study the expression of astrocyte specific human ApoE isoforms (Sun et al., 
1998). In addition, other transgenic lines where ApoE expression was restricted to neurons was 
developed driven by a neuron-specific enolase promoter.  
APOE transgenic mice used in this thesis were generated by targeted replacement of the 
endogenous mouse APOE with human APOE without altering any endogenous regulatory 
sequences (Sullivan et al., 1997, Sullivan et al., 1998, Wang et al., 2005). The expression of ApoE 
mRNA in brain and other tissues were comparable to those found in WT mice since transgene 
expression in these mice is under the control of endogenous promoters and only the coding 
region is replaced. In addition, there were no differences in the cholesterol and triglyceride 
levels in fasted plasma between the APOE3-targeted replacement (ApoE3-TR) mice and WT 
counterparts. 
2.3.7.8 ApoE in Preclinical Experimental Stroke 
Transgenic mice expressing human ApoE isoforms have been utilized in ischemic stroke. 
Specifically, ApoE4  ε4 mice have been shown to have bigger infarcts compared to ApoE ε3 
mice after transient focal ischemia (Sheng et al., 1998). In addition, ApoE4 isoforms have been 
shown to aggravate delayed infarction and reactive astrocytosis after permanent focal ischemia 
when compared to ApoE3 and ApoE2 isoforms and pharmacological modulation of astrocytosis 
was associated with better outcome (Mori et al., 2004, Mori et al., 2005). ApoE4 isoform was 
found to have a poorer outcome in global ischemia where significantly larger hippocampal 
damage was observed in the hippocampal area of ApoE4 mice (Horsburgh et al., 2000). In 
addition, ApoE4-targeted replacement mice showed increased prevalence of ICH, and it is 
associated with predominant vascular amyloid deposition (Sullivan et al., 2008). When ICH was 
induced by injection of clostridial collagenase in ApoE4-targeted replacement (ApoE4-TR) mice, 
they showed increased cerebral edema and poor functional outcome in rotarod (James et al., 
2009). Taken together, it is evident that the APOE ε4 allele is associated with poorer outcome 
following stroke which coincides with the result that is often seen in clinical subjects. 
The fact that the APOE ε3 allele is associated with smaller brain damage compared to APOE 
ε4 may be attributed to the attenuation of NMDA-mediated glutamate excitotoxicity (Aono et 
al., 2003, Aono et al., 2002, Buttini et al., 1999, Qiu et al., 2003). In addition, ApoE4 isoforms have 
been shown to reduce glutamate receptor function and synaptic plasticity that might affect the 
outcome after stroke (Chen et al., 2010). The antioxidant properties of ApoE are documented in 
a number of studies (Hayek et al., 1994, Kitagawa et al., 2002, Praticò et al., 1998). In vitro studies 
have demonstrated the isoform specific protection of neurons from hydrogen peroxide- and 
Aβ-induced oxidative damage in the order ApoE2 > ApoE3 > ApoE4 (Miyata and Smith, 1996). 
On the other hand, the ApoE4 isoform was shown to increase lipid peroxidation in post-
mortem brain sample and elevated hydroxyl radical in blood (Jofre-Monseny et al., 2008). 
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Moreover, the ApoE4 isoform was shown to increase intracellular calcium and thus 
excitotoxicity when compared to the ApoE3 isoform further illustrating the negative effect of 
ApoE4 on neurodegenerative disease (Veinbergs et al., 2002). Overall, ApoE4 isoforms appear 
to modulate neurotoxicity while ApoE2 and ApoE3 are associated with neuroprotection. 
The neuroinflammatory effect of ApoE4 was first demonstrated in human AD brains where 
microglial activation was demonstrated in frontal and temporal lobes (Egensperger et al., 1998). 
However, most of the evidence on the role of ApoE on inflammation comes from mice 
engineered to express human E2, E3 and E4 isoforms. Mice expressing ApoE ε4 allele were 
shown to have significantly higher levels of IL-6 and TNF-α in both brain and periphery in 
response to LPS administration (Lynch et al., 2003). Microglial activation but not astrocyte 
activation was observed in ApoE4 mice brains relative to ApoE3 mice brains. Subsequently, 
microglia from ApoE4 mice produce greater amounts of NO than ApoE3 mice (Jofre-Monseny 
et al., 2008). Even though the exact mechanism by which ApoE modulate these effect is not 
known, one study point towards the NF-kB activation (Ophir et al., 2005) while the other study 
hypothesizes that ApoE mediated effect in microglia are p38MAPK dependent(Maezawa et al., 
2006). 
2.3.7.9 Role of ApoE in other neurological disorders 
APOE genotypes have been shown to be involved in a wide range of neurological disorders. In 
TBI, presence of the APOE ε4 allele has been linked with poorer neurological outcomes in a 
number of studies (Friedman et al., 1999, Verghese et al., 2011). One study has demonstrated 
that patients with APOE ε4 allele have unfavorable outcomes compared to the non-carriers 
(Teasdale et al., 1997). In addition, APOE ε4 in particular have been shown to predispose and 
reduce the age of onset of Down’s syndrome-associated dementia in contrast to APOE ε2 that 
has a protective role (Verghese et al., 2011). In multiple sclerosis (MS), a higher frequency of 
APOE ε4 allele has been observed in the Danish population; however other studies have found 
no association with APOE ε4 allele frequency and MS susceptibility (Burwick et al., 2006, 
Ghaffar et al., 2010, Høgh et al., 2000). Likewise, APOE ε4 genotypes have been found to be 
associated in a number of diseases including Parkinson’s disease (PD), Amyotrophic lateral 
sclerosis, Huntington’s disease and Temporal lobe epilepsy even though controversies do exist 
(Verghese et al., 2011). 
2.2.8 Other risk factors for stroke 
Various other modifiable and non-modifiable risk factors influence the susceptibility and 
outcome of stroke. Heart disease and impaired cardiac function have strong interaction with 
stroke. People with ischemic heart disease, congestive heart failure and left ventricular 
hypertrophy have double the risk of stroke compared to a person lacking these disorders. Atrial 
fibrillation is also a primary cardiac condition and accounts for 1 of 6 ischemic stroke cases 
(Hart et al., 2002). Arterial fibrillation accounts for almost half of all cardioembolic stroke (Panel 
et al., 1997). Obesity is also linked with an increased risk of stroke since obese people have high 
blood pressure, blood glucose and atherogenic serum lipids. 
2.4 EXPERIMENTAL MODELS OF CEREBRAL ISCHEMIA 
A large number of approaches to study cerebral ischemia have been developed during the last 
30-50 years with the aim to elucidate the molecular and cellular mechanism underlying stroke 
and hence explore the potential therapeutic options. In vitro models using primary cultures, cell 
lines and tissue culture are widely used to study the ischemia at cellular level and can provide 
valuable information of individual cellular components and their biological functions. On the 
other hand, in vivo models provide the information of the molecular and cellular interactions 
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and their physiochemical properties that ultimately lead to brain injury.  In vivo animal models 
of stroke comprise models of: a) global ischemia, b) focal ischemia and c) hypoxia ischemia 
(Woodruff et al., 2011). 
2.4.1 Global ischemia 
Global ischemia is characterized by transient blockage of blood flow into the entire brain (Mohr 
et al., 2011). Global ischemia results in delayed selective neuronal loss and delayed neurological 
deficits leading to cognitive impairments (Lo et al., 2003). Only selected neuronal populations 
such as pyramidal neurons in hippocampal CA1, hilar neurons of dentate gyrus and Purkinje 
neurons of the cerebellum are vulnerable to ischemic damage (Harukuni and Bhardwaj, 2006, 
Mohr et al., 2011). Global ischemic models have significant clinical relevance as it resembles 
cardiac arrests and asphyxia in humans (McBean and Kelly, 1998). There are several ways to 
produce global ischemia; however, the most common method involves the occlusion of 
vertebral and common carotid arteries for short duration.  The most commonly used models for 
global ischemia are (a) the four vessel occlusion in rats; (b) the two vessel occlusion or bilateral 
common carotid artery occlusion in gerbils or mice and (c)  two vessel occlusion in combination 
with hypotension in rats (McBean and Kelly, 1998, Traystman, 2003, Woodruff et al., 2011). The 
four vessel occlusion involves a permanent coagulation of vertebral arteries and a temporary 
ligation of two common carotid arteries.  In contrast, the two vessel occlusion model involves 
the temporary ligation of two common carotid arteries for a brief period.  Gerbils serve as a 
relatively simple model for global forebrain ischemia because of the lack of posterior 
communicating arteries with highly reproducible hippocampal damage (Woodruff et al., 2011). 
2.4.2 Focal ischemia 
Focal ischemia is most commonly produced by the occlusion of MCA and can be either 
permanent or transient. Even though the MCA is occluded, collateral circulation can provide 
blood flow into the compromised area and hence reduce the impact of occlusion. Various 
animal models have been employed to study stroke-related injuries. Rodent models are  
extensively used because of their low cost, the relatively small size of the animal, and their 
consistent circulatory anatomy (Woolsey et al., 1996). There are a number of ways in which 
MCAo can be performed, and the occlusion can be either permanent or temporary at either 
distal or proximal part of the MCA (Traystman, 2003). 
Transient MCA occlusion 
The filament model originally described in 1986 has been routinely used to produce either 
permanent or transient MCAo in rodents (Koizumi et al., 1986). In this model, MCA  is 
subjected to occlusion by ligating the common carotid and external carotid arteries and then 
inserting a nylon suture into the internal carotid artery and then advancing the thread to block 
the MCA (Koizumi et al., 1986, Longa et al., 1989). Later, a poly-L-lysine coated suture was 
found to produce more uniform infarct (Belayev et al., 1996). After occlusion, CBF was reduced 
to less than 15% in the core area while in penumbra area it was 40%. Removal of the suture 
allows the reperfusion of blood to the affected area and animal can then be used for assessment 
of behavioral outcome (DeVries et al., 2001). By varying the occlusion time, severity of the 
damage can be controlled.  
Permanent MCA occlusion 
Permanent MCA occlusion model was originally described in 1981 (Tamura et al., 1981). This 
model involves the permanent occlusion of the MCA and results in infarction of cortex and 
caudoputamen areas. In a distal model of permanent occlusion, the precise site and extent of 
MCA occlusion was demonstrated to influence the neurological outcome in addition to 
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inconsistent infarct size. In fact, avoiding lenticulostriate and small cortical branches from the 
proximal and distal sources allowed the formation of consistent lesion size (Bederson et al., 
1986). 
However, several modifications have been applied to the original method. For instance, 
occlusion of MCA via a burr hole made through temporoparietalis bone can produce consistent 
lesion (Koistinaho et al., 2002, Welsh et al., 1987). This proximal occlusion method involves the 
exposure of temporalis muscle, drilling of the temporal bone above the MCA at the level of 
inferior cerebral vein, removal of dura, and permanent cauterization of MCA using a 
thermocoagulator. Occlusion of MCA was also demonstrated using mechanical clips or ligature 
(van Bruggen et al., 1999). In permanent MCA occlusion, blood flow is not restored and has 
clinical significance since not all the human stroke cases are associated with reperfusion.  
2.4.3 Hypoxia ischemia 
This model involves the transient unilateral occlusion of common carotid arteries combined 
with hypoxia and is exclusively used in young or neonatal animals. Hypoxic condition can 
cause delayed neuronal death hippocampus, striatum and neocortex in neonatal mice (Adén et 
al., 2002). Hypoxic ischemic conditions have been suggested to contribute to brain damage 
through excitotoxic and apoptotic mechanisms (Beilharz et al., 1995, Northington et al., 2011). 
2.5 BEHAVIORAL TESTING IN MOUSE MODELS OF FOCAL CEREBRAL 
ISCHEMIA 
There are a number of different ways to produce ischemia in animal models with differences in 
the resulting lesion size and the specific site of the lesion. These differences ultimately affect the 
sensitivity and selectivity for various behavioral deficits (Mustafa et al., 2012). Finally, age, co-
morbidities as well as strains of the animal used also influence the behavioral outcome 
(Fahlström et al., 2012, Manwani et al., 2011, Mustafa et al., 2012, Sweetnam et al., 2012). Thus, 
various parameters should be taken into account while designing the experiment that involves 
behavioural assessments following stroke. In fact, a large amount of behavioural testing has 
been successfully applied to mouse models of focal ischemia that were initially applied to rat 
models but later validated in mouse models of focal ischemia (Mustafa et al., 2012). Some of the 
most important behavioral tests are described below. 
2.5.1 Rotarod 
Rotarod was first described in rat and later successfully tested in mice for the evaluation of 
motor coordination and balance and has been applied in variety of stroke models and mouse 
strains with variable sensitivity (Dunham and Miya, 1957, Jones and Roberts, 1968, Mustafa et 
al., 2012). The setup consists of a rotating cylinder separated into several compartments. Mice 
are placed on a rotating rod with constant speed or with accelerated speed where they try to 
remain on the rod and avoid falling. The latency to fall is then used to evaluate motor functions. 
Rotarod shows short term sensitivity for up to 4 days in both transient and permanent proximal 
MCAo while no sensitivity was observed in distal MCAo. Mice should undergo preoperative 
testing and baseline determination to differentiate between actual learning and recovery after 
stroke (Mustafa et al., 2012). 
2.5.2 Adhesive removal test 
Adhesive removal tests were initially described in rats to determine sensorimotor deficits after 
unilateral lesions involving sensorimotor cortex and striatum (Schallert et al., 1982). This test 
shows sensitivity for both proximal and distal MCAo. In this test, circular adhesive patches of a 
certain diameter are attached to animal’s forepaws in alternating sequences with equal pressure 
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(Bouet et al., 2009). The mouse is then released into the testing cubicle or testing cage and the 
latency of contact and removal of the patches is recorded. The maximum number of trials per 
day is 3 and duration of each trial is set to 2 min.  In addition, preoperative testing is carried out 
before the ischemia to determine the baseline. In proximal MCAo, the sensitivity was reported 
to last  for 4 to 6 weeks depending upon the duration of occlusion and animal models (Balkaya 
et al., 2013, Bouet et al., 2009, Bouët et al., 2007, Leconte et al., 2009) while in distal MCAo, the 
sensitivity has been shown to persist for up to 3 weeks in Swiss mice (Freret et al., 2009). 
2.5.3 Corner test 
The corner test is used to identify and quantify sensorimotor deficits, as well as postural 
asymmetries. The test was first developed in rats (Schallert et al., 1982) but later adopted in 
mice (Zhang et al., 2002). The apparatus consists of two boards placed together in 30 degree 
with a small slit at the junction to motivate the mice to move to the corner. The animal is then 
placed halfway facing the corner and as the animal approaches the corner, vibrissae on both 
sides will be simultaneously stimulated and animal will rear and turn either left or right. Intact 
or naïve mice show no preference on the direction to turn while animals with unilateral damage 
will prefer their ipsilateral side for rearing and turning (Li et al., 2004, Schaar et al., 2010). The 
corner test can detect both mild and chronic deficits in mice (Schallert, 2006). Preoperative 
testing to obtain baseline data and to compare pre-stroke and post-stroke values is important 
for the reduction of variability and identification of the preferential side. Corner tests have been 
successful in detecting the functional deficits at early time points following the proximal 
transient filament occlusion (Mustafa et al., 2012). However, no sensitivity was observed in the 
distal MCAo (Freret et al., 2009, Lubjuhn et al., 2009). Likewise, sensitivity was observed up to 
90 days after embolic MCAo (Zhang et al., 2002). Thus, the corner test can detect the 
sensorimotor asymmetry at both early and late time points where striatal damage is involved. 
2.5.4 Catwalk gait analysis 
Gait impairment is one of the visible deficits in clinical stroke and is often the focus of post-
stroke therapy (van de Port et al., 2007). Conventional gait analysis involves the use of ink on 
animal paws followed by walking over the length of paper (de Medinaceli et al., 1982). This 
technique allows evaluation of gait parameters like stride length and hind paws drag. 
Nowadays, a computer aided system with a catwalk is designed to detect gait impairment in 
rodent models. This system consists of a long transparent glass platform in which the animal 
walks, and the walking is recorded using a video camera underneath the glass plate. This 
system generates a vast amount of data and allows the detection of even slight deficits in gait. 
However, speed variation during the run and loss of body weight after stroke may hinder the 
analysis. There are only few papers that have reported the use of catwalk gait analysis in the 
mouse model of proximal MCAo with deficits in various parameters like stand duration, duty 
cycle, swing speed, stride length etc., (Balkaya et al., 2013, Encarnacion et al., 2011, Hetze et al., 
2012, Lubjuhn et al., 2009). 
2.5.5 Wire hang test 
The wire hang test, used to evaluate grip strengths, endurance and balance, is a simple test in 
which mice are suspended using their front paws on a horizontal wire 50-60 cm above the 
ground (Hattori et al., 2000, Mustafa et al., 2012). The hind paws are covered with adhesive to 
prevent their use while hanging and latency to fall is used to access motor performance. In 
proximal filamentous MCAo, the wire hang test has shown sensitivity ranging from 1-3 weeks 
depending on the strain of mice used (Abe et al., 2009, Gertz et al., 2006). The wire hang test is 
suitable for detecting early and late post-stroke deficits where striatal damage is involved. 
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2.5.6 Other behavioral tests 
In addition to the above described tests, there are a number of other options to detect  
behavioral deficits which include the pole test, an open field test, cylinder test, handedness test, 
staircase test, foot fault test, ladder rung test and grip strength (Balkaya et al., 2013). Ultimately, 
successful testing procedures involve the choice of the animal strain as well as the model of 
ischemia used. Some tests might be useful in some models and stains and not the other. Thus, 
important consideration should be taken into account when designing the experiment 
paradigm involving behavioral testing in mice. 
2.6 CLUSTER OF DIFFERENTIATION (CD36) AS A THERAPEUTIC TARGET IN 
PERMANENT FOCAL CEREBRAL ISCHEMIA 
2.6.1 Overview 
CD36, or simply known as fatty acid translocase, is a transmembrane, highly glycosylated, 
88KDa glycoprotein that belongs to class B scavenger receptors (Cho and Kim, 2009). CD36 was 
initially described as a platelet receptor for thrombospondin (TSP). Later it was found to be 
expressed on a wide variety of cells including neurons, microglia and astrocytes in brain, 
monocytes/macrophage, platelets, microvascular endothelium, skeletal muscle cells, adipocytes 
and dendritic cells in the periphery (Abumrad et al., 1993, Albert et al., 1998, Febbraio and 
Silverstein, 2007, Huh et al., 1996, Husemann et al., 2002, Medeiros et al., 2004, Swerlick et al., 
1992). In the brain, CD36 is especially expressed in neurons on ventral CA1 hippocampal 
region, perirhinal cortex and ectorhinal cortex and brainstem nuclei (Glezer et al., 2009). CD36 
has an extracellular domain flanked by two transmembranes and two cytoplasmic domains. 
The extracellular domain contains a hydrophobic region that interacts with the plasma 
membrane and a proline rich region (Collot-Teixeira et al., 2007). CD36 can bind to a wide array 
of ligands including collagen, TSP, oxidized LDL (ox-LDL), phospholipids, long chain fatty 
acids (LCFA) and fibrillar Aβ (Febbraio and Silverstein, 2007) and is involved in wide biological 
functions including angiogenesis, atherosclerosis, phagocytosis and inflammation (Febbraio 
and Silverstein, 2007, Hirano et al., 2003). 
2.6.2 Role of CD36 in Ischemia induced inflammation  
Under normal conditions, the brain expresses low levels of CD36. However, following cerebral 
ischemia, CD36 has been shown to be upregulated in infiltrating macrophages in the infarct 
area whereas astrocytic expression of CD36 has been reported on the peri-infarct area. Neuronal 
expression of CD36 was nearly absent (Cho and Kim, 2009). It is well known that CD36 acts as a 
receptor for extracellular matrix proteins TSPs, TSP-1 and TSP-2 and is involved in endothelial 
cell apoptosis (Jiménez et al., 2000). Following ischemic stroke, biphasic expression of TSP-1 was 
observed at 1 and 72 hours whereas TSP-2 was expressed during the recovery or resolution 
phase (Lin et al., 2003). Thus, TSP-1 and CD36 interaction may be involved in stroke 
pathogenesis during the early phase of ischemia through apoptosis mediated by caspase-3-like 
effector (Jiménez et al., 2000, Dawson et al., 1997). CD36 is a molecular sensor for innate 
immune response and accumulating evidence suggest that CD36 activation results in 
proinflammatory signaling. Therefore, it is not surprising that CD36 has a pathogenic role in 
brain ischemia. Following brain injury or tissue damage, innate immune response may mediate 
inflammatory responses against endogenous danger signals in the post-ischemic brain via 
pattern recognition receptors like CD36 (Matzinger, 2002, Cho and Kim, 2009). CD36 is involved 
in sterile inflammation where it contributes to tissue damage through free radical generation 
(Cho et al., 2005). CD36 deficient mice have been reported to develop smaller lesions compared 
to WT mice after stroke most probably through inhibition of NF-kB activation (Kunz et al., 2008, 
Kim et al., 2008, Cho et al., 2007). In addition, genetic deletion of CD36 has also been shown to 
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actuate brain injury following acute neonatal stroke (Woo et al., 2012). CD36 also contributes to 
exacerbated brain damage in co-morbid conditions like hyperlipidemia and diabetes (Cho and 
Kim, 2009). CD36 was reported to counteract with TLR2/1 heterodimers to induce 
neuroinflammation in post-ischemic brain (Abe et al., 2010). In addition, interaction of CD36 
with fibrillar Aβ and integrins also results in the expression of proinflammatory cytokines and 
chemokines (Cho, 2012). Likewise, CD36 has been shown to contribute to inflammation through 
regulation of calcium influx in response to ER stress and formation of prostaglandin E2 in vitro 
(Kuda et al., 2011). Taken together, these data suggest an inflammatory nature for CD36 in 
cerebral ischemia and targeting CD36 might provide a therapeutic strategy for stroke. 
 There are only two published inhibitors for CD36. One such inhibitor, peptide SS31, has 
been shown to attenuate ischemia by downregulating CD36 mediated pathways in vivo. Most of 
the studies involving inhibition of CD36 have arised from in vitro studies (Angin et al., 2012, 
Geloen et al., 2012, Kuda et al., 2013, Min et al., 2013). Another potential inhibitor of CD36 in 
vitro is sulfosuccinimidyl oleate (SSO) (Coort et al., 2002). SSO has been shown to bind CD36 
and thus inhibit fatty acid uptake and intracellular calcium signalling along with inhibition of 
ox-LDL uptake by macrophages (Kuda et al., 2013). In addition, it has been shown to inhibit 
complex III of the mitochondrial respiratory chain (Drahota et al., 2010). However, the potential 
therapeutic effect of SSO is yet to be explored and belongs to the focus of this study. 
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3 Aim of the study 
Stroke mainly affects the elderly population affected with other co-morbidities. Even though 
recombinant tPA is the only approved drug for the treatment of stroke, its effectiveness is 
limited to a very narrow therapeutic time window. Moreover, hemorrhagic complications often 
occur following tPA administration and alternative treatment paradigms are being explored. 
Indeed, a number of compounds have proven to be beneficial in preclinical models of stroke. 
However, these treatment regimens have all failed in clinical studies. This might be attributed 
to the fact that while most of the treatment strategies in preclinical models have been performed 
in homogenous young cohorts, stroke typically affects elderly with accompanied co-
morbidities. Thus, exploring the effect of co-morbidities like aging, diet, infections and 
apolipoprotein genotype in preclinical studies should provide the next level of understanding 
in the pathophysiology and mechanisms of ischemic stroke and ultimately lead to successful 
treatment paradigms. The main focus of this study is how co-morbidities and aging affect the 
outcome of ischemic stroke. Moreover, we aimed to perform initial trials for a new therapeutic 
strategy for experimental stroke. The main goals of this study were: 
1. To explore the impact of HF diet on sensorimotor deficits and inflammation following 
pMCAo in aged male mice expressing human ApoE3 (ApoE3-TR) and (ApoE4-TR) 
isoforms in C57Bl/6j background. 
2. To determine the effect of chronic peripheral Th1 shifted infection modelled by Trichuris 
muris (T. Muris) parasites  in aged C57Bl/6j mice subjected to pMCAo 
3. To investigate the effects of CD36 inhibitor, SSO, on the outcome following ischemic 
stroke in young Balb/CaBom mice. 
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4 Material and Methods 
4.1 ANIMALS AND TREATMENT GROUPS (I-III) 
All animal experiments were approved by National Animal Experiment Board of Finland and 
followed the Council of European Legislation and Regulation for Animal protection. ApoE3-TR 
and ApoE4-TR mice on a C57Bl/6j background with 8X generation backcross were obtained 
from Duke University Medical Center courtesy of Patrick M Sullivan. The transgenic mice were 
generated without altering any endogenous regulatory sequences as described elsewhere 
(Sullivan et al., 2008, Sullivan et al., 1997). These mice along with other strains including 
C57Bl/6j and Balb/cABom used in this study were housed in light and humidity controlled 
environment with free access to food and water available ad libitum. For the study involving 
human ApoE isoforms, thirteen month-old ApoE3-TR, ApoE4-TR and C57Bl/6j mice were 
divided into three subgroups: ischemic mice fed with HF diet (HF + Isch), ischemic mice fed 
with normal diet (ND + Isch) and sham operated mice fed with normal diet (ND + Sham). 
Western type HF diet (Teklad TD88137 containing 48.5 % carbohydrates, 21.2 % fat and 0.2 % 
cholesterol with energy density of 4.5 kcal / g, Harlan Laboratories, WI, USA) or normal diet 
(ND; Teklad 2016S containing 48.5 % carbohydrates, 4 % fat and 0 % cholesterol with energy 
density of 3.0 kcal / g, Harlan Laboratories) was fed to the corresponding groups for 15 weeks. 
Separate cohorts of young mice were also used for the study. In a separate study involving 
chronic infection, young C57Bl/6j mice aged 4 months and old C57Bl/6j aged 18-22 months were 
both subdivided into uninfected and infected groups. In this study, 10 infective T. Muris egg 
suspended in 50μl of phosphate-buffered saline were introduced by oral gavage into the 
stomach of the mice while those in uninfected groups received saline as a vehicle. These mice 
underwent ischemic surgeries after 35 days on per oral administration of infective eggs when 
the Th1 polarized immune response peaks (Dénes et al., 2010). In the study involving CD36 
inhibition, 4 month-old Balb/cABom from Taconic was used.  
4.2 ANIMAL RANDOMIZATION (I-III) 
In all the experiments, animals were randomized into the respective treatment groups using 
Graph Pad QuickCalcs (GraphPad Software, Inc. La Jolla, CA, USA). All data were analyzed 
blinded to the treatment groups. 
4.3 CEREBRAL ISCHEMIA (I-III) 
All the animals used in this study underwent permanent occlusion of MCA as described 
previously (Koistinaho et al., 2002). The mice were anesthetized with 5% isoflurane (in 70% 
N2O/30% O2) and maintained at 1.8%-2% isoflurane during surgery. The body temperature of 
the mice was maintained at 36.7 ± 0.7 during the surgery using a thermostatically controlled 
rectal probe connected to a homeothermic blanket (PanLab, Harvard Apparatus, Barcelona, 
Spain). During the surgery, the temporal bone of the mouse was exposed, and a small hole of 1-
mm diameter was drilled at the level of inferior cerebral vein. Saline was applied to the drilled 
area to prevent heat injury. The dura was then carefully removed to expose the MCA and the 
MCA was permanently cauterized using a thermocoagulator (Bovie Medical Corporation, 
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Clearwater, FL, USA). Following the electrocoagulation, the temporalis muscle was replaced 
and the wound was sutured. The mice were then allowed to recover from anesthesia. Sham-
operated animals underwent the same procedure except the MCA occlusion. After the end of 
the experiment, the mice were anesthetized with 250mg/kg Avertin and transcardially perfused 
with heparinized saline (2500 IU/L). Alternatively, following anesthesia, the brain was removed 
and freshly frozen.  
 4.4 PHYSIOLOGICAL PARAMETERS (I-III) 
Physiological parameters were measured immediately after the onset of ischemia from blood 
samples drawn from the saphenous vein. Blood glucose levels were measured using the free 
style glucose monitoring system (Abbott, Alameda, CA, USA). The partial pressure of carbon 
dioxide and oxygen and pH were measured using an i-STAT analyzer (Abbott, Abbott Park, Il, 
USA).  
4.5 CHOLESTEROL MEASUREMENT (I) 
Blood samples collected via cardiac puncture 10 days post-surgery were used to quantify the 
serum total cholesterol levels. Right before perfusion, blood samples were collected in 
nonheparinized state and allowed to stand at room temperature for 30-90 min and centrifuged 
at 3500 rpm for 15 minutes. The serum samples that were frozen until further analysis were 
thawed at room temperature and cholesterol measurement was done using a cholesterol 
measurement kit according to manufacturer’s instruction (Cayman Chemicals, Ann Arbor, MI, 
USA). Data were collected using a Wallace 1420 workstation (Perkin Elmer, Waltham, MA, 
USA).  
4.6 ASSESSMENT OF ISCHEMIC DAMAGE (I-III) 
The volume of the infarct size in ischemic animal was assessed either ex vivo or in vivo using a 
vertical 9.4 T Oxford NMR 400 Magnet (Oxford Instrument Plc, Abingdon, UK) interfaced to a 
Varian DirectDrive console (Varian Inc, Palo Alto, CA, USA).  For the in vivo measurement of 
infarct size, the mice were anesthetized and maintained with isoflurane as describe in section 
3.3.  A quadrature volume RF coil was used for transmission and reception (Rapid Biomedical 
GmBH, Rimpar, Germany). Scout images were obtained to locate the area of the brain, and the 
axial sections were acquired right from the start of olfactory bulbs. Multislice T2 weighted 
images (repetition time 3,000 ms, echo time 40 ms, matrix size 128×256, field of view 19.2×19.2 
mm2, slice thickness 0.8 mm and number of slices 12) were obtained with double spin-echo 
sequence with adiabatic refocusing pulse. For the ex vivo measurement of the infarct size, brain 
submerged in 4% paraformaldehyde (PFA) 24 hours following perfusion was used. The 
procedure remained the same as in in vivo infarct measurement except the repetition time of 2.5 
s and 15 consecutive slices. The obtained images were analyzed by defining the region of 
interest using in-house made software (Aedes) under the Matlab environment (Math-works, 
Natick, MA, USA). The total infarction volume and the volumes of left and right healthy 
hemispheres were calculated from either 12 or 15 consecutive slices. The lesion volume was 
determined by multiplying the number of pixel with pixel size and slice thickness. 
Alternatively, the relative percentage of the infarction volume was determined using the 
formula as described previously (Shuaib et al., 2002). 
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4.7 ADHESIVE REMOVAL TEST (I) 
Adhesive removal test was used to determine the sensorimotor deficits following cerebral 
ischemia in study involving aged ApoE3-TR, ApoE4-Tr and C56Bl/6j mice. This study involves 
the use of circular adhesive patches of 6.5mm diameter (Bel-Art products, Wayne, NJ, USA). 
The mouse is taken from the home cage and adhesive patches were placed on front paws in an 
alternate pattern as describe in section 2.5. The mouse was then placed in a transparent cubical 
box and the latency from sensing to removal of the patches was recorded. Each mouse 
underwent 3 trials per day with duration of each trial being 120 seconds. Animals were tested 3 
days prior and 3 and 7 days post-ischemia. Testing and evaluation was carried out by the same 
people in a blinded fashion (Bouet et al., 2009). 
 4.8 IMMUNOHISTOCHEMISTRY (I-III) 
For immunohistochemical analysis, mice were anesthetized with 250mg/kg of Avertin and 
perfused transcardially with heparinized (2500IU/L) saline. The brains were dissected out and 
post-fixed in 4% PFA for 24 h followed by cryoprotection in 30% sucrose for 48-72 hours. The 
brains were then snap frozen in liquid nitrogen and cut into 20 μm thick coronal sections using 
a cryostat (Leica Microsystems GmbH, Wetzlar, Germany). For each staining, a set of six 
sections that are 400 μm apart spanning through the lesion area were taken.  
For the detection of astrogliosis, microgliosis, neurogenesis, neutrophils and COX-2, brain 
sections were reacted against appropriate antibodies overnight at room temperature Following 
overnight incubation, the sections were washed with PBS containing 0.5% Tween20 (Sigma-
Aldrich, St. Louis, MO, USA). The sections were then incubated with appropriate biotinylated 
secondary antibody for 2 hours and subsequently reacted against avidin-biotin complex reagent 
according to manufacturer’s instructions (1:200 dilution; Vector, Burlingame, CA, USA).  
Alternatively, Alexa 568 conjugated secondary antibody (1:200 dilution; Invitrogen, Eugene, 
OR, USA) was used. The bound immunoreactivity was visualized by development with nickel-
enhanced 3,3’-diaminobenzidine. Immunoreactivity was imaged using an AX70 microscope 
(Olympus Corporation, Tokyo, Japan) on 10X magnification with an attached digital camera 
(Soft Imaging System, Munster, Germany). All immunoreactive areas were quantified blinded 
to the study group using ImagePro Plus Software (Media Cybernetics, Rockville, MD, USA) at a 
predefined range and represented as percentage of positively strained immunoreactive area.  
4.8.1 Ionized calcium binding adapter molecule-1 (Iba-1) (I-III) 
Microgliosis was analyzed using Iba-1 for detecting microglia along with infiltrating 
macrophages either at day 1, 3 and 10 days post-ischemia. The sections were reacted against 
primary Iba-1 antibody (1:250 dilution; Wako Chemicals GmbH, Neuss, Germany) and 
followed the procedure described above. For the quantification of Iba-1 immunoreactivity in the 
peri-ischemic area, a 712μm*512μm or 720μm*530μm area adjacent to the infarct border was 
imaged from the six consecutive sections. In addition, the corresponding area in the 
contralateral side was also imaged.  
4.8.2 GFAP (I & III) 
Astrogliosis was analyzed using GFAP to detect reactive astrocytes at day 3 and 10 days post-
ischemia. Primary GFAP antibody (1:500 dilution; DAKO, Glostrup, Germany) was reacted 
against the brain sections and essentially followed the step as described above. GFAP 
immunoreactivity was visualized from 712μm*512μm area adjacent to the ischemic area. In 
addition, images from the corresponding contralateral hemisphere were also taken. 
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4.8.3 Cycloxygenase-2 (COX-2) (I & III) 
COX-2 immunostaining was performed using primary COX-2 antibody at day 3 post-ischemia 
(1:500 dilution, Cayman Chemicals) which then followed the procedure as above. For 
visualizing COX-2 immunoreactivity, an area of 712μm*512μm adjacent to the ischemic area on 
the ventral side of the brain was taken in addition to the corresponding side on the contralateral 
hemisphere.  
4.8.4 Neutrophils (II) 
For detecting neutrophils, sections were incubated with primary anti-neutrophil antibody 
(1:5000 dilution; Serotec, Kidlington, UK) and followed the process described above. However, 
an area of 720μm*530μm right on the lesion site was used to quantify the neutrophils. Since the 
contralateral side was devoid of neutrophils, no images were taken from the contralateral side. 
4.8.5 Doublecortin (DCX) 
Neurogenesis was analyzed from the brain sections of animals sacrificed 10 days post-ischemia. 
For detecting neurogenesis, sections were incubated with primary DXC antibody (1:200 
dilution; Cell signaling, Danvers, MA, USA). DCX immunoreactivity was visualized from six 
consecutive sections in 400μm intervals from the subventricular area of 718μm*532μm adjacent 
to the wall of lateral ventricles from both hemispheres.  
4.9 CYTOKINES (I & II) 
Cytokines were measured from plasma samples as well as from freshly frozen brain samples. 
For the measurement of cytokines from the plasma sample, blood was collected from either 
saphenous vein or cardiac puncture using 1:10 volume of sodium citrate (3.8%) as an 
anticoagulant. The blood samples were then centrifuged at 1500g for 10 min and plasma was 
withdrawn and snap frozen in liquid nitrogen until further analysis. In the study using targeted 
replacement mice, cytokines including IL-6, IL-10, MCP-1, TNF, IFN-γ and IL12p70 were 
analyzed from the blood drawn via cardiac puncture at day 3 post-ischemia using Cytometric 
Bead Array (CBA) and Mouse inflammation kit (BD Biosciences, San Jose, CA, USA) according 
to manufacturer’s instructions. The samples were run on FACS Caliber flow cytometer (BD 
Biosciences) and analyzed using FCAP Array 2.0 software (Soft Flow Hungary Ltd, Pecs, 
Hungary). The concentration of MCP-1 was further analyzed by MCP-1 ELISA kit (Thermo 
Fischer Scientific, Rockford, IL, USA).  
Likewise, arrays of cytokines were measured from plasma samples taken 1 and 4 after 
ischemia as well as from freshly frozen brain section 24h post-ischemia. Cytokines including 
RANTES, MCP-1, Keratinocyte chemoattractant (KC), IL-6, IL-1β, IL-1α, IL-17α, IL-10, IFN-γ 
and GCSF in brain and plasma were measured using CBA kit as described above. To analyze 
the brain cytokines, brain areas were dissected into three regions: a) lesion area clearly visible as 
a white area consisting of dead tissue, b) peri-ischemic area as 1-mm wide area surrounding the 
lesion area and c) corresponding contralateral area. The brain samples were snap frozen in 
liquid nitrogen until further analysis. The frozen brain samples were homogenized in lysis 
buffer at 4°C as described earlier (Dénes et al., 2010). Plasma level of RANTES was also 
measured 1 day prior to ischemia. In addition, selected cytokines like IL-1, IL-4, IL-6, IL-10, IL-
17α, IFN-γ and TNF-α was also measured from the plasma sample taken at the end time point 
of 24 hours using CBA Flex Sets (BD Biosciences).  
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4.10 ASSESSMENT OF ATHEROSCLEROTIC LESIONS (I) 
For the determination of atherosclerotic lesion, the heart was removed and fixed in 4% 
paraformaldehyde for 4-6 hours after perfusion at day 3 post-ischemia. Following fixation, the 
heart was stored in PBS and the apex of the heart was removed and the base of the heart was 
casted in paraffin with ventricles down and aorta up. Five micrometer sections were collected 
from the aortic valves perpendicular to the lumen towards the base of the heart. Every fifth 
section and a total of 6-8 sections were stained with hematoxylin-eosin to observe the possible 
lesions. 
4.11 IN VITRO NO RELEASE ASSAY AND LATEX BEAD PHAGOCYTOSIS (III) 
To determine if the application of the SSO reduced the phagocytosis activity of BV-2 microglial 
cells, BV-2 microglial cells were plated in 96 well plates (9000 cells/well) in a 100μl of RPMI-
1640 medium (Sigma-Aldrich, Cat# R0883) containing 10% fetal bovine serum and 5μg/ml 
gentamicin. Twenty-four hours after plating, the medium was replaced with serial dilution of 
50μl of SSO and 50μl of 100ng/ml lipopolysaccharides (LPS) (Sigma) and incubated for the next 
24 hours. After incubation, 50 μl of medium was used for NO release assay using Griess 
reagent. For the remaining 50μl media, additional 50μl of fluorosphere fluorescent bead 
suspension diluted to 1:500 was added and incubated for an additional 5 hours. Following 
incubation, the culture medium was removed and the cells were washed with PBS and lysed. 
Extent to phagocytosed beads was assayed by measuring fluorescence at 485nm/590nm 
excitation/emission wavelength on vector II multilabel reader (Perkin-Elmers). Cell viability 
was measured separately where treatment media was removed after 24 h and replaced with 
100μl of 10μM pre warmed resazurin. The plates were then incubated for 2h at 37°C in 5% CO2 
and resazurin fluorescence measured again. 
4.12 STATISTICAL ANALYSIS AND EXCLUSION CRITERIA (I, II, III) 
Statistical analysis was performed using either GraphPad prism or SPSS 19 software (IBM SPSS 
Inc., Chicago, IL, USA) when appropriate. The effect of treatment and genotype as dependent 
variable was analyzed by two way analysis of variance followed by Sidak Post-hoc test and 
logarithmic transformation was applied to normalize the data when appropriate. One way 
analysis of variance with Bonferroni post-hoc test was also applied where appropriate. Data are 
either expressed as mean±SD or mean±SEM and P<0.05 was considered statistically significant. 
Exclusion criteria were set prior to the experiment and included: statistical outliers as analyzed 
by Graph Pad Quickcalcs, mice with bleeding during surgery, hemorrhage visible as black spots 
in ischemic hemisphere in magnetic resonance imaging (MRI) image were excluded from the 
experiments.  
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5 Results 
5.1 PHYSIOLOGICAL PARAMETERS WERE UNALTERED BETWEEN THE 
STUDY GROUPS (I & II)  
Following ischemic stroke, several physiological parameters including body temperature, blood 
glucose, and partial pressure of oxygen and carbon dioxide maybe altered and might affect the 
outcome after ischemic stroke. We, therefore, analyzed these parameters immediately  after 
MCA occlusion (Sorce et al., 2010). We observed no significant differences in pH, glucose, pCO2 
and pO2 following ischemia in any of the study groups (Study I, table 1). 
5.2 APOE ALLELE MODIFIES INFLAMMATORY RESPONSE IN BOTH CNS AND 
PERIPHERY AND CONTRIBUTES TO FUNCTIONAL DEFICITS FOLLOWING 
ISCHEMIC STROKE (I) 
5.2.1 HF diet accompanies increased body weight and cholesterol in both ApoE-TR and 
ApoE4-TR mice 
Body weight of the mice was monitored before and after the HF diet. Prior to the HF diet, 
ApoE3-TR mice reveled 20% greater body weight compared to ApoE4-TR and WT mice. 
ApoE3-TR mice weighed on average 38.1 ± 6.0 g whereas ApoE4-TR and WT mice weighed 31.4 
± 3.4 g and 30.5 ± 3.1 g respectively. This significant difference in weight (p<0.001) between 
ApoE3-TR mice versus ApoE4-TR mice and WT mice lasted throughout the HF diet period.  
The weight of all the mice peaked at 13 weeks and reached a stable plateau thereafter. At the 
end of 15 weeks on HF diet, the average weight of ApoE3-TR mice was 46.2 ± 2.55, ApoE4-TR 
mice 39.3 ± 1.49 g and WT mice 40.7 ± 2.10 g (mean±SEM). Compared to mice fed on ND diet, 
serum cholesterol levels were increased to a significant extent in all strains. However, the serum 
cholesterol level on WT mice on HF was significantly lower compared to ApoE3-TR mice on the 
same diet.  Intriguingly, ApoE3-TR mice fed with normal chow exhibited significantly higher 
cholesterol compared to ApoE4-TR mice on same diet (Study I, Figure 1). 
5.2.2 Sensorimotor deficits were pronounced in ApoE4-TR mice on HF diet  
The distal pMCAo model used in this study produces a small cortical infarct. Here, we 
examined the effect of ApoE isoform alone or in combination of HF diet on the infarct size using 
MRI images obtained 3-day post-ischemia. Data from the MRI analysis revealed no differences 
between the study groups even though there was a mild tendency towards increased infarct 
size in WT and ApoE4-TR mice fed with a HF diet (Study I, Figure 2A). Since the lesion in our 
pMCAo model develops in the somatosensory cortex, we examined the adhesive removal test 
to determine the effect of ApoE isoforms and HF diet on the behavioral outcome. Irrespective of 
lesion size, long term intake of a HF diet resulted in clear sensorimotor deficits in ApoE4-TR 
mice when compared to ApoE3-TR mice on the same diet at day 3- and 7 post-ischemia (Study 
I, Figure 2B and 2C). An interesting observation in this study was the ability of sham-operated 
ApoE3-TR mice on ND to remove the adhesive patches faster when compared to sham-
operated mice of other genotypes on the same diet. Stroke induced sensorimotor deficits were 
observed in ApoE3-TR mice at both 3 and 7 days post-ischemia. In contrast, stroke induced 
sensorimotor deficits were apparent in WT mice at day 7 post-ischemia. 
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5.2.3 Altered inflammatory response in brain and periphery of mice fed on a HF diet 
Altered glial activation is a hallmark of cerebral ischemia. We thus analyzed the brain glial 
activation at day 3 and 10 post-ischemia by using Iba-1 and GFAP antibodies. Following 
ischemia, there was significant upregulation of both glial markers in the peri-ischemic area 
when compared to the contralateral side in all treatment groups at day 3 and 10. Ischemia 
induced GFAP upregulation in the peri-ischemic area to a similar extent in all strains fed on a 
ND at 3 days post-ischemia (Study I, Figure 3A). However, HF diet further actuated the GFAP 
upregulation to a significant level in ApoE3-TR and ApoE4-TR mice but not in WT mice at 3 
days post-ischemia. In contrast, HF diet-accompanied upregulation in astrocytic activation was 
not observed at 10 days post-ischemia. Microglial activation as revealed by Iba-1 
immunoreactivity did not differ between the genotypes regardless of the dietary intervention at 
either 3 or 10 days post-ischemia (Study I, Figure 3B). Because of plethoric inflammatory 
response occurring in the brain following ischemia, glial activation does not necessarily reveal 
all the events occurring following ischemia. We thus examined the effect of genotypes and HF 
diet on ischemia induced peri-ischemic COX-2 activation. Quantification of COX-2 
immunoreactivity revealed ischemia induced significant upregulation of COX-2 in the peri-
ischemic area of all treatment groups except ApoE3-TR mice on ND. Interestingly, a HF diet 
was found to cause significant upregulation of COX-2 in ApoE4-TR mice in contrast to other 
genotypes on a HF diet (Study I, Figure 4A). 
Experimental stroke has been shown to rapidly activate the peripheral immune system with 
concomitant upregulation of several cytokines and chemokines (Ferrarese et al., 1999, Offner et 
al., 2006). Taking into account the contribution of peripheral inflammatory cells and their 
release of toxic inflammatory molecules in ischemic stroke, we sought to determine a panel of 
cytokines that might be affected following ischemia. In fact, we analyzed various cytokines (Il-6, 
IL-10, MCP-1, TNF, IFN-γ and IL-12p70) and only IL-6 and MCP-1 were found within the 
detectable limits in the plasma samples analyzed 3 days post-ischemia. CBA assay revealed a 
significant upregulation of IL-6 in plasma of ApoE4-TR mice on HF diet compared to ApoE4-TR 
on normal chow (Study I, Figure 4H). In addition, the plasma level of IL-6 on ApoE4-TR on HF 
diet was significantly higher compared to WT mice on the same diet. ELISA of MCP-1 did not 
reveal any significant differences between the study groups (Study I, Figure 4I). 
Atherosclerosis is accompanied by inflammation in concurrent to lipid accumulation in the 
artery wall. ApoE3-TR and ApoE4-TR mice have been shown to develop atherosclerotic plaques 
following an atherogenic diet (Knouff et al., 1999, Sullivan et al., 1997). We thus sought to 
determine if the mice in this study developed atherosclerosis accompanied by inflammation 
and whether this contributed to the poor behavioral outcome. However, none of the study 
groups showed foam cell or fatty streak formation on the endocardial surface of the valve 
leaflets indicating that the intake of a HF diet was unable to induce atherosclerosis in any of the 
strains.  
5.2.4 Isoform specific ischemia-induced induction of neurogenesis 
During the late phase of ischemia, neurogenesis is one of the endogenous mechanisms 
associated with improved recovery. Since ApoE ε4 allele has been shown to dampen 
neurogenesis following ischemia (Crawford et al., 2009, Li et al., 2009), we hypothesized that 
poorer outcome in behavioral test in ApoE4-TR mice might be accompanied by decline in 
ischemia-induced neurogenesis. Quantification of DCX staining revealed that ischemia failed to 
upregulate significant neurogenesis in WT and ApoE4-TR mice but not in ApoE3-TR mice fed 
on a ND (Study I, Figure 6). However, a HF diet did not have any additional impacts on 
endogenous neurogenesis. 
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5.3 CHRONIC PERIPHERAL INFECTION IN AGED ANIMALS EXACERBATE 
BRAIN DAMAGE (II) 
5.3.1 Brain damage in aged infected mice correlates with pre-ischemic plasma RANTES 
Assessment of the ischemic damage was carried out using ex vivo MRI. Quantification of MRI 
images revealed that the infection specifically in aged mice contributes to the exacerbated brain 
damage when compared to young mice (Study II, Figure 1). However, aging alone had no effect 
of the size of lesion volume. Likewise, young mice with or without infection did not show any 
difference in lesion size suggesting that infection has no detrimental role in young cohorts. 
Administration of T. muris has been shown to cause Th-1 polarized immune response and 
significant upregulation of RANTES that peaks at 4-5 weeks post infection (Dénes et al., 2010). 
We thus determined the pre-ischemic plasma level of RANTES and checked the correlation of 
circulating plasma RANTES level with infarct size. Indeed, we observed significant 
upregulation of RANTES in both young and old infected mice when compared to their 
uninfected counterparts (Study II, Figure 2A). We also found a significant correlation exists 
between the plasma RANTES level and infarct size in old ischemic infected mice but not young 
ischemic infected mice (Study II, Figure 2B).  
5.3.2 Levels of plasma GCSF-1, KC and IL-6 increased within hours after stroke 
Dysregulation of immune system and inability to respond to the pathological insults are 
hallmarks of aging as described previously (Dorshkind et al., 2009, Plackett et al., 2004, Raynor 
et al., 2012). An altered immune system following aging increases the susceptibility of people to 
infections thus increasing the risk of various insults including ischemic stroke. Thus, we sought 
to determine the effect of aging and chronic infection on various inflammatory mediators in 
both plasma and brains of young and old infected mice at 1 and 4 hours post-ischemia. An 
array of cytokines were analyzed including TNF-α, RANTES, MCP-1, KC, IL-6, IL-1β, IL-1α, IL-
17α, IL-10, IFN-γ and GSCF-1 but only plasma levels of GCSF-1, KC and IL-6 was significantly 
upregulated at 4 hours following ischemia when compared to 1 hour post-ischemia in all study 
groups irrespective of age and infection. 
5.3.3 Brain microgliosis remained unaltered while neutrophil infiltration was highly 
upregulated in aged infected mice 
Brain microgliosis as assessed by immunohistochemical staining using Iba-1 antibody was 
found to cause a significant upregulation of ischemia induced Iba-1 immunoreactivity in the 
ipsilateral side when compared to the contralateral side. However, no difference in Iba-1 
immunoreactivity was observed in the peri-ischemic area between treatment groups (Study II, 
Figure 3). Neutrophil infiltration as analyzed by anti-neutrophil antibody revealed that aging 
with preceding chronic infection causes a massive infiltration of neutrophils in the lesion site 
(Study II, Figure 4A). However, infection did not alter the level of infiltrated neutrophils in 
young mice. Aging alone was insufficient to cause increased infiltration of neutrophils. 
Moreover, the size of the infarction also correlated with neutrophil infiltration (Study II, Figure 
4B). Contralateral hemisphere was devoid of any neutrophils.  
5.3.4 Peri-ischemic levels of GCSF-1 and MCP-1 was compromised in aged infected mice  
Cortical brain samples were dissected 24 hours post-ischemia from all treatment groups and 
were further analyzed to determine the levels of various cytokines and chemokines including 
TNF, RANTES, MCP-1, KC, IL-6, IL-1β, IL-1α, IL-17α, IL-10, IFN-γ and G-CSF using CBA kit. 
Infection alone (independent of aging) was able to upregulate the peri-ischemic levels of G-CSF, 
MCP-1 and KC in all the study groups even though differential effects were observed in IL-1 α 
and RANTES in both young infected and young uninfected mice (Study II, Figure 5). Moreover, 
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ischemia upregulated the cytokines to a greater extent in aged mice when compared to young 
mice. However, the levels of GCSF-1 and MCP-1 were significantly attenuated in aged mice. 
Likewise, cytokine levels in plasma were also analyzed 24 h post-ischemia. Of various cytokines 
analyzed, significant alterations were found in the levels of TNF-α and IL-17α (Study II, Figure 
6A and 6B). Infection along with aging was found to cause significant upregulation of TNF-α 
when compared to young infected or uninfected mice. Aging alone had no effect on the plasma 
level of TNF. Likewise, old infected mice also exhibited a higher plasma level of IL-17α when 
compared to young infected but not old or young uninfected. 
5.4 SSO PROTECTS AGAINST CEREBRAL ISCHEMIA INDUCED BRAIN 
DAMAGE (III) 
5.4.1 Regulation of phagocytosis and NO release in BV-2 microglial cells by SSO 
Microglia are immunocompetent cells with the ability to phagocytose cellular debris following 
acute insult. However, they also release a number of potential proinflammatory molecules that 
can harm the surrounding cells during their activation phase. Thus, suppression of microglial 
activation can be beneficial following ischemic stroke. Here, we tried to determine if the 
treatment with SSO can reduce the activation of microglial cells following insult or stimulation 
by LPS in vitro. Indeed, SSO was able to reduce the microglial activation at varying 
concentrations without affecting the cell viability (Study III, Figure 4D and 4F). In addition, 
microglial stimulation resulted in a rapid increase in NO production (Figure 4E). SSO was able 
to significantly reduce the release of NO even at low concentrations. 
5.4.2 Ischemia induced brain damage in mice is attenuated by SSO 
To evaluate the efficacy of SSO on neuroprotection after focal brain ischemia, Balb/CABom mice 
were subjected to permanent electrocoagulation of MCA and the brain damage was assessed 
using T2-weight MRI 3 days post-ischemia. Quantification of in vivo MRI images revealed that 
ischemic brain damage was significantly reduced in mice treated with 50mg/kg SSO when 
compared to the control mice treated with vehicle. Percentage of the infarction volume in 
treated and untreated mice was 16.5±1.7 and 14.9±1.3 respectively (Study III, Figure 1A and 1B). 
5.4.3 Peri-ischemic COX-2 and Iba-1 immunoreactivity were significantly reduced in SSO 
treated mice 
Brain astrogliosis and microgliosis are induced upon ischemia and contribute to secondary 
ischemic damage. We thus analyzed the brain microgliosis and astrogliosis using Iba-1 antibody 
and GFAP antibody respectively in both SSO treated and control mice. We found significant 
upregulation of ischemia induced Iba-1 immunoreactivity in the peri-ischemic area on the 
ipsilateral side in both treatment groups when compared to the the contralateral side (Study III, 
Figure 2B and 2G-2J). However, peri-ischemic Iba-1 immunoreactivity was significantly 
reduced in SSO treated mice indicating the efficacy of the drug in reducing the ischemia 
induced microgliosis and subsequent production of various inflammatory mediators. Likewise, 
GFAP immunoreactivity for astrocytosis was also significantly upregulated in the peri-ischemic 
area on the ipsilateral side when compared to contralateral side in both groups (Study III, 
Figure 2A and 2C-2F). SSO was unable to alter astrogliosis following stroke. Due to the 
deleterious role of COX-2 in ischemia, we sought to determine if the levels of COX-2 
immunoreactivity are upregulated upon ischemia and whether SSO has a downregulating 
effect. In fact, following ischemia, levels of COX-2 immunoreactivity were significantly 
upregulated in the peri-ischemic area of both SSO and vehicle treated mice. In addition to these 
observations, we detected significant downregulation of COX-2 immunoreactivity in the peri-
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ischemic area in SSO treated mice when compared to the same area in vehicle treated mice 
(Study III, Figure 3A-3E).  
5.5 MAIN FINDING OF THE THESIS 
 
Paper Main Findings 
1 
a) Aged mice expressing human ApoE4 are more susceptible to sensorimotor 
deficits upon ischemia when fed on a HF diet. 
b) In brain, HF diet was able to increase COX-2 activity in ApoE4-TR mice but not 
ApoE3-TR and WT mice.  
c) In periphery, plasma level of IL-6 was significantly upregulated in a HF diet fed 
ApoE4-TR mice when compared to the mice on normal chow. There was no 
alteration in IL-6 levels in both ApoE3-TR and WT mice. 
d) Ischemia induced endogenous neurogenesis was impaired in ApoE4-TR mice 
compared to ApoE3-TR mice that displayed higher neurogenesis. 
2 
a)  Th-1 polarized chronic infection renders the aged animal more vulnerable to 
ischemic insult when compared to young animals. 
b) Pre-stroke level of RANTES correlated with infarct size in aged mice. 
c) Chronic peripheral infection in aged mice was accompanied by massive influx 
of neutrophils into the lesion site. 
d)  Aged infected mice exhibit attenuated levels of GCSF and MCP-1 in the brain. 
e) Aged infected mice showed increase plasma levels of  IL-17 and TNF-α and this 
increase might have resulted in rapid influx of neutrophils in lesion area 
3 
a) SSO was able to reduce the phagocytic activity of BV-2 microglial cells  in vitro 
without altering cell viability 
b)  Massive release of NO by phagocytic BV-2 cells following LPS stimulation was 
significantly attenuated by SSO even at lower concentration. 
c)  Following pMCAo, SSO was found to attenuate the infarct size to a significant 
extent when compared to vehicle group. 
d)  In addition, SSO was able to reduce the inflammation in the brain by reducing 
Iba-1 and COX-2 activity 
 
 
 
49 
 
 
 
6 Discussion 
Stroke is a complex neurodegenerative disease which often leads to long-term hospitalization 
and in extreme cases the death of the patient. The mortality rate of 1.1 million per year in 
Europe alone signifies the economic burden caused by the disease. Considering the vast amount 
of resources that need to be mobilized for both treatment and long-term rehabilitation, a great 
deal of research has focused on the discovery of therapeutic drugs. To this date, only tPA has 
been proven to be safe and effective in the treatment of stroke but often only in a limited 
number of patients. Moreover, the therapeutic time window for the treatment of stroke using 
tPA is limited to 3-4 hours that hinders the treatment of the patient who arrives at the hospital 
too late. So, strategies for prolonging the efficacy of the tPA beyond 4 hours’ time or alternatives 
to tPA in the treatment of stroke patients are currently under intensive investigation. In fact, a 
number of drugs with potential therapeutic efficacy in pre-clinical stroke studies have 
undergone clinical trials. However, none of the drugs has been able to achieve the safety and 
efficacy in humans. The reason for the failure might stem from using young homogenous 
cohorts of animals in preclinical trials while stroke typically affects aged humans suffering from 
accompanying co-morbid conditions like atherosclerosis, infections, diabetes and obesity 
(Cheng et al., 2004). The present study aimed to clarify the impact of co-morbid conditions on 
the pathophysiology of ischemic stroke in preclinical settings with the attempt to better 
understand how stroke modelling needs to be improved.  Specifically, in this study, we studied 
the impact of ApoE4 on aged mice fed on a HF diet and assessed both behavioral and 
inflammatory outcome following ischemic stroke. Likewise, the effect of pre-ischemic infection 
by common gut parasite T. muris on the outcome after stroke was also studied. Finally, the 
efficacy of CD36 inhibition on the mouse model of ischemic stroke outcome was assessed. 
6.1 FUNCTIONAL OUTCOME IS ALTERED IN AGED APOE4 MICE FED ON A HF 
DIET (I) 
APOE has an important role in lipoprotein metabolism. However, existence of three different 
isoforms of ApoE (ApoE2, ApoE3 and ApoE4) has various pathological consequences. Among 
these isoforms ApoE4 has been extensively studied in various models of neurodegeneration. In 
this study, we showed that the combination of co-morbid conditions like aging and HF diet 
renders transgenic mice harboring human APOE ε4 allele prone to sensorimotor deficits 
following cerebral ischemia compared to those mice fed on a normal diet. In fact, ApoE4 
isoforms have been shown to confer the greater risk of developing various neurodegenerative 
disease including AD, ICH, TBI and CAA (Verghese et al., 2011). A number of studies have 
demonstrated the relationship of APOE ε4 with cognitive decline in clinical subjects (Albert et 
al., 2007, Caselli et al., 1999, Mayeux et al., 2001, Schiepers et al., 2012). In addition, ApoE4 has 
been linked to a rapid decline in motor function in aged human subjects (Buchman et al., 2009). 
Considerable efforts have been put forth in understanding the cause of cognitive decline in 
human subjects harboring ApoE4 using targeted replacement mice in which human ApoE 
isoforms are replaced by human isoforms. In pre-clinical models, ApoE4-TR mice exhibit 
significantly fewer and shorter dendritic spines in cortical pyramidal neurons when compared 
to ApoE3-TR and C57Bl mice suggesting reduced synaptic plasticity underlying learning and 
memory (Dumanis et al., 2009). In addition, decreased spine density in old age can be 
attributed to increased spine elimination which further impairs the synaptic plasticity. 
50 
 
 
 
However, in the hippocampus, no difference was observed in the spine density among different 
isoforms. In line with these observations, a recent article by Rodriquez and colleagues found 
significantly fewer and shorter dendritic spines in the medial enthorinal cortex in ApoE4-TR 
mice when compared to ApoE3-TR mice. This was associated with  poor spatial learning and 
memory in ApoE4-TR mice at both young and old age as assessed by the Barnes maze 
(Rodriguez et al., 2013). Moreover, ApoE4-TR mice were also shown to possess lower excitatory 
synaptic activity in amygdala when compared to ApoE3-TR, C57Bl6, ApoE-ko and ApoE2/4-TR 
mice thus leading to cognitive impairment (Klein et al., 2010).  
The associations between stroke subtypes and ApoE4 have also been studied in both pre-
clinical and clinical subjects. In clinical subjects, APOE ε4 allele has been shown to be associated 
with poor neurological outcome after SAH and ICH (Lanterna et al., 2005, Martínez-González 
and Sudlow, 2006, McCarron et al., 2003)  but not ischemic stroke. However, other studies point 
towards the impairment of cognition in the early phase after stroke in carriers with either one or 
two alleles of APOE ε4 (Wagle et al., 2009). The progression of the cognitive decline is also faster 
in aged stroke patients with early cognitive impairment (Ballard et al., 2004, Dik et al., 2000). 
Thus, ApoE4 can be attributed to poor cognition following stroke.  
Western type diet has been implicated in the development of atherosclerosis, obesity, 
neurodegenerative disease and cardiovascular disease (Francis and Stevenson, 2013). A number 
of studies have linked the possible relationship between HF diet and cognitive impairment in 
clinical studies (Kalmijn et al., 2004, Morris et al., 2004). Moreover, Aging and HF diet have 
been shown to accelerate the decline in cognitive functions (Okereke et al., 2012) even though 
conflicting data do exist where no association between aging and cognition was reported 
following high saturated fat diets (Naqvi et al., 2011). However, in animal models, HF diet 
along with aging has been found to increase hippocampal oxidative stress and cognitive 
impairment. The cognitive function mainly affected by HF diet involves hippocampus and 
prefrontal cortex which are the major brain areas involved in memory, attention and learning. 
HF diet has been found to reduce hippocampal brain derived neurotropic factors, increase 
oxidative stress and increase the inflammatory process thus affecting neuronal plasticity, 
learning and memory (Francis and Stevenson, 2013, Molteni et al., 2002, Pistell et al., 2010).  
Even though a large number of studies point towards the impairment in memory and 
cognition following stroke in ApoE4-TR mice, the combined effect of co-morbidities like aging 
and HF diet is poorly understood in relation to motor function. Given that motor cortex is 
involved in processing the cognitive information related to sensorimotor function (Bonnard et 
al., 2004), we aimed to establish the underlying effect of co-morbid conditions in sensorimotor 
functions following ischemic stroke such that it bears clinical relevance to a sub population of 
patients. Here, we modelled the impact of HF diet in the context of different ApoE genotypes by 
feeding 16-month-old ApoE3-TR, ApoE4-TR and C57Bl/6j mice on a HF diet and subjected the 
mice to pMCAo. For the first time, we observed significant sensorimotor deficits in ApoE4-TR 
mice fed on a HF diet compared to ApoE3-TR mice on the same diet independent of the infarct 
size. Thus, the expression of ApoE4 isoforms along with HF diet is more likely to interfere with 
the recovery following brain infarction. The superior performance of ApoE3-TR mice when 
compared to ApoE4-TR mice and WT C57Bl mice on the adhesive removal test might be due to 
the complex branching pattern of dendrites and enhanced excitatory activity of ApoE3-TR 
which is not reduced even upon aging (Klein et al., 2010). ApoE4-TR mice exhibit reduced long 
term potentiation and poor spatial learning and memory (Rodriguez et al., 2013). Now we show 
that they also display poor sensory-motor outcome upon stroke. Endogenous repair 
mechanisms are activated following stroke to compensate the lost neuronal function. It has been 
shown that ApoE4 isoforms dampen neurogenesis in the hippocampus (Li et al., 2009). 
Specifically, neuronal maturation and development of hippocampal neurons in ApoE4-TR mice 
is impaired and this impairment was shown to occur due to the reduced survival and function 
of GABAergic interneurons in the hippocampus (Li et al., 2009). Thus, we sought to explore 
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whether neurogenesis is impaired in ApoE4-TR animals. To our knowledge, the neurogenesis 
was also reduced in ApoE4-TR mice compared to ApoE3-TR mice in the sub ventricular zone 
suggesting a better ability of ApoE3-TR mice to cope with ischemia induced brain damage.  
In preclinical studies, ApoE4 genotype has been found to increase brain damage following 
pMCAo and ischemia-reperfusion model (Mori et al., 2004, Sheng et al., 1998). However, in our 
model we were not able to find any differences in the infarct size between the genotypes. The 
reason for the contradiction between these studies and our study is most likely due to the 
model. In fact, our model of pMCAo produces a small and strictly cortical lesion while the 
model used by Mori and colleagues involved transient occlusion of CCA and thus resulted in 
bigger ischemic damage. In order to validate and exclude the effect of aging, we also used 
young ApoE4-TR and C57BL/6j mice and subjected them to pMCAo. However, young ApoE4-
TR animals also showed similar infarct size compared to the old animals used in this study. In 
addition, the infarct size in young ApoE4-TR and WT mice was relatively the same. 
Overall, our main finding in this study was that aged ApoE4-TR mice fed with a HF diet 
showed increased deficits in motor coordination compared to ApoE3-TR mice as assessed by 
the adhesive removal test and this observation is supported by a number of studies showing 
detrimental effects of ApoE4 genotype in neurodegenerative diseases. 
6.2 CNS INFLAMMATION IS INFLUENCED BY CO-MORBIDITIES (I, II) 
Following ischemic stroke, a number of molecular and cellular inflammatory mediators are 
either upregulated or downregulated. Inflammatory cells, mainly microglia and astrocytes, get 
activated in the early phase of stroke and contribute to the outcome of stroke. Microglial 
activation occurs within hours following stroke and they transform to a phagocytic phenotype 
in order to clear dead cells and debris (Perego et al., 2011). In addition, they also release a 
number anti-inflammatory cytokines and growth factors for maintenance and removal of 
injured neurons. In addition, microglia secrete pro-inflammatory cytokines, ROS and NO, 
thereby exacerbating secondary brain damage (Gehrmann et al., 1995). In addition to 
microgliosis, astrogliosis is an important contributor of the ischemic outcome through  secretion 
of various pro-inflammatory mediators (Lakhan et al., 2009).  
 In our study with ApoE-TR mice (I), we found significant induction in microgliosis in the 
peri-ischemic area in all genotypes when compared to the contralateral side according to the 
published literature. However, HF diet had no effect on the peri-ischemic activation of 
microglia in any of the phenotypes tested; however, it was indeed interesting to find higher 
levels of microglial activation in ApoE4-TR when compared to C57Bl mice. Aging is 
accompanied with the atrophy of both white and gray matter due to the loss of neurons. In 
contrast, glial cells get activated in an aging brain. ApoE4-TR mice have been shown to have 
higher production of NO through utilization of arginine by microglia when compared to 
ApoE3-TR mice thus adversely affecting the nearby neurons (Brown et al., 2002, Czapiga and 
Colton, 2003). Astrocytosis was also significantly induced in the peri-ischemic area of all the 
genotypes tested at both 3 and 10 day post-ischemia.  However, HF diet further actuated the 
astrogliosis in ApoE3-TR and ApoE4-TR but not in WT mice at 3 days post-ischemia with no 
difference at 10 days post-ischemia. In addition to its protective role, astrocytes are known to 
release a variety of neurotoxic inflammatory molecules and even glutamate which might 
potentially contribute to the neuronal damage (Zhao and Rempe, 2010). Our results showing 
that HF induced astrocytic activation are in agreement with a study showing that high 
cholesterol diet increased astrogliosis in the cerebral cortex of naïve mice (Crisby et al., 2004). In 
addition, Badan et. al. showed that generation of glial scar was accelerated in the aged rats and 
correlated with reduced functional recovery (Badan et al., 2003).  Their results together with 
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data obtained from our study suggest that aging and HF diet typical of western cuisine leads to 
the altered glial activation after stroke in animals carrying different ApoE isoforms.  
In addition to microgliosis and astrogliosis, inflammatory enzymes like COX-2 are also 
involved in the development of brain damage. Following ischemic injury and other forms of 
neuronal injury in the brain, COX-2 catalyzes the conversion of arachidonic acid to 
prostaglandins which together with prostaglandin receptor mediate the toxic effects in the brain 
(Andreasson, 2010). In addition, a HF diet has been found to promote neural inflammation in 
the cerebral cortex in naïve mice through dramatic increase in expression of COX-2 and thus 
prostaglandin E2 (Zhang et al., 2005). We thus tried to elucidate the effect of COX-2 on HF diet 
and cerebral ischemia in the context of APOE background. We found ischemia induced 
upregulation of COX-2 immunoreactivity in the peri-ischemic area in all treatment groups 
except ApoE3-TR mice on a normal diet. HF diet significantly actuated the COX-2 
immunoreactivity in ApoE4-TR mice but not in WT and ApoE3-TR mice even though there was 
a trend towards increased COX-2 activation on a HF diet fed treatment group. We thus 
hypothesize that COX-2 is involved in HF diet induced neural inflammation in ApoE4-TR mice 
following ischemia. 
Pre- and post-ischemic infections are also co-morbid risk factors that negatively affect the 
outcome after stroke. Pre-ischemic infections increase the risk of stroke while post-ischemic 
infections are associated with aggravated brain damage and hence poor neurological outcome. 
Stroke incidence is increased during the season with high occurrence of respiratory and urinary 
tract infections and both acute and chronic infections originating from bacteria, virus and 
fungus are thought as possible triggers for acute ischemic stroke (Grau et al., 2010). Chronic 
infections by H. Pylori, C. pneumoniae and influenza virus in clinical subjects are associated with 
stroke risk and the risk increased with the number of chronic infections (Emsley and Tyrrell, 
2002, Grau et al., 2010). The contribution of chronic pre-stroke infection by influenza virus and 
T. muris in the exacerbation of brain injury has been demonstrated in pre-clinical models as well 
(Dénes et al., 2010, Muhammad et al., 2011). These studies showed the impact of peripheral 
infections and inflammation in young animals. When modelling a disease of the elderly, one 
should bear in mind that aging is a non-modifiable risk factor for stroke and is known to be 
associated with altered immune response following stroke (Popa-Wagner et al., 2007, Sieber et 
al., 2011). We thus aimed to investigate the impact of aging on ischemic stroke following 
chronic infection (II). In this study, chronic peripheral infection was modelled by administration 
of T. muris parasite eggs to young and agedC57Bl/6j mice. This model induces Th-1 polarized 
immune response. Here, we demonstrated that infarct size in aged mice was similar to young 
mice and that chronic peripheral infection markedly increased ischemic brain damage 
specifically in aged mice. Aging is associated with a dysregulated immune system and chronic 
infection and inflammation are more often present in older people. Thus, the aggravated 
ischemic damage seen in this study bears clinical relevance.  
As discussed earlier, neuroinflammation after stroke is associated with glial cell activation 
and upregulation of a number of cytokines and chemokines that are often produced by these 
inflammatory cells. However, the effect of chronic infection and aging on neuroinflammation 
following ischemic stroke is not well documented. We thus investigated the glial activation and 
activation of various inflammatory mediators in aged ischemic mice subjected to chronic 
peripheral infection. In this study, brain microgliosis was significantly upregulated in the peri-
ischemic area of all treatment groups when compared to contralateral sides. However, brain 
microgliosis was not altered between any of the treatment groups. Glial cells are not the sole 
source of inflammation in the brain following neurodegeneration and other types of cells are 
also responsible for the production of various inflammatory mediators. Moreover, 
quantification of stroke induced Iba-1 and GFAP immunoreactivities do not necessarily reflect 
subtle changes that may occur at the cellular level and may still have a significant impact on the 
outcome of stroke. We thus analyzed the inflammatory profile of the ischemic brains by using 
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CBA at 24 hours post-ischemia. In this analysis, the levels of G-CSF, MCP-1, KC, IL-1α and 
RANTES were elevated after ischemia in aged mice when compared to their young 
counterparts. Surprisingly, aged mice with chronic peripheral infection failed to upregulate G-
CSF and MCP-1 to similar levels as seen in aged uninfected mice suggesting the dysregulation 
of an immune response in aged infected mice. G-CSF is a member of the cytokine family of 
growth factors that was used initially to treat neutropenia (Nguyen, 1994) but was later shown 
to be upregulated in the peri-ischemic area following stroke (Schneider et al., 2005b). In an 
experimental model of stroke, G-CSF was shown to reduce infarct size and early neurological 
outcome most likely through inhibition of apoptosis mediated by caspase 3 and prevention of 
pro-inflammatory cytokine expression (Görgen et al., 1992, Solaroglu et al., 2009). G-CSF was 
shown to confer neuroprotection directly by binding to its receptors G-CSFR which in turn 
activates signal transducer and activator of transcription 3 (STAT-3) proteins. STAT-3 protein 
then mediates anti-apoptotic functions by activating Bcl-2 (Schäbitz et al., 2003a, Schäbitz et al., 
2000). In addition, G-CSF confers neuroprotection through stem cell mobilization and 
promotion of neurogenesis (Schneider et al., 2005a, Sehara et al., 2007). Given these facts, a 
lower level of G-CSF in the peri-ischemic area of the brain found in aged infected mice may 
correlate with increased neutrophils infiltration into the brain. We thus performed 
immunohistochemical staining for neutrophil and found that there is a massive infiltration of 
neutrophils in the lesion area in aged infected mice.  In addition, we also saw decreased levels 
of G-CSF in the peri-ischemic area. Thus, we can speculate that dysregulation of G-CSF in the 
brain following ischemic stroke in aged infected mice is accompanied by massive neutrophil 
infiltration and thus aggravated brain damage in our model. Neutrophils are amongst the first 
leukocytes to infiltrate into the brain parenchyma in response to ischemic stroke and are shown 
to exacerbate ischemic neuronal damage through MMP-mediated BBB damage, release of 
variety of pro-inflammatory cytokines and chemokines and excessive production of ROS (Jin et 
al., 2010).  MCP-1 that is secreted by neurons and astrocytes following ischemic stroke is a 
known contributor for neuronal  damage (Che et al., 2001). MCP-1 deficiency has been 
demonstrated to impair the expression of G-CSF in a mouse model of transient MCAo (Strecker 
et al., 2011) and thus we can hypothesize that the decreased levels of MCP-1 and G-CSF 
together with increased neutrophil infiltration in aged infected mice leads to aggravated brain 
damage. 
6.3 CO-MORBIDITIES ALTER THE SYSTEMIC INFLAMMATORY STATUS IN 
THE PERIPHERY BOTH PRE- AND POST-ISCHEMIA (II) 
It is a well-known fact that central inflammatory responses play an important role in ischemic 
brain damage. Pre-existing peripheral inflammation induced by co-morbid conditions such as 
hypertension, infection, atherosclerosis and diabetes also increase the risk of brain damage. 
Inflammatory conditions associated with atherosclerosis and rupture of atherosclerotic plaques 
is amongst the leading causes of stroke. In addition, preceding infections of bacterial, viral and 
fungal origins modify the systemic inflammatory status in the periphery and hence contribute 
to the ischemic brain damage. In fact, acute infection of bacterial origin mostly affecting 
respiratory and urinary tract has been shown to increase the risk for stroke (Clayton et al., 2008, 
Smeeth et al., 2004). Likewise, post-ischemic peripheral inflammation also contributes to the 
aggravated brain damage and neurological outcome (Kwan et al., 2013, Wartenberg et al., 2011, 
Westendorp et al., 2011). Following cerebral ischemia, a number of inflammatory cells of 
peripheral origin including neutrophils and monocytes infiltrate into the brain parenchyma and 
produce an array of cytotoxic mediators involved in exacerbation of the brain damage (Buck et 
al., 2008, Emsley et al., 2003). In addition, adhesion molecules like VCAM-1, ICAM-1, selectins 
and integrins that are required for the transmigration of leukocytes are also upregulated 
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following ischemia.  Moreover, plasma CRP, IL-6 and leukocyte counts are elevated following 
stroke and correlated with the outcome after stroke (Basic Kes et al., 2008, Muir et al., 2007, 
Waje-Andreassen et al., 2005). 
Peripheral infections accompanied with systemic inflammation have been shown to 
exacerbate brain damage in the rodent model of focal ischemia (Dénes et al., 2010, Muhammad 
et al., 2011). Both these studies utilizing young animals point to RANTES as the mediator of 
chronic infection-induced stroke exacerbation. In this study, we found a significant elevation in 
plasma levels of RANTES in both young and old infected mice 1 day pre-ischemia in agreement 
with previous studies. In addition, we also found a significant correlation between circulating 
pre-ischemic RANTES levels and the infarct size in aged infected mice. Levels of RANTES were 
also elevated in the brain following ischemia in both old infected and uninfected mice when 
compared to the contralateral hemisphere. Both aged infected and uninfected mice exhibited 
higher levels of RANTES following ischemia thus encompassing the adverse effect of RANTES 
following ischemic events. 
In addition, we evaluated the impact of aging and infection on peripheral cytokines and 
chemokines in plasma at 1 and 4 hours post-ischemia. Of various cytokines analyzed, we found 
that the levels of G-CSF, KC and IL-6 were significantly induced at 4h post-stroke when 
compared to 1h post-stroke in all study groups indicating the insignificance of aging and 
infection at these time points. Indeed,  IL-6 was found to be sharply increased following stroke 
in a rodent model of cerebral ischemia independent of infection (Dénes et al., 2010). We can thus 
speculate that IL-6 levels sharply rise following ischemia irrespective of the preceding infection 
or that preceding infection has no effect on the levels of IL-6. IL-6 has been demonstrated to be 
upregulated in the acute phase of stroke in human subjects and this upregulation correlates 
with the larger infarct size and poorer neurological outcome (Emsley et al., 2003, Smith et al., 
2004, Whiteley et al., 2009). Thus, an increase in level of IL-6 following stroke is related to 
ischemic insult itself and not infection.   
Twenty-four hours after ischemia, plasma levels of proinflammatory cytokines such as TNF-
α and IL-17A were significantly increased in aged infected mice. TNF-α is a well characterized 
proinflammatory mediator implicated in the pathogenesis of ischemic stroke (Hallenbeck, 
2002). TNF-α levels in the periphery have been shown to be increased in both preclinical and 
clinical subjects following ischemic stroke and might serve as a potential inflammatory 
biomarker (Sotgiu et al., 2006, Yousuf et al., 2013). IL-17A, on the other hand, is secreted by 
multiple cell types including CD4+ δβ T cells, γδ T cells, natural killer cells and neutrophils 
(Roark et al., 2008). IL-17A has been shown to be a critical mediator of neutrophil infiltration 
and recruitment in ischemia reperfusion injury in hepatic injury (Kono et al., 2011) as well as in 
a cardiac transplantation model (Zhu et al., 2013). In cerebral ischemia, IL-17A mainly produced 
by γδ T cells in the brain has been shown to be involved in neutrophil infiltration to the site of 
ischemic damage and the blockage of IL-17A  pathway is associated with reduced brain damage 
and improved clinical outcome (Gelderblom et al., 2012). This effect is mainly mediated by 
astrocyte derived CXCL-1. In addition, γδ T cells have been shown to infiltrate into the ischemic 
brain parenchyma from the periphery at the later stages of the injury where they contribute to 
the increased levels of IL-17A in the brain (Li et al., 2005, Shichita et al., 2009). In our study, we 
detected increased plasma levels of IL-17A in aged infected mice when compared to young 
infected mice possibly reflecting increased activation of γδ T cells. Indeed, one study has 
reported that aging together with infection in mice is associated with a rapid increase of 
peripheral IL-17A and neutrophil activation in a case of liver injury (Stout-Delgado et al., 2009). 
Even though we didn’t examine γδ T cells in the brain and periphery, we can hypothesize that 
increased plasma levels of IL-17A in aged infected mice may be one of many reasons leading to 
increased infiltration of neutrophils in these mice when compared to other treatment groups. 
Other co-morbid conditions like atherosclerosis and increased cholesterol levels in plasma 
also alter the outcome before and after stroke. ApoE, especially ApoE4, is pro-inflammatory and 
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is associated with increased risk of atherosclerosis that ultimately determines stroke outcome. 
Inclusion of HF diet to this already pre-existing genetic risk factor for atherosclerosis in aged 
mice has been the focus of our study. In study I, we assessed the levels of cholesterol after HF 
diet in ApoE3-TR, ApoE4-TR and WT mice. We found that ApoE4-TR in general has lower 
levels of total serum cholesterol compared to ApoE3-TR mice. These results are in contrast to 
the previous reports where VLDL cholesterol have been found to be lower in young female 
ApoE3-TR mice compared to ApoE4-TR mice of the same sex (Knouff et al., 1999). The levels of 
total cholesterol were elevated to a similar extent in both ApoE3-TR and ApoE4-TR mice but 
not in WT mice. In agreement with previous observations, ApoE3-TR had a significantly higher 
amount of cholesterol compared to WT mice (Sullivan et al., 1997). However, the increase in 
serum cholesterol did not correlate with the atherosclerosis plaque or foam cell formation in 
ApoE-TR mice fed on a HF diet in contrast to previous observations (Knouff et al., 1999, 
Sullivan et al., 1997). This might be attributed to differences in sex, diet and age of the animals 
used in these studies. In fact, the diet used in our study is better representative of western type 
diet typical to human cuisine where the diet used by them was high in cholate. Thus, clear 
atherosclerotic changes did not play any role in our study. However, following stroke, a 
number of peripheral cytokines and chemokines are upregulated that might have affected the 
outcome. We determine the cytokine levels in plasma using CBA assay. Of various cytokines 
analyzed, we detected a clear increase in IL-6 in ApoE4-TR mice fed on a HF diet compared to a 
normal diet. Peripheral IL-6, unlike brain IL-6, has been shown to be associated with a worse 
cognitive outcome in elderly people and in APOE ε4 carrier (Economos et al., 2013, Schram et 
al., 2007). Thus, we can hypothesize that APOE ε4 can modify peripheral inflammatory 
response and affect cognition in CNS diseases.   
6.4 CD36 CAN BE A POTENTIAL THERAPEUTIC TARGET FOR TREATING 
ISCHEMIC STROKE  
Most of the clinical trials involving a single drug to target a single pathway in the treatment of 
ischemic stroke have often failed due to the heterogeneity of stroke pathophysiology.  However, 
a strategy to target a single molecule that is involved in multiple pathogenic mechanisms in 
stroke is not well understood. CD36 is one such receptor that is involved in atherosclerosis, 
lipid metabolism, inflammation and ischemic stroke (Cho and Kim, 2009). Following ischemia, 
various ligands for CD36 including oxLDL, TSP and LCFA are produced which might 
contribute to brain injury (Cho and Kim, 2009). Thus utilizing therapeutic drugs with an aim to 
inhibit CD36 might provide overall protection against ischemic damage. The deleterious role of 
CD36 in cerebral ischemia was first shown by Cho et. al.. They observed a 50% reduction in 
infarct volume in CD36 null mice compared to WT mice in a transient filament occlusion model. 
However, a therapeutic drug to suppress the activity of CD36 has not been addressed up to 
now and is the focus of this study. SSO, a LCFA, is a specific inhibitor of CD36 and is involved 
in the inhibition of fatty acids uptake by adipocytes (Harmon et al., 1991). In addition, SSO was 
found to inhibit signaling for intracellular calcium and restrict uptake of ox-LDL by 
macrophages (Kuda et al., 2013). Given the inhibitory effect of SSO on CD36 and lack of studies 
using pharmacological inhibition of CD36 in cerebral ischemia, we aimed to determine if SSO 
could, in fact, attenuate ischemic brain injury following pMCAo. 
In this study, we found that oral administration of SSO following ischemia was 
neuroprotective against brain damage as analyzed by MRI. Our results are in agreement with 
the previous findings showing that CD36 deletion can have a neuroprotective effect following 
ischemia even though the approach was different. Several studies have linked microglia and 
ROS production in cerebral ischemia via NADPH oxidase, cytokines and MMP-9 (del Zoppo et 
al., 2007, Jin et al., 2010, Pun et al., 2009). Considering that CD36 is predominantly expressed in 
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microglia/macrophage in the ischemic territory at early phase after stroke, Cho et al.  proposed 
that CD36 mediates ischemic damage via ROS production (Cho et al., 2005).  We also assessed 
whether treatment with CD36 inhibitor SSO would reduce the stroke induced activation of 
microglia and astrocytes. We show that the microgliosis was significantly attenuated in SSO 
treated mice compared to control mice. Thus, the neuroprotection seen in our study might be 
due to reduced microglial activation and subsequent ROS production even though we did not 
analyze ROS production in our study. We also assessed the phagocytic activity of microglial 
BV-12 cells in vitro using latex bead phagocytosis and the capacity of SSO to reduce microglial 
activation. As expected, phagocytic capacity of microglial cells was reduced by SSO. In 
addition, there was a massive decrease in the release of NO by these cells in higher 
concentrations of SSO. Thus, we can stipulate that ROS alongside reactive nitrogen species 
produced by microglial cells might contribute to the brain damage that we see in vivo. In 
addition to glial cell mediated inflammation, we also analyzed whether inflammatory enzyme 
COX-2 is involved in the mediation of ischemic brain damage. Here, we found that COX-2 
immunoreactivity was significantly higher in control mice compared to SSO treated mice. These 
results indicate that SSO may restrict formation of proinflammatory eicosanoids by inhibiting 
COX-2 activity. In fact, CD36 has been shown to contribute the generation of proinflammatory 
eicosanoids in vitro and our observations in vivo further verify the fact (Kuda et al., 2011). In 
vitro, CD36 has also been linked to regulation of membrane calcium influx in response to ER 
stress and SSO was shown to inhibit calcium signaling by binding to CD36 lysine 164 (Kuda et 
al., 2011, Kuda et al., 2013). Taken together, we show that CD36 is involved in a number of 
pathological processes taking place upon ischemic insults and inhibition of CD36 by SSO may 
provide a treatment paradigm for ischemic stroke  
 6.5 ADVANTAGES AND DISADVANTAGES OF ANIMAL MODEL USED IN THIS 
STUDY 
There are a number of ways in which both permanent and transient ischemia can be induced in 
rodent models of stroke. Examples include insertion of the suture, electrocoagulation, 
endothelin-1 injection, and photothrombosis etc. However, none of these models reflectsthe true 
clinical situation. Permanent occlusion where there is no recanalization occurs in a very small 
proportion of population (Jin et al., 2010). Likewise, transient ischemic models involve occlusion 
of the artery for a short duration whereas human ischemic stroke is of longer duration before 
spontaneous recanalization (Fisher et al., 2009). Thus, the use of animal models depends on the 
specific question raised. For example, effect of a thrombolytic drug can be studied using 
thromboembolic stroke; anti-inflammatory drugs can be tested in permanent focal ischemia; 
and a free radical scavenger can be used to test in transient ischemia (Macrae, 2011). In addition, 
the mouse model should reflect the heterogeneous risk factors associated with clinical stroke to 
test the efficacy of neuroprotective compounds. This can be achieved by inducing co-morbidity 
in aged animals. 
In this study we used permanent methods to occlude MCA. This model provides good 
reproducibility of the lesion size and the successful occlusion of the MCA can be visually 
confirmed. In addition, mortality rate of the animals is very low thus reflecting the need to use 
less animals compared to transient models where mortality rates are often high depending on 
the duration of occlusion (Macrae, 2011). In addition, the surgical procedure is relatively quick 
thus minimizing the amount of time the animal spends under neuroprotective anesthetics (Seto 
et al., 2014). The major drawback of this model is that the ischemic surgery requires craniotomy.  
The Stroke Therapy Academy Industry Roundtable (STAIR) has emphasized the use of 
animal models with accompanying co-morbid risk factors before testing the efficacy of drugs in 
clinical subjects (Fisher et al., 2009). However, there are only a handful of studies that have been 
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published so far focusing on heterogeneity of ischemic stroke. In this thesis, we aimed to do that 
by modelling co-morbidities that are typically present in humans. We have shown that the 
inflammatory status in the brain and periphery of aged animals with predisposing risk factors 
are completely different than observed in young animals. In fact, this might be an important 
determinant for the clinical failure of several neuroprotective drugs. Even though we tried to 
mimic some aspect of the human stroke in preclinical model, the model used in this study 
reflects only two of the many conditions. For example, some cases of human stroke are often 
presented with predisposing infections prior to the ischemic event while other cases might 
present diabetes, hyperlipidemia and other risk factors. Thus, there is no universally accepted 
animal model of cerebral ischemia, and the usability of the models depends upon the 
compromise and specific questions that are often asked before designing the experiment 
(Howells et al., 2010).  
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7 Summary and Conclusions 
The present study was carried out to assess the role of various co-morbid conditions on the 
outcome of ischemic stroke. The influence of western-type diet on aged mice expressing E3 and 
E4 isoforms of human ApoE was assessed. The effect of pre-disposing infection using gut 
parasite was studied in both aged and young mice with an emphasis on inflammation. In 
addition, the therapeutic potential of SSO in ischemic stroke was explored. The results obtained 
from these studies are listed below.  
I. In study I, we demonstrated that aged ApoE4 mice fed a HF diet are more susceptible to 
sensorimotor deficits when compared to aged ApoE3 and -WT mice on the same diet following 
pMCAo. Those deficits were most likely due to the increased peripheral inflammation 
contributed by IL-6. In addition, impaired neurogenesis, increased COX-2 enzyme and 
increased astrogliosis in the CNS may have contributed to the worse outcome after stroke. 
II. In the second study, we demonstrated that aged mice subjected to predisposing chronic 
infection by gut parasite T. muris. displayed larger ischemic damage and this damage correlated 
with the pre-stroke level of plasma RANTES. Infected aged mice also displayed significant 
infiltration of neutrophils into the infarct core along with increase of plasma levels of IL-17α 
and TNF-α when compared to the young infected and uninfected animals. 
III. In study III, we assessed the effect of SSO administration on the outcome of ischemic stroke 
in young mice. We observed that per oral treatment of mice immediately after pMCAO 
protected the brain from ischemic damage. This protection might be due to reduced 
microgliosis and COX-2 expression in the brain. In addition, the protection may be explained by 
the reduction in NO as demonstrated by in vitro experiments. 
In summary, we have demonstrated that the inflammatory status in the brain and periphery 
in aged mice under co-morbid conditions are completely different to those of a homogenous 
cohort of young mice (Figure 6). We show that ApoE allele modifies the inflammatory status in 
the brain and the periphery thus contributing to functional outcome after stroke. In addition, 
our results show that chronic peripheral infection in aged animals renders the brain more 
susceptible to ischemic damage possibly through altering the inflammatory status in both brain 
and periphery. Finally, SSO was able to protect the brain from damage following ischemia in 
young mice by modifying the inflammatory status in the brain. Based on these results we see 
that the age of animals used for preclinical experiments affects the results obtained. We also 
know that aging along with other co-morbid conditions carries the highest risk of stroke. 
Therefore, this study bears clinical significance when designing drug studies in the future. 
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Figure 6: Role of stroke associated risk factors on inflammation and proposed therapeutic target of 
SSO. Stroke accompanied by infections and other risk factors increases RANTES level in the 
peripheral circulation. The circulating RANTES then induces MIP-2 and ultimately facilitates the 
transmigration of neutrophils into the ischemic territory. At the ischemic site, microglia, astrocytes, 
neurons and infiltrating leukocyte secrete various mediators thus promoting inflammation and 
apoptosis. Astrocytes secrete ceramide and diacylglycerol following early ischemic event that can 
increase the amount of proinflammatory cytokines via NF-kB pathway. In addition, injured neurons 
promote CD36 induction. SSO is proposed to provide the neuroprotection following ischemic stroke 
via inhibition of CD36 and decreased production of ceramide. Abbreviations: RANTES, Regulated on 
activation, normal T cells expressed and secreted; MIP-2, Macrophage inflammatory protein 2; DAG, 
Diacylglycerol; IL, Interleukin; HMGB-1. High-mobility group protein B1; HSP60, Heat Shock Protein 
60; Aβ, Amyloid beta; DAMPs, Danger associated Molecular Patterns; TLRs, Toll like Receptors; 
CD36, Cluster of differentiation 36; NF-kB, Nuclear factor kappa beta; COX-2, Cyclooxygenase 2; 
iNOS, inducible nitric oxide synthase; TNF, Tumor necrosis factor 
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8 Future Perspective of Stroke Modelling and 
Neuroprotective Treatment Remedies 
Preclinical trials are the basis for translation of therapeutic strategies into clinical subjects. 
During the past 20 years or so, many drugs targeting various pathways in the ischemic cascade 
have been carried out in animal models and later tested in humans. However, they have often 
failed with little or no success (Minnerup et al., 2012). We can point out many reasons for the 
failure in the translation. First, the pathophysiological mechanism contributing to the ischemic 
damage in humans might be more complex than that of those in animal models (Endres et al., 
2008). Second, stroke typically occurs in old age when patients often suffer from various co-
morbid conditions like obesity, diabetes, atherosclerosis, and infections just to name a few. 
However, most of the preclinical research is still being carried out in young, homogenous 
cohorts of animals with no accompanying risk factors. Third, the model of stroke that we use to 
limit the blood flow to the brain may not be good when considering the heterogeneous nature 
of human stroke. 
Then how to model stroke properly? There is no particular answer to this question. Ischemic 
damage in humans comes in many shapes and sizes considering the heterogeneity of the 
cerebral vasculature. However, occlusion of MCA is the most common type of human ischemic 
stroke. In animal models, this is achieved by either permanent ligation of MCA or transient 
occlusion of the blood flow for a desired duration as discussed elsewhere (Howells et al., 2010). 
In addition, the thromboembolic model in which murine thrombin is pneumatically injected 
into MCA of the mouse is also slowly gaining traction (Orset et al., 2007). The fact that thrombin 
is used to clot the blood right at the MCA bifurcation is a very relevant approach as it better 
represents the clinical situation. However, all these animal experiments are done at the expense 
of anesthetics. There are a number of studies where neuroprotective effects of various 
anesthetics have been demonstrated, and these are sure to affect the final outcome after stroke. 
So, an approach to keep the time of anesthesia to a minimum or development of occlusion 
model in which the animal can be awake without being invasive can provide the direction for 
the future (Seto et al., 2014). However, the ultimate occlusion method used for any study 
depends on the specific question that is addressed.  
In addition, to better model human stroke, co-morbid conditions should be taken into 
account and it is often a neglected fact in most preclinical studies (Casals et al., 2011, Howells et 
al., 2010, Mergenthaler and Meisel, 2012). Aging is one of the non-modifiable risk factors for 
stroke that is often accompanied by various pathological complications. In this thesis, we tried 
to model these complexities in aged mice and came to the conclusion that discrepancies do exist 
between aged and young mice when using the same method of occlusion. Thus, failure to 
include the risk factors often seen in clinical conditions will ultimately result in a failure in 
translational research. So, a better approach to study the therapeutic efficacy of a drug would be 
to include the animal model of co-morbidities.  
Finally, most of the drugs that are used in the preclinical trial only target a single ischemic 
cascade whereas ischemic stroke involves multiple overlapping ischemic cascades. So the use of 
combinational therapy targeting different mediators of the ischemic event might be a suitable 
treatment strategy for stroke treatment (Culmsee et al., 2004). Alternatively, molecules capable 
of targeting the multiple cellular mechanisms involved in the ischemic event can also be 
helpful. In this regard, CD36 is one of the receptors involved in various pathophysiological 
processes ranging from atherosclerosis, inflammation to ischemic stroke (Cho and Kim, 2009). 
In this study, we also aimed to inhibit CD36 using its inhibitor, SSO, in an attempt to modulate 
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the inflammatory response and have it shown that targeting this receptor may provide 
neuroprotection following ischemia.  
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Stroke is characterized by sudden 
disruption of blood flow into the 
brain resulting in disability and 
death. This thesis focuses on model-
ling the heterogenic conditions of 
human stroke in preclinical settings. 
This study demonstrates that preced-
ing infection, diet and genetic com-
position of the animal models alter 
the ischemia induced inflammatory 
status especially in aged mice. Our 
data pinpoint the need to consider 
heterogeneity of human stroke in 
preclinical settings when testing new 
potentially neuroprotective drugs. 
